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Abstract 
Osteoporosis is the most common age-related bone disease. It is clinically 
symptomless until the first fracture happens and once diagnosed it is often found to 
be associated with low bone mineral density (LBMD) of T-Score ≤ -2.5. Circulating 
microRNAs (miRNAs) have been used successfully as promising biomarkers to 
diagnose and assess the progression of complex diseases such as cancer and 
cardiovascular diseases, as well as the effectiveness of treatment.  
This research aims to identify circulatory miRNAs associated with the progression of 
osteoporosis in a test group of patients using advanced PCR arrays initially and the 
identified differentially-expressed miRNAs were validated in individual clinical 
specimens using RT-qPCR.  The potential target genes were analyzed using 
bioinformatics tools. 
Ethical approval was obtained prior to patient recruitment. A total of 161 participants 
were recruited and assigned to five groups: Non-Osteoporosis control group (T-Score 
≥-1), osteopenia (T-Score <-1 and >-2.5 SD), osteopenia with fracture (T-Score <-1 
and >-2.5 SD), osteoporosis (T-Score ≤ -2.5 SD) and osteoporosis with fracture (T-
Score ≤ -2.5 SD).  RNAs were extracted and analyzed from all serum and plasma 
samples.  
A panel of 49 differentially expressed miRNAs (up or down by >3 fold) between 
osteopenia and osteoporosis patient groups was identified using a miRNA PCR Array.  
Six miRNAs: miR-215-5p, miR-99a-5p, miR-100, miR-373-5p, miR-4516 and miR-122-
5P, were significantly differentially-expressed between osteoporosis and osteopenia 
patients by initial RT-qPCR screening. Further analysis showed that the levels of 
circulating miRNAs: hsa-miR-373-5p, hsa-miR-122-5p and hsa-miR-215-5p and 
plasma hsa-4516 were associated with fragility fracture, and correlated with low 
bone mineral density. The results suggest that these miRNAs could be potential 
diagnostic biomarkers for osteoporosis in the future. Potential target genes of these 
miRNAs were also analyzed using bioinformatics tools. The project demonstrated 
that circulating miRNAs can be purified from serum and plasma and could be 
developed as critical diagnostic tools for osteoporosis. 
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1.1 Bone Biology 
1.1.1 Bone Function  
Bone plays multifunctional roles as structural connective tissue that provides 
mechanical support and protection for vital organs, maintaining mineral haemostasis 
and haematopoiesis (Harada and Rodan, 2003, Taichman, 2005). 
Bone also acts as an endocrine system that regulates the mineral haemostasis and 
energy metabolism as well as responding to other vital tissue systems, such as kidney, 
parathyroid gland, vascular, adipose tissue and hypothalamus (Fukumoto and 
Martin, 2009, Confavreux, 2011), by secreting fibroblast growth factor 23 (FGF-23) 
and osteocalcin (OCN) (Burr and Akkus, 2014). Most of FGF-23 is produced by 
osteocytes and causes a reduction of renal reabsorption of phosphate and decreases 
serum level of vitamin D3 (Burr and Akkus, 2014).  
1.1.2 Bone Structure 
Bones comprises two types of component: cortical bone (85% of bone), which is 
dense, solid, and surrounds the marrow space, providing mechanical and protective 
function, and the trabecular bone (15% of bone), which is composed of a spongy 
network of trabecular plates and rods interspersed in the bone marrow 
compartment and is involved in metabolic function (Burr and Akkus, 2014). 
1.1.3 Bone Composition 
Both cortical and trabecular bone mass material contains organic and mineral 
components. The organic component (Osteoid) accounts for 20-25% of total bone 
mass and is composed mostly of cross linked type I collagen (90%), the remainder 
being proteoglycan & non-collagenous proteins such as osteocalcin, osteopontin and 
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osteonectin. 65% of bone mass is mineral matrix, mainly calcium and phosphorus in 
the form of insoluble hydroxyapatite, as well as other ions,  Mg2+, Na+, K+, Cl-, HCO3- 
and the remaining 10% is water (Burr and Akkus, 2014). Both collagen(s) and the 
minerals combine to form a composite material that provides rigidity to the structure 
and the collagen provides resilience and ductility (Florencio-Silva et al., 2015). 
1.1.4 Cells of Bone 
Bone contains four cell types: osteoblasts, osteocytes, bone lining cells and 
osteoclasts (Buckwalter et al., 1996, Downey and Siegel, 2006), (Figure 1-1). 
Osteoblasts, osteocytes and bone lining cells are derived from mesenchymal stem 
cells, whereas osteoclasts originate from haemopoietic stem cells (Downey and 
Siegel, 2006).  
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Figure 1-1: Light micrograph of a portions of mouse bone  
Bone Cells; HE-stained section showing a portion of a bony trabecula with a) 
osteoblasts, b) osteoclasts, and c) and osteocytes. By kind permission of Prof van’t 
Hof (University of Liverpool).  
1.1.4.1 Osteoblasts 
Osteoblasts are cuboidal cells that are located along the bone surface, comprising 4–
6% of the total resident bone cells, derived from mesenchymal stem cells (MSC) 
(Capulli et al., 2014). Functionally, the osteoblast is responsible for production of the 
organic matrix, which is composed of Type 1 Collagen and non-collagenous proteins, 
including osteocalcin (Ducy et al., 2000, Everts et al., 2002). In addition, osteoblasts, 
under the influence of parathyroid hormone and local cytokines, release protein 
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mediators such as Receptor Activator of the NF-κB (RANK) Ligand (RANKL) that 
activate osteoclasts (Downey and Siegel, 2006, Udagawa et al., 1999). 
Eventually, osteoblasts follow one of three developmental pathways: they may 
remain active osteoblasts on the edge of the bone matrix, they may become 
surrounded by matrix and become osteocytes, or become relatively inactive and 
form bone lining cells, referred to as ‘resting osteoblasts’ (Downey and Siegel, 2006). 
1.1.4.2 Osteocytes 
Osteocytes are located within lacunae surrounded by mineralized bone matrix and 
account for 90-95% of the bone cells with a lifespan of up to 25 years (Franz-
Odendaal et al., 2006). Osteocytes are derived from osteoblasts by differentiation. 
As osteoblasts mature, and more matrix is laid down, they become embedded within 
the bone matrix, and become osteocytes that act both as mechanosensors, 
responsible for the adaptation of bone to mechanical force, and as endocrine cells 
that produce hormones (Bonewald and Johnson, 2008, Florencio-Silva et al., 2015). 
In addition, osteocytes are considered to be the major source of molecules that 
regulate the generation and activity of osteoclasts, such as the decoy receptor 
osteoprotegerin (OPG) and the RANKL (Kramer et al., 2010, Xiong and O'Brien, 2012, 
Bellido, 2014).  
1.1.4.3 bone lining cells 
Bone lining cells are quiescent flat-shaped osteoblasts covering bone surfaces (Figure 
1-1), and thought to have a specific role in linking bone resorption to bone formation 
(Florencio-Silva et al., 2015). Lining cells in the presence of PTH secrete matrix 
metalloproteases (MMPs) that remove the osteoid covering of the bone matrix in 
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preparation for osteoclastic removal of bone (Everts et al., 2002), and possibly later 
differentiate into bone-forming osteoblasts (Delaisse, 2014, Andersen et al., 2009). 
Lining cells prevent the direct interaction between osteoclasts and the bone matrix, 
when bone resorption should not occur, and participate in osteoclast differentiation 
from mononuclear cells of the hematopoietic stem cell lineage by producing 
osteoprotegerin (OPG) and the RANKL (Florencio-Silva et al., 2015). 
1.1.4.4 Osteoclasts 
Osteoclasts are multinucleated cells, that arise from the fusion of their mononuclear 
precursors in the hematopoietic stem cell lineage (Florencio-Silva et al., 2015). These 
precursor cells express the cell surface receptors for the macrophage colony-
stimulating factor (M-CSF), secreted by osteoprogenitor mesenchymal cells and 
osteoblasts, and RANKL, secreted by osteoblasts, osteocytes, and stromal cells 
(Crockett et al., 2011a). 
Osteoclast differentiation from its mononuclear precursors is triggered through a 
cell-cell contact between osteoclast precursor cells with upregulated expression of 
RANK and its ligand (RANKL) that is expressed by osteoblasts, stromal cells and more 
predominantly in osteocytes (Nakashima et al., 2011). RANK signalling is tightly 
regulated by a decoy receptor for RANKL, osteoprotegerin (OPG), that can block 
osteoclast formation which is produced by osteoblasts and stromal cells (Crockett et 
al., 2011b) and osteocytes (Bellido, 2014). 
1.1.5 Bone Remodeling (Build up/Break down) 
The health of bone is maintained through a delicate and continuous balanced process 
of bone remodelling that takes place throughout life to maintains the structural 
Chapter 1: Introduction 
7 | P a g e  
 
integrity and strength of the bone, by removing old or damaged bone and replacing 
it with new, strong bone (Raisz, 1999).  
Remodeling occurs in a temporary anatomic unit of osteoclasts and osteoblasts 
called a bone multicellular unit (BMU) (Seeman, 2008). This involves the initiation of 
bone degradation and resorption of bone mineral by osteoclasts (Teitelbaum, 2007). 
Cytokines are released at the site of bone remodeling by osteoblasts to recruit the 
osteoclasts from their mononuclear precursors, allowing them to adhere to the bone 
surface (Teitelbaum, 2007). Osteoclasts release hydrogen ions that create an acidic 
microenvironment, dissolving the mineralised component, which is degraded by 
Cathepsin k (Wilson et al., 2009). Subsequently, the reversal phase, the switch from 
degradation, to synthesis, begins by osteoblast (Andersen et al., 2013) and lining cells 
(Delaisse, 2014) preparing the bone surface for new osteoblasts, derived from 
mesenchymal cells, followed by the secretion by osteoblasts of bone matrix proteins, 
called osteoid, that become mineralized to form new bone (Karsenty et al., 2009). As 
the osteoblasts continue to differentiate, 5 to 20 % of mature osteoblasts become 
entombed in the matrix that they generate and subsequently mineralizes, and some 
are restored on the bone surface, others differentiate into either osteocytes or bone 
surface lining cells (Bellido, 2014) (Figure 1-2). These delicate interrelationships can 
become unbalanced and lead to conditions such as osteoporosis. 
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Figure 1-2: Bone remodelling (build up/break down): 
a) Resorption: Stimulated osteoclasts erode bone, creating a cavity. b) Reversal: 
osteoblastic reversal cells (osteoblasts and lining cells) prepare bone surface for 
osteoblasts to begin forming bone. c) Formation: Osteoblasts replace resorbed bone 
and fill the cavity with new bone d) Resting: Bone surface rests until a new 
remodeling cycle begins. 
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1.2 Osteoporosis 
Osteoporosis is the most common bone disease worldwide (Johnell and Kanis, 2006), 
characterized by unbalanced bone remodeling (Kanis, 1994), low bone mass and 
altered bone architecture leading to increased susceptibility to bone fragility (Kanis 
et al., 1997), as shown in Figure 1-3B, reduced mobility and altered quality of life 
(Svedbom et al., 2013). Osteoporosis occurs when the activity of bone-resorbing 
osteoclasts surpasses that of bone-forming osteoblast (Bell et al., 1999).  
 
 
Figure 1-3: Diagrammatic difference between normal bone tissue (trabecular) and 
Osteoporotic Bone tissue.  
Courtesy of Prof Alan Boyde (Queen Mary University of London)  
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1.2.1 Epidemiology 
An overall estimate of incidence of osteoporotic fractures worldwide is more than 
8.5 million persons aged over 50 years (Johnell and Kanis, 2006), with approximately 
3.5 million in the 27 countries of the European Union (EU27) (Hernlund et al., 2013), 
and one third (34%) of osteoporotic sufferers are men (Hernlund et al., 2013). The 
estimated ratio of these cases in the UK alone is about one in two women and one in 
five men over the age of 50 years, with annual cost to health service of around £3.5 
billion of direct cost of treatment and long term fracture care (Svedbom et al., 2013) 
and the costs are expected increase 25% by year 2025 (Hernlund et al., 2013). 
According to a study conducted in 2010, 536,000 new osteoporotic fragility fractures 
occur each year in the UK, including 79,000 hip fractures, 69,000 forearm fractures, 
66,000 vertebral fractures and 322,000 other fractures (pelvis, rib, humerus, tibia, 
fibula, clavicle, scapula, sternum and other femoral fractures) (Svedbom et al., 2013).  
1.2.2 Burden of Osteoporotic Fracture 
Nearly 75% of all hip fractures occur in women (Jordan and Cooper, 2002), and 
around 53% of patients suffering a hip fracture can no longer live independently and 
28.7% die within 12 months of the fracture.  
Ethnic differences could attribute in bone resistance to fracture. Black, Hispanic and 
Asian people in the USA have lower fracture rates than Caucasians (Wright et al., 
2012, Cauley et al., 2011), and in the UK, black individuals have lower rates of fragility 
fracture than Caucasians, see (Figure 1-4) (Curtis et al., 2016). 
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Figure 1-4: Incidence of hip/femur and fragility fractures (all types) by ethnicity in 
men and women aged over 50 years in the UK. 
Chart adopted from (Curtis et al., 2016) 
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1.2.3 Diagnosis 
1.2.3.1 Dual-energy X-ray Absorptiometry (DXA) 
The diagnosis of osteoporosis can be made using conventional radiography (X-ray 
absorptiometry) and by measuring the bone mineral density (BMD), the amount of 
bone mass per unit area (areal density, g/cm2) or per unit volume (volumetric 
density, g/cm3), using the Dual-energy X-ray (DXA) (Kanis and Johnell, 2005) and high 
resolution peripheral quantitative computed tomography (HR-pQCT) (Nishiyama et 
al., 2013). However, DXA is the most common technique used for assessing the risk 
of osteoporosis (Kanis, 1994). 
The WHO study group (Simon and Mack, 2003), based on the DXA diagnostically, 
categorised women into four general groups. The first group is considered normal if 
the BMD value is within 1 standard deviation (SD) of the young female adult 
reference mean (T-score ≥ -1). The second group is osteopenia, bone condition with 
BMD less than normal and greater than osteoporosis, if the value of the BMD is <-1 
and >-2.5 SD. The third group is diagnosed as osteoporosis, if the value of the BMD is 
T-score ≤ -2.5 SD, and the last group is a severe osteoporosis, if the value of the BMD 
is  -2.5 SD in the presence of one or more fragility fractures (Kanis, 1994, Simon and 
Mack, 2003). Current guidelines favour the measurement of BMD at both the femoral 
neck and at the lumbar spine and patients are defined as having osteoporosis based 
on the lower of the two T-scores so obtained (Compston et al., 2017). 
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1.2.3.2 Fracture Risk Assessment 
The risk of fracture increases approximately 3-fold for each SD decrease in BMD, but 
the rise of risk varies according to the patient’s age, the site of fracture, the technique 
used to assess fragility fracture and the outcome of multiple risk factors (Johnell et 
al., 2005, Compston et al., 2017). This includes the sex of patient, ethnicity, number 
of previous falls, smoking, disorders associated with osteoporosis such as alcohol 
intake, use of glucocorticoids, diagnosis of rheumatoid arthritis and  disorders 
strongly associated with osteoporosis such as inflammatory bowel disease, 
endocrine disorders and diabetes (Compston et al., 2017, Rossini et al., 2016), using 
established WHO fracture risk assessment prediction tools, such as FRAX®, 
QFractureScores®, and the Garvan Institute fracture calculator (Das and Crockett, 
2013, Sandhu and Hampson, 2011). 
1.2.3.3 Bone Turnover Markers 
Diagnosis of osteoporosis is made by doing routine blood tests for calcium, 
phosphorus, non-specific alkaline phosphatase, oestrogen, Vitamin D and 
parathyroid hormone levels (Jones et al., 1998, Vieth et al., 2003), as well as the 
biochemical assessment based on bone resportion, such as serum and urine level of 
type I collagen C- (CTX) and N-telopeptides (NTX) and urine level of pyridinolines 
(PYD) and deoxypyridinolines (DPD) (Emami et al., 1999, Ohishi et al., 1998), tartrate-
resistant acid phosphatase (TRAcP) (Stoffel et al., 2007) and cathepsin K (Karsdal et 
al., 2005, Holzer et al., 2005), as well as indices for bone formation markers such as 
bone specific ALP (Bowles et al., 1997), osteocalcin (Veitch et al., 2006, Stoffel et al., 
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2007), serum and urine level of type I collagen C- (PICP) (Veitch et al., 2006, Bone, 
1992), N-telopeptides (PINP) ((Hanson et al., 1992) (Table 1-1). 
Table 1-1: Biochemical Bone Turnover Markers (BTM) commonly used in clinical 
practice 
Table was adapted from (Vasikaran et al., 2011, Sandhu and Hampson, 2011) 
Bone Turnover Markers (BTM)  Analytical body fluid 
sample 
Bone resorption markers 
 
Pyridinoline (PYD) Urine 
Deoxypyridinoline (free DPD, total DPD) Urine 
C-terminal crosslinked telopeptide (S-bCTX, CTX) Urine and serum/plasma 
Carboxyterminal telopeptide of type I collagen 
(ICTP) 
Serum 
N-terminal crosslinked telopeptide (NTX) Urine and serum/plasma 
Tartrate resistant acid phosphatase – 5b (TRAcP-
5b) 
Serum 
Bone formation markers 
 
Procollagen type I C-terminal propeptide (PICP) Serum 
Procollagen type I N-terminal propeptide (PINP) Serum/plasma 
Bone Alkaline Phosphatase (Bone ALP) Serum 
Osteocalcin (OC): intact, total, or 
undercarboxylated 
Serum/plasma/Urine 
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1.2.3.3.1 Biochemical Markers of Bone Resorption  
1.2.3.3.1.1 Pyridinoline and deoxypyridinoline  
The collagen crosslinks, pyridinoline (PYD) and deoxypyridinoline (DPD) are found in 
fibril-forming types of collagen (types I, II and III), formed during the extracellular 
maturation of fibrillar collagens and are released into the circulation as degradation 
products of mature collagen (Naylor and Eastell, 2012, Seibel, 2005). Crosslinked 
collagens are proteolytically broken down and the crosslinked components are 
released into the circulation and the urine (Seibel, 2005). DPD is almost solely found 
in bone (Naylor and Eastell, 2012), while PYD is found in cartilage (Naylor and Eastell, 
2012). Therefore, the ratio of DPD/PYD is higher in bone compared to other tissues. 
Crosslinked collagens can be measured accurately in urine by high-performance 
liquid chromatography (HPLC) and free DPD can be measured by ELISA (Kamel et al., 
1995, Naylor and Eastell, 2012). In addition, the measurement of urinary crosslinked 
collagen is not affected by dietary sources, and is currently considered the best index 
for assessing bone resorption (osteoporosis, Paget’s disease of bone, vitamin D 
deficiency, hyperparathyroidism, corticosteroid therapy, etc.) (Seibel, 2005). 
1.2.3.3.1.2 C-telopeptide of type-I collagen (CTX) and N-telopeptide of type-I collagen 
(NTX) 
The carboxy- and amino-terminal (NTX) cross-linked telopeptides (CTX and NTX) are 
collagen type I peptide fragments, that are released into the blood circulation during 
the bone resportion process (Seibel, 2005). Serum/plasma CTX was recommended 
by the International Osteoporosis Foundation (IOF) to be used as a reference marker 
for bone turnover (Vasikaran et al., 2011). The elevated serum concentration of CTX 
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has been reported in patients with increased bone resorption, compared to patients 
taking bisphosphonate antiresorptive therapy (Christgau et al., 2000). However, its 
contribution to the diagnosis of osteoporosis is low (Mohamed et al., 2014), and the 
technique is used mainly for therapeutic monitoring. 
1.2.3.3.1.3 The Carboxy-terminal Telopeptide of type-I collagen (ICTP) 
C-terminal crosslinking telopeptide of type I collagen (ICTP) is separated from 
collagen by metalloproteinases (MMP-2, -9, -13, or -14) and is measured by 
Radioimmunoassay (Risteli et al., 1993). The assay has been shown to be sensitive 
for pathological bone resorption, such as in multiple myeloma and metastatic bone 
disease (Seibel, 2005). Serum ICTP level has been shown to be elevated after 
osteoporotic fragility fracture in patients (Takahara et al., 2007). 
1.2.3.3.1.4 Enzymes derived from osteoclasts 
TRAcP 5b is a member of the acid phosphatase family, that is resistant to inhibition 
by tartrate and is expressed by osteoclast cells (Halleen et al., 2006). The elevated 
level of serum TRAP 5b level has been associated with increased fracture risk for up 
to a decade in elderly women (Ivaska et al., 2010), and found to be a useful 
therapeutic monitoring marker for anti-resorptive treatment (Nenonen et al., 2005). 
However, its activity has be found to be increased in patients with bone metastases 
from cancers in other tissues (Chao et al., 2010). 
Cathepsin K, a member of the peptidase C1 protein family, is a proteolytic enzyme 
that is abundant in osteoclasts (Saftig et al., 1998) that plays a vital role in the 
degradation of bone type I collagen (Atley et al., 2000) and may participate partially 
in the disorder of bone remodelling. Circulating serum cathepsin K expression has 
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been shown to be higher in osteoporosis & Paget’s disease patients (Meier et al., 
2006), as well as in rheumatoid arthritis compared to healthy subjects (Skoumal et 
al., 2005). In contrast, there was no significant difference in serum cathepsin K level 
between four study groups (postmenopausal: healthy women, osteoporosis, 
osteopenia; premenopausal: healthy women) (Adolf et al., 2012). Therefore, further 
clinical evaluation is required for this potential biomarker (Naylor and Eastell, 2012). 
1.2.3.3.2 Biochemical markers of bone formation 
Formation markers, products of osteoblast activity, are expressed during different 
phases of osteoblast differentiation and extracellular matrix maturation (Naylor and 
Eastell, 2012), and they are particularly useful for monitoring bone formation 
therapies and antiresorptive therapies (Eastell et al., 2006, Vasikaran et al., 2011). 
1.2.3.3.2.1 Propeptides of type I procollagen 
Procollagen type I propeptides are derived from collagen type I, which is the most 
common collagen type found in mineralized bone (Krieg et al., 1988). The formation 
of procollagen type I requires the cleavage of propeptides: procollagen type I C-
terminal (PICP) and N-terminal (PINP) (Francini et al., 1993). Both propeptides (PICP 
and PINP) are released into the circulation (Francini et al., 1993) and their 
concentrations reflect the synthesis rate of collagen type I (Francini et al., 1993). PINP 
is considered to be the most sensitive marker of bone formation(Naylor and Eastell, 
2012); it can be measured by radioimmunoassay (Melkko et al., 1996) and is primarily 
used for osteoporosis antiresorptive therapeutic monitoring (Eastell et al., 2006). 
However, the direction of diagnostic interpretation depends on the antiresorptive 
therapy used. For instance, there was an increased level of serum procollagen type I 
Chapter 1: Introduction 
18 | P a g e  
 
propeptides (PINP) in >20% in osteoporosis patients after 3-6 months of teriparatide 
therapy, which indicated an adequate therapeutic response (Eastell et al., 2006). In 
contrast, there was a decreased PINP level of up to 70% from baseline after 6 months 
of therapy in patients taking bisphosphonate therapy (McClung et al., 2005). 
1.2.3.3.2.2 Non-collagenous proteins 
1.2.3.3.2.2.1 Bone specific Alkaline Phosphatase (BALP) 
Alkaline Phosphatases (ALP) are membrane-bound glycoproteins produced by 
various tissues (liver, bone, intestine, placenta and kidney) (Weiss et al., 1986, Seibel, 
2005). Bone ALP (BALP) represent approximately 50% of total ALP activity in adults 
with normal liver function, whereas up to 90% arises from bone in children and 
adolescents (Seibel, 2005). BALP are more specific for bone formation than total ALP 
and is used to assess clinical conditions such as osteoporosis, Paget’s disease and 
chronic kidney disease (Naylor and Eastell, 2012). However, cross-reactivity between 
liver and bone ALP (up to 20%) could happen in some clinical conditions, such as the 
case with biliary obstruction (Seibel, 2005). 
1.2.3.3.2.2.2 Osteocalcin (OC)  
Osteocalcin (OC) is a non-collagen protein that binds to hydroxyapatite deposited in 
the bone matrix, that is synthesized by osteoblasts  and hypertrophic chondrocytes 
(Seibel, 2005), and is widely accepted as a specific marker of bone osteoblastic 
activity (Brown et al., 1984). After its release from osteoblasts, much of the 
osteocalcin is incorporated into the extracellular bone matrix (EBM), but some is 
released to the circulation, where it can be detected by immunoassay (Seibel, 2005). 
Decreased level of osteocalcin was observed in postmenopausal osteoporosis and 
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osteopenia patients after 6 to 12 months of hormone replacement therapy (HRT) 
based on percent baseline changes in lumbar BMD (Chen et al., 1996) and in patients 
taking antiresorptive agents (bisphosphonates or hormone replacement therapy) of 
> 20% from baseline after 3 to 6 months of therapy (Delmas et al., 2000). Indeed, 
elevated levels of osteocalcin could be released during osteoclastic bone resorption 
as well as during bone formation (Cloos and Christgau, 2004). However, biological 
variation has been encountered when different methodologies were used (Seibel et 
al., 2001). 
1.2.3.3.3 Limitations of Current Bone Turnover Marker (BTM) Measurement 
The use of BTM as routine markers remains a challenge due to their broad biological 
and analytical variation, even with identical assays and methods, which may be as 
much as a 7.3-fold difference (Sandhu and Hampson, 2011). The study was 
conducted by (Seibel et al., 2001) between 73 laboratories using two serum and two 
urine pools from several healthy volunteers and tested  eight different bone turnover 
markers: bone-specific alkaline phosphatase (ALP), serum osteocalcin (OC), urinary 
free and total deoxypyridinoline (DPD), urinary pyridinoline, urinary N-terminal 
crosslinked telopeptide (NTX), serum C-terminal telopeptide of type I collagen (ICTP) 
and urinary hydroxyproline (Seibel et al., 2001). 
1.2.3.3.3.1 Non-modifiable Preanalytical Variability 
There are two main groups of confounding factors for BTMs’ pre-analytical 
variability: Non-modifiable and modifiable factors (Naylor and Eastell, 2012). The 
non-modifiable factor includes: age, sex and ethnicity/race, geographical location, 
medication such as glucocorticoids, antiresorptive drugs (bisphosphonates, selective 
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estrogen receptor modulators [SERMs], hormone replacement therapy [HRT]) and 
hormonal contraceptives; diseases such as primary hyperparathyroidism, Paget’s 
disease, myeloma, Inflammation (RA), chronic kidney disease and liver disease 
(Naylor and Eastell, 2012). 
1.2.3.3.3.2 Modifiable Preanalytical Variability 
The modifiable factors include circadian rhythms, which are more noticeable for 
bone turnover markers than those of bone formation. For instance, mean 
concentrations of Beta-CTX were higher 66%  in samples obtained in the early hours 
of the morning (0130 and 0430) than in samples obtained in the late morning and 
afternoon (1100 and 1500) (Wichers et al., 1999). Further modifiable factors include 
seasonal changes, stage of menstrual cycle of the subject, level of exercise and finally 
meal intake are also confounding factors for the biological variability. It has been 
noticed that patients have reduced serum CTX‑I levels (20%) 1 hour after breakfast, 
attributed to the production of the gut hormone, glucagon-like peptide 2 (GLP-2) 
(Henriksen et al., 2003).     
In conclusion, the existing biomarkers are unsatisfactory in many respects; they are 
not useful diagnostic tool for osteoporosis (Sandhu and Hampson, 2011, Vasikaran 
and Chubb, 2016) and their best-established clinical use is in monitoring treatment 
efficacy and compliance (Sandhu and Hampson, 2011). In addition, variation of 
reported levels of BTM has been encountered between clinical laboratories using 
identical assays and methods (Seibel et al., 2001), and a very abnormal BTM value 
may be a clue to the presence of bone pathology other than uncomplicated 
osteoporosis (Vasikaran and Chubb, 2016). 
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1.2.4 RNA 
A key step in the production of any protein is transcription of Ribonucleic acid (RNA) 
and then its translation to peptides, however, RNA is no established to have a 
number of essential roles in a number of biological processes such as coding, 
decoding, regulation, and expression of genes (Alberts et al., 2015).  
The most well characterised forms of RNA are single stranded messenger RNA, 
transfer RNA and ribosomal RNA (mRNA, tRNA, rRNA). mRNA carries the code for 
protein structure from the DNA to ribosomes where it can be used to produce 
proteins, tRNA decodes the message in mRNA by matching amino acids to the mRNA 
code, and ribosomal RNA (rRNA) form the structure of the ribosome (Alberts et al., 
2015). 
Recently, new types of protein non-coding small silencing RNAs that guided complex 
and diverse organisation of  gene regulation in plants and animals were identified 
(Ghildiyal and Zamore, 2009), such as microRNAs (miRNAs), small interfering RNAs 
(siRNAs) and Piwi-interacting RNAs (piRNAs).  
MiRNAs that were discovered have wide and far reaching biological regulatory 
actions (He and Hannon, 2004) and, as we will see may provide a new source of 
diagnostically useful biomarkers for bone diseases (Hackl et al., 2016, Lian et al., 
2012, van Wijnen et al., 2013). 
1.2.4.1 MicroRNAs 
MicroRNAs (miRNAs) are endogenous non-coding RNA molecules of small size, 
approximately 21-23 nucleotides, that are involved in diverse signalling pathways, 
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including control of cellular developmental timing, proliferation, differentiation and 
apoptosis (Bartel, 2004, Ambros, 2004).  
miRNAs post-transcriptionally down regulate the expression of up to 60% of human 
protein-coding genes, either by translation inhibition of target messenger RNA 
(mRNA) (Li et al., 2013) or promoting mRNA degradation and/or directly interfering 
with protein translation (Friedman et al., 2009, Bartel, 2009) (Figure 1-5 (Guay and 
Regazzi, 2013).  
However, there is evidence indicating that miRNAs can also activate translation 
(Vasudevan et al., 2007), through the AU-rich elements (AREs) binding protein, HuR, 
and its related family of ELAV proteins and conserved miRNA target sites in mRNA 3' 
untranslated regions (3'UTRs). They may also induce positive transcriptional 
regulation of mRNAs, directly or indirectly, in conjunction with associated effector 
proteins (microribonucleoproteins, microRNPs) (Vasudevan, 2012, Valinezhad Orang 
et al., 2014), by targeting sites in gene promoter regions (Place et al., 2008).  
Notably, a single miRNA can regulate many different protein coding genes and a 
single gene can be targeted by a group of miRNAs, providing fine-tuning of a single 
mRNA target expression (Doench and Sharp, 2004, Lewis et al., 2003). 
A miRNA is produced from a stem-loop RNA precursor that is generated from an 
independent transcriptional unit or from an intron of a genes that encodes a protein 
(Rodriguez et al., 2004), transcribed by either RNA polymerase II (Lee et al., 2004) or 
RNA polymerase III (Cai et al., 2004, Borchert et al., 2006) into a primary miRNA 
transcript (pri-miRNA), which is then processed by the endonuclease Drosha into an 
approximately 70nt hairpin structure (precursor miRNA) (Lee et al., 2003, Cullen, 
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2004). This is then exported to the cytoplasm via an Exportin‑5-dependent process 
(Guay and Regazzi, 2013, Ruby et al., 2007).  
The resulting short hairpin RNA (precursor miRNA) undergoes cleavage by Dicer and 
gives rise to a short mature miRNA-duplex (Winter et al., 2009) and generates 
imperfect miRNA duplexes consisting of a guide strand (miRNA) and passenger strand 
miRNA, termed miRNA* (Cifuentes et al., 2010). After strand separation, either the 
5’ (miRNA-5p) or 3’ (miRNA-3p) region of the miRNA becomes selectively 
incorporated into the miRNA induced silencing complex (miRISC) (Bartel, 2009) and 
guides translational repression by pairing with specific partially complementary 3′-
UTR regulatory elements of the target mRNAs (Ambros, 2001).  
Alternatively, the miRNA can be released by the cell with the mature miRNA bound 
to RNA-binding proteins such as Argonaute-2 (Arroyo et al., 2011) or to lipoproteins 
(Vickers et al., 2011). The other strand miRNA*, is degraded. Or else, miRNAs can be 
loaded in microvesicles (Kosaka et al., 2010) formed by plasma membrane blebbing 
or in exosomes (Taylor and Gercel-Taylor, 2008, Valadi et al., 2007) that are released 
into the extracellular space upon exocytic fusion of multivesicular bodies with the 
plasma membrane (Guay and Regazzi, 2013). 
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Figure 1-5: miRNA Biogenesis.  
(1) Ribonuclease III Drosha enzyme cleaves the Pri-miRNA into Pre-miRNA. (2) The 
pre-miRNA is transported into the cytoplasm by Exportin 5. (3) It further cleaved by 
Dicer enzyme yielding 21-23 nucleotide duplexes. (4) One strand can associate to the 
RNA Induced Splicing Complex (RISC) and guide translational repression of target 
mRNAs or (5) Released by the cell and the mature miRNA binds to RNA-binding 
proteins such as Argonaute-2 or (6) to lipoproteins. (7) Alternatively, the miRNA can 
be loaded in microvesicles formed by plasma membrane blebbing or in (8) into 
exosomes that are released in the extracellular space upon exocytic fusion of 
multivesicular bodies with the plasma membrane. This figure was taken from (Guay 
and Regazzi, 2013). 
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1.2.4.1.1 Role of miRNA in skeletal development and disease 
Many reports have highlighted the involvement of miRNAs as key regulators of 
osteoblast-mediated bone development, homeostasis (Lian et al., 2012, Sera and Zur 
Nieden, 2017) and bone remodelling (van Wijnen et al., 2013, Lian et al., 2012) (Table 
1-2). Furthermore, it has been shown that cytokines and hormones that are involved 
in bone development and bone remodeling, such as bone morphogenic protein 
(BMP) (Salazar et al., 2016), RANKL (Kagiya and Nakamura, 2013) and estrogen 
(Sugatani and Hruska, 2013, An et al., 2013), have impact in miRNA expression. 
1.2.4.1.2 Circulating miRNA as Osteoporosis Biomarkers 
Studies on circulating miRNAs in patients with bone diseases have only recently been 
reported  (Hackl et al., 2016) (Table 1-2). Some of the pilot studies were restricted to 
circulating monocytes, as these are the cells that can differentiate into osteoclasts 
and secrete osteoclastogenic factors (Cao et al., 2014, Wang et al., 2012c), while 
some studies were conducted on serum/plasma samples of postmenopausal women 
with low bone mineral density (BMD) compared to postmenopausal women with 
normal BMD (Li et al., 2014, Yavropoulou et al., 2017) and on osteoporotic fractured 
patients compared to control groups (Panach et al., 2015, Seeliger et al., 2014, 
Weilner et al., 2015). In addition, one study was conducted on whole blood of 
postmenopausal women with low BMD compared to postmenopausal women with 
normal BMD (Meng et al., 2015). 
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Table 1-2: Overview of studies on miRNA expression in blood circulation and bone tissues in the context of human osteoporosis 
miRNAs Specie (s) Target gene(s) Endogenous miRNA 
expression 
miRNA function Related disease(s) References 
133a-3p Mouse C2C12 
mesenchymal 
cells 
Human 
monocytes and 
plasma 
Runx2, 
CXCL11, 
CXCR3 and 
SLC39A1 
Upregulated in 
monocytes and plasma 
of osteoporosis 
patients 
Inhibits osteogenesis Osteoporosis (Mencia 
Castano et al., 
2016, Wang et 
al., 2012c, Li et 
al., 2014, Li et 
al., 2008) 
let-7g-5p Human 
adipose-
derived 
stromal/stem 
cells (hADSCs) 
human 
mesenchymal 
stem cells 
(hMSCs) 
HMGA2 
Not 
mentioned 
Downregulated in the 
serum of patients with 
osteoporosis. 
Promotes osteogenic 
differentiation 
Osteoporosis (Wei et al., 
2014, Weilner 
et al., 2015) 
miR-100-
5p 
Human 
adipose-
derived 
mesenchymal 
stem cells 
(hASCs) 
BMPR2 Upregulated in the 
serum of osteoporotic 
fractured patients 
Inhibits osteogenic 
differentiation 
Osteoporosis (Zeng et al., 
2012a, 
Seeliger et al., 
2014) 
miR-10a-
5p 
Human 
Unrestricted 
somatic stem 
Not 
mentioned 
Upregulated in the 
serum of patient with 
osteoporosis  
Upregulated during 
osteogenic differentiation 
Osteoporosis (Trompeter et 
al., 2013, 
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miRNAs Specie (s) Target gene(s) Endogenous miRNA 
expression 
miRNA function Related disease(s) References 
cells (USSC, 
SA5/73 and 
SA8/25) and 
hMSCs 
Weilner et al., 
2015) 
miR-10b-
5p 
human hMSCs Not 
mentioned 
Upregulated in the 
serum of osteoporotic 
fractured patients 
Upregulated during 
osteogenic differentiation 
Osteoporosis (Weilner et al., 
2015) 
miR-122-
5p 
Mouse bone 
mesenchymal 
stem cells 
(MSCs) 
Human serum 
Tbr1 
Not 
mentioned 
Upregulated in 
patients with 
osteoporotic fracture 
Downregulate the 
expression of bone 
mesenchymal stem cells 
Osteoporosis  (Yang et al., 
2017, Seeliger 
et al., 2014, 
Panach et al., 
2015) 
miR-124-
3p 
Mouse BMMs 
Human serum 
NFATc1 
Not 
mentioned 
Upregulated in the 
serum of patients with 
osteoporotic fracture 
Inhibits osteoclast 
differentiation 
Osteoporosis  (Lee et al., 
2013, Seeliger 
et al., 2014, 
Yavropoulou 
et al., 2017) 
miR-125a  human CD14+ 
peripheral 
blood 
mononuclear 
cell (PBMC) 
TRAF6  Dramatically 
downregulated during 
osteoclastogenesis 
Inhibit osteoclastogenesis  May be involved in 
metabolic disease  
(Cheng et al., 
2013, Guo et 
al., 2014) 
miR-125b-
5p 
mouse MSCs 
Human 
Lin-28 
Not 
mentioned 
Upregulated in the 
serum of patients with 
osteoporosis 
Inhibits osteogenic 
differentiation 
Osteoporosis  (Mizuno et al., 
2008, Seeliger 
et al., 2014, 
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miRNAs Specie (s) Target gene(s) Endogenous miRNA 
expression 
miRNA function Related disease(s) References 
Panach et al., 
2015) 
miR-130b-
3p 
Human 
(Osteosarcoma 
cell line) 
NKD2 Upregulated in the 
whole blood of 
patients with 
osteoporosis 
targets NKD2 and 
regulates the Wnt 
signalling to promote 
proliferation and inhibit 
apoptosis of OS cells 
Osteosarcoma (Li et al., 
2016c) 
miR-133a Human PBMCs Not 
mentioned 
Upregulated in the 
monocytes of low 
BMD postmenopausal 
women 
Not mentioned Postmenopausal 
osteoporosis 
(Wang et al., 
2012c) 
miR-133b Mouse C2C12 
MSCs 
Human serum 
Runx2 
Not 
mentioned 
upregulated in the 
plasma of patients 
with osteoporosis, in 
contrast 
it shown to be 
downregulated in the 
serum of patients with 
osteoporosis by 
Weilner et al 2015 
Inhibits osteogenic 
differentiation via Runx2 
Osteoporosis (Li et al., 2008, 
Weilner et al., 
2015, Li et al., 
2014) 
miR-143-
3p 
Mouse C2C12 
MSCs 
Human serum 
MyoD, MyoG, 
myf5, and 
MyHC 
Not 
mentioned 
Upregulated in the 
serum of patients with 
osteoporosis 
Upregulated during 
myoblast differentiation 
Osteoporosis (Panach et al., 
2015, Du et al., 
2016) 
Chapter 1: Introduction 
30 | P a g e  
 
miRNAs Specie (s) Target gene(s) Endogenous miRNA 
expression 
miRNA function Related disease(s) References 
miR-148a  Human CD14+ 
PBMCs, mouse 
C57BL/6 
ovariectomized 
MAFB Upregulated during 
osteoclast 
differentiation  
Unregulated in serum 
of osteoporotic 
fractured patients 
Upregulated in plasma 
of osteoporosis 
women  
Promote 
osteoclastogenesis  
Osteoporosis, 
contributes to low 
BMD in lupus 
patients 
(Seeliger et al., 
2014, Cheng et 
al., 2013, Liu et 
al., 2015, 
Bedene et al., 
2016) 
miR-151a-
3p 
Human whole 
blood 
Not 
mentioned 
Upregulated in the 
whole blood of 
patients with 
osteoporosis 
Not mentioned Osteoporosis  (Meng et al., 
2015) 
miR-155  mouse RAW 
264.7 Cells, 
mouse with 
Dicer 
deficiency in 
osteoclasts 
(cKO mutant), 
C57BL/6, IFNb 
and IFNAR1 
deficient 
mice 
SOCS1, MITF, 
SHIP 
RANKL treatment 
suppress miR-155 
levels in BMMs from 
Dicer-deficient mice 
Suppress osteoclast 
differentiation  
Osteoclast-mediated 
diseases 
(Mizoguchi et 
al., 2010, 
Mann et al., 
2010, Zhang et 
al., 2012) 
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miRNAs Specie (s) Target gene(s) Endogenous miRNA 
expression 
miRNA function Related disease(s) References 
miR-194-
5p 
Human whole 
blood 
Not 
mentioned 
Upregulated in the 
whole blood of 
patients with 
osteoporosis 
Not determined Osteoporosis (Meng et al., 
2015) 
miR-210-
3p 
Human serum 
and bone 
metastasis 
tissue 
NFKB1 Upregulated in bone 
metastasis 
Downregulated in the 
serum of osteoporotic 
fractured patients 
activation of NF-κB 
signalling pathway 
Prostate Cancer Bone 
metastasis  
Osteoporosis 
(Panach et al., 
2015, Ren et 
al., 2017) 
miR-21-5p wild-type (wt), 
ER deficient, 
C57BL/6J, 
DGCR8- 
floxed 
(DGCR8F/F) 
and MiR-21 
floxed (miR-
21f/f) mice  
human serum 
FasL & PDCD4 
Not 
mentioned 
Upregulated in RANKL-
induced 
osteoclastogenesis 
Promotes osteogenic 
differentiation and 
impairs adipogenic 
differentiation 
Downregulated in the 
serum of Low BMD 
compared to control 
Enhances osteoclast 
differentiation & Inhibits 
osteoclast apoptosis 
Postmenopausal 
osteoporosis 
(Sugatani et 
al., 2011, 
Sugatani and 
Hruska, 2013) 
(Trohatou et 
al., 2014, 
Seeliger et al., 
2014, 
Yavropoulou 
et al., 2017) 
miR-223  mouse 
RAW264.7 
cells 
human 
rheumatoid 
arthritis (RA) 
Not 
mentioned  
NFIA  
Downregulated in 
osteoclast 
differentiation  
Downregulated in 
osteoclast 
differentiation  
Overexpression 
completely blocks 
osteoclast formation 
Inhibits osteoclast 
differentiation  
Might be related to 
bone metabolic 
disorders 
Bone destruction in 
rheumatoid arthritis 
(Kagiya and 
Nakamura, 
2013, Sugatani 
and Hruska, 
2007) 
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miRNAs Specie (s) Target gene(s) Endogenous miRNA 
expression 
miRNA function Related disease(s) References 
synovium and 
PBMC 
(Shibuya et al., 
2013) 
miR-22-3p Human 
Unrestricted 
somatic stem 
cells (USSC) 
and serum 
Not 
mentioned 
Upregulated in the 
serum of patients with 
osteoporosis 
Upregulated during 
osteogenic differentiation 
Osteoporosis  (Trompeter et 
al., 2013, 
Weilner et al., 
2015) 
miR-23a-
3p 
Mouse 
preosteoblast 
Cell line 
MC3T3-E1 
Human serum 
SATB2 Upregulated in the 
serum of osteoporotic 
fractured patients 
Inhibits osteogenic 
differentiation via SATB2 
Osteoporosis (Hassan et al., 
2010, Seeliger 
et al., 2014) 
miR-24-3p Mouse 
preosteoblast 
Cell line 
MC3T3-E1 
Human serum 
SATB2 
Not 
mentioned 
Upregulated in 
patients with 
osteoporotic fracture 
Inhibits osteogenic 
differentiation via SATB2 
Osteoporosis  (Hassan et al., 
2010, Seeliger 
et al., 2014) 
miR-29  Mouse 
monocytic cell 
line RAW264.7 
CDC42, 
SRGAP2, NFIA, 
CD93, CALCR 
Increased during 
osteoclast 
differentiation  
miR-29 family member 
that sustains migration 
and commitment of 
precursors to 
osteoclastogenesis  
Possibly related to 
increased osteoclast 
formation with aging 
(Franceschetti 
et al., 2013) 
miR-29a  Rat bone tissue Not 
mentioned  
Reduced expression in 
glucocorticoid-induced 
bone loss 
Inhibits GC-induced 
osteoclast differentiation 
Glucocorticoid-
induced bone loss 
(Wang et al., 
2013) 
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miRNAs Specie (s) Target gene(s) Endogenous miRNA 
expression 
miRNA function Related disease(s) References 
miR-29b  human PBMCs c-Fos, MMP2  Downregulated in 
RANKL induced 
osteoclastogenesis 
Inhibits osteoclast 
differentiation  
Multiple myeloma-
related bone disease 
(Rossi et al., 
2013) 
miR-31 mouse bone 
marrow-
derived 
macrophages 
(BMM) 
RhoA Highly upregulated 
during osteoclast 
development upon 
RANKL stimulation 
promote ring-shaped 
mature osteoclasts 
formation, attributed to 
cytoskeleton organization 
Not mentioned (Mizoguchi et 
al., 2013) 
miR-328-
3p 
Human serum Not 
mentioned 
Downregulated in the 
serum of patients with 
osteoporotic fracture 
Not mentioned Osteoporosis  (Weilner et al., 
2015) 
miR-34a-
5p 
Mouse 34a- 
Tie2-Tg 
cultures 
Human bone 
tissues and 
serum 
Tgif2 
Not 
mentioned 
Downregulated during 
osteoclast 
differentiation 
blocks osteoporosis and 
bone metastasis by 
inhibiting 
osteoclastogenesis and 
Tgif2 
Osteoporosis, 
osteosarcoma  
(Krzeszinski et 
al., 2014) 
(Wang et al., 
2015c, Panach 
et al., 2015) 
miR-378 Mouse 
RAW264.7 and 
MOCP-5 cells 
Not 
mentioned 
Upregulated in 
osteoclast 
differentiation 
Not mentioned Osteolytic bone 
metastasis 
(Kagiya and 
Nakamura, 
2013, Ell et al., 
2013) 
miR-422a  human 
monocytes 
CBL, CD226, 
IGF1, PAG1, 
TOB2 
Upregulated with 
marginal significance 
in the low BMD 
Not mentioned  Osteoporosis (Cao et al., 
2014) 
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miRNAs Specie (s) Target gene(s) Endogenous miRNA 
expression 
miRNA function Related disease(s) References 
postmenopausal 
women 
miR-503 human PBMCs RANK Markedly reduced in 
postmenopausal 
osteoporosis women 
Inhibits RANKL-induced 
osteoclast differentiation 
osteoporosis (Chen et al., 
2014a) 
miR-590-
5p 
Human 
mesenchymal 
stem cells 
(HMSCs) and 
whole blood 
APC Upregulated in the 
whole blood of 
patients with 
osteoporosis 
Upregulated during 
osteogenic differentiation 
Osteoporosis (Wu et al., 
2016, Meng et 
al., 2015) 
miR-660* Human whole 
blood 
Not 
mentioned 
Upregulated in 
postmenopausal 
osteoporosis women 
Not mentioned osteoporosis (Meng et al., 
2015) 
miR-93 Mouse 
C57BL/6 cells 
Human serum 
Sp7 
Not 
mentioned 
Upregulated in the 
serum of osteoporotic 
fractured patients 
Attenuates osteoblast 
mineralization 
Osteoporosis (Yang et al., 
2012, Seeliger 
et al., 2014) 
*Not validated 
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1.2.4.2 miRNAs as biomarkers. 
miRNAs can pass into the blood or other body fluids with potential paracrine or 
endocrine functions and can be monitored as biomarkers for a multitude of disease 
states (Mitchell et al., 2008, Gennari et al., 2016) and could be promising novels 
biomarkers for bone diseases diagnosis (van Wijnen et al., 2013, Gilad et al., 2008, 
Hackl et al., 2016, Ji et al., 2016). They could be reliable as far as their efficiency 
(specificity & sensitivity) and cost effectiveness, and could surpass the current 
diagnostic biomarkers.  
Discovery of differentially-expressed miRNAs associated with osteoporosis and/or 
osteoporotic fractures, by quantitative real time (RT-qRT) PCR could be of benefit to 
the diagnosis of osteoporosis in the future, due to their availability and stability in 
serum (Mitchell et al., 2008, Kroh et al., 2010, Cortez and Calin, 2009) and other body 
fluids (Kosaka et al., 2010). Indeed, they fulfil the essential criteria of a valuable 
biomarker: measurability, reliability and cost effectiveness (Morrow and de Lemos, 
2007), and have potential to serve as non-invasive biomarkers for bone diseases 
(Hackl et al., 2016).  
1.3 Aims of the Research 
The aim of the research project is to identify changes in the levels of circulating 
miRNA that might be associated with osteoporosis in human patients and to assess 
the potential benefit to the diagnosis of osteoporosis in clinical specimens.  
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2.1 Materials 
2.1.1 Blood Collection and Sample Processing Materials 
No. Item Cat# Source 
1.  SARSTEDT S-Monovette® 
7.5mL. Serum Tube (Clotting 
Activator) 
01.1601.001 STARLAB Ltd, UK 
2.  SARSTEDT S-Monovette® 9mL 
K3E, Potassium EDTA 
02.1066.001 STARLAB Ltd, UK 
3.  Ficoll-Paque Premium 
1.077g/mL 
17-5442-02 GE Healthcare Life 
Sciences, UK 
4.  Greiner Bio-One 10 mL 
Leucosep™ tube, sterile for 3-8 
mL blood 
163290  Greiner bio-one Ltd, UK 
5.  Filter Tip (Sterile), 0.5-10µL 02-707-442 Fisher Scientific Ltd, UK 
6.  Filter Tip (Sterile), 0.5-10µL 02-707-442 Fisher Scientific Ltd, UK 
7.  Filter Tip (Sterile), 2-20µL 02-707-432 Fisher Scientific Ltd, UK 
8.  Filter Tip (Sterile), 100-1000µL 02-707-404 Fisher Scientific Ltd, UK 
9.  1.5mL Ultra High Recovery 
(UHR) Microcentrifuge Tube  
E1415-2600 STARLAB Ltd, UK 
10.  2.0mL Ultra High Recovery 
(UHR) Microcentrifuge Tube 
I1420-2600 STARLAB Ltd, UK 
11.  STARLAB 15 mL Polypropylene 
Centrifuge Tubes 
E1415-0200 STARLAB Ltd, UK 
12.  STARLAB 50 mL Polypropylene 
Centrifuge Tubes 
E1450-0200 STARLAB Ltd, UK 
 
2.1.2 Molecular Biology Materials. 
No. Item Cat# Source 
1.  RNaseZap® Solution AM9782 Life Technologies Ltd, UK 
2.  Trizol LS Reagent 10296028 Life Technologies Ltd, UK 
3.  Chloroform [Sigma] (>99.5% 
Purity, 119.38 g/mol (mW)) 
C2432-500mL Sigma-Aldrich Company 
Ltd., UK 
4.  UltraPure™ Glycogen (20 μg/μL 
in RNase-free water) 
10814010 Life Technologies Ltd, UK 
5.  Ethyl alcohol, Pure ≥95% 
[Sigma] 
E7148-500mL Sigma-Aldrich Company 
Ltd., UK 
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No. Item Cat# Source 
6.  5nM Sysn-cel-miR-39’ reagent MSY0000010 QIAGEN Ltd, UK. 
7.  miRNeasy Mini Kit 217004 QIAGEN Ltd, UK. 
8.  miScript II RT Kit 218161 QIAGEN Ltd, UK. 
9.  miScript SYBR Green PCR Kit 218073 QIAGEN Ltd, UK. 
10.  Hs_RNU6-2_11 (RNU6-6P) 
miScript Primer Assay  
MS00033740 QIAGEN Ltd, UK. 
11.  Hs_SNORD96A_11 miScript 
Primer Assay 
MS00033733 QIAGEN Ltd, UK. 
12.  miScript miRNA PCR Array 
Human Serum & Plasma 384HC 
MIHS-3106Z QIAGEN Ltd, UK. 
13.  Multiply® µStrip 0.2 mL, white, 
strip of 8 without lid, 120 strips 
in the minigrip bag 
72.985.092 STARLAB Ltd, UK 
14.  Multiply® µStripPro strip of 8 
with attached flat lid, 
transparent 
72.991.103 STARLAB Ltd, UK 
 
2.2 Documents and Forms  
No. Item Ref No. 
1.  North West-Greater Manchester West National 
Research Ethics Service (NRES) Committee 
11/NW/0593 
2.  Royal Liverpool and Broadgreen University Hospitals 
NHS trust 
4195/UOL 000760 
3.  The Royal Liverpool and Broadgreen University 
Hospitals NHS Trust Approval Letter for Non-CTIMP 
Studies. 
15/EE/0051 
23/06/2015 
4.  Letter of invitation to participant [Letter to patient -
Molecular Regulators in Osteoporosis]. 
Ver. 1.2, 
25/08/2015 
5.  Participant Information Sheet (PIS) for the Patient 
Molecular- Regulators in Osteoporosis. 
Ver. 1.2, 
25/02/2015 
6.  Participant Information Sheet for Healthy Volunteer- 
Molecular Regulators in Osteoporosis. 
Ver. 1.1. 
25/02/2015 
7.  Participant Consent Form Ver. 1.2. 
25/02/2015 
8.  Osteoporosis Patient Medical Form  
9.  Osteoporosis Clinical Specimen Form  
10.  Healthy Control Clinical Specimen Form  
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2.3 Methods 
This study has been carried out under ethical approval from the England Health 
Research Authority National Research Ethics Service Committee, North West-Greater 
Manchester West [REC reference: 11/NW/0593] and East of England-Essex [REC 
reference 15/EE/0051].  
Informed consent was obtained for all participants prior to sample collection. Clinical 
samples were obtained from participants including local healthy volunteers and 
patients who were referred to the Royal Liverpool Broadgreen University Hospital 
NHS Trust based in Liverpool who either presented at the Bone clinic or at the 
Department of Radiology for a bone mineral density (BMD) scan. 
Briefly, all participants, including patients and healthy volunteers (non-osteoporosis), 
were invited to participate in the research study and had been given participant 
information sheet (PIS) ‘Patient Information-Molecular Regulators in Osteoporosis’ 
to read (see Appendix 8.3). The aim of the research, patient selection criteria, what 
will happen if they like to take part, what will happen to the collected blood sample, 
and the ethical issues related to the confidentiality of information obtained from the 
patient medical file had been highlighted, (see Appendix 8.3). They had an 
opportunity to read and ask any questions or discuss any concerns related to this 
study. Upon their approval, patient consent form was read to them, and each patient 
gave their own agreement and signed the form before having their blood sample 
taken (Figure 2-1). The form consists of three parts; one copy was handed to the 
patient; another copy was placed in the patient’s medical file and the third copy was 
kept in the university file as part of ethical approval documentation. The 
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‘Osteoporosis Patient’ medical form was completed by a medical doctor. The form 
consists of patient demographic information, site of fracture, BMD T-score, 
frequency of fracture, medication, risk factors and any special notes (Figure 2-2).  
An anonymised identification number was created for all participants, and their age 
and gender were recorded in the ‘Osteoporosis Patient’ Medical record file as shown 
in Table 2-1.
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Table 2-1: Sample of ‘Osteoporosis Patient’ Medical Record File 
For details refer to appendix 8.4 
No. Date of 
Clinic 
Sample ID 
YYMMDD
OP## 
DOB Age Sex 
F/M 
T Score 
Lumba
r Spine 
(LS) 
T Score 
Femor
al 
Neck 
(FN) 
T score 
Total  
IP (TH) 
Numbe
r of 
Fractur
es 
Position of 
Fracture 
Wrist [W] 
Vertebrae 
[V] 
Hip [H] 
Rib [R] 
Ankle [A 
Other [O] 
Date of 
last 
Fracture 
Medicatio
n History 
Calcium 
Vitamin D 
Bisphosph
onates 
Prodelos 
Denosuma
b 
Others 
Risk 
Factors 
Type OP  Notes 
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Figure 2-1: Consent Form 
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Figure 2-2:Osteoporosis Patient Medical Form 
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2.4 Sample Collection and Preparation 
Blood samples were drawn by qualified phlebotomists in the blood collection area at the 
RLBUHT following standard Safety Protocol. Samples of blood (approximately 25mL) for 
isolation of serum and plasma were obtained, using two 7.5mL S-Monovette® with (Clotting 
Activator) and one 9mL S-Monovette® K3E, Potassium EDTA tubes (Blood Collection and 
Sample Processing Materials 2.1.1). Samples were inverted gently for approximately 10 times, 
and kept in an upright position at room temperature for 0.5 to 2hrs. Collection’s date and 
time were documented in the collected tubes and on the patient’s medical form (Figure 2-3). 
Each participant’s specimens were given a unique and anonymised alphanumeric 
identification number (ID) composed of six digits made up from the year, month and day of 
collection, followed by two letters, either OP for osteoporosis or HC for healthy volunteer, 
two digits from the participant serial number. Finally, the ‘S’ alphabet for serum or ‘PE’ for 
plasma/EDTA and sample number.  Additionally, a unique aliquot letter, a, b, c, d, …etc., were 
used when there were multiple similar samples blood components aliquots as shown in 
example below. 
Example: 130709OP01 S1a 
  (YYMMDDXX## A#n) 
Patients clinical information and sample ID were documented in the ‘Osteoporosis Clinical 
Specimen form’ (See below). 
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Figure 2-3: Osteoporosis Clinical Specimen Form 
 
2.4.1 Serum and Plasma Preparation 
Serum and plasma were obtained from the blood specimens by centrifuging the collected 
samples at 2,500 x g (Thermo Heraeus Megafuge 16R centrifuge) for 30 minutes at room 
temperature. The supernatant yields of approximately 3-3.5mL were initially transferred into 
three new sterile 1.5 mL Micro tubes (Blood Collection and Sample Processing 
Materials2.1.1). A further centrifugation step for these aliquots was carried out at 14,000 x g 
(Thermo IEC Microcentrifuge CL 17 R) for 30 minutes at 4C, to maintain RNA stability and to 
remove additional cellular and protein debris. Approximately 1.2mL of the supernatants were 
then transferred into a new RNAse free Micro tubes. The final yield obtained from the 
collected blood samples was 2-3 aliquots of approximately 1.2mL each for both serum and 
plasma samples. Specimens were then stored in a -80C freezer for future analysis. 
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2.4.2 Isolation of Peripheral Blood Mononuclear Cells [PBMC]  
Peripheral blood mononuclear cells (PBMCs) were isolated from 1:2 diluted EDTA packed red 
blood cells containing the buffy coat (see Figure 2-4) with Dulbecco's Phosphate Buffered 
Saline (DPBS) (Blood Collection and Sample Processing Materials 2.1.1) in 15 mL 
Polypropylene Centrifuge Tubes.  
 
Figure 2-4: EDTA Blood Components. 
 
Initially, 3mL of Ficoll-premium (1.077g/mL) solution was added into the bottom of a Greiner 
Bio-One 10 mL Leucosep™ tube and centrifuged at room temperature for 1 minute at 900 x 
g, so the separation medium is now located below the porous barrier. Approximately 6 mL of 
the PBS-diluted [1:2] EDTA blood samples were carefully pipetted down the side of the 
Leucosep™ tube held at 45 degrees and the tube was centrifuged at 900 x g for 30 minutes at 
room temperature (Thermo TX-400 Swinging Bucket Rotor and Thermo Heraeus Megafuge 
16R), and slowed without the brake to prevent swirling of the samples. The interface layer 
(buffy coat) that contained the PBMC was collected into a sterile 15 mL polypropylene 
centrifuge tubes, and washed with PBS at room temperature, (see Figure 2-5). Cell pellets 
were suspended in 10mL of cold Ammonium-Chloride-Potassium Lysing Buffer, incubated at 
4C for 1 minute, centrifuged at 2,500 x g for 5 minutes at 4C. Following two washing steps, 
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each using 10 mL PBS, centrifugation at 2,500 x g at room temperature for 5 minutes, the cell 
pellets were resuspended with 0.5mL PBS, transferred into 1.5 mL Micro tubes, centrifuged 
at 14,000 x g at 4C for 5 minutes to form a tight cell pellet. Cell pellets were stored frozen at 
-80°C to await further analysis. 
 
Figure 2-5: PBMC isolation using Ficoll-premium (1.077g/mL density gradient) solution. 
1) Pour the approximately 6mL PBS-diluted EDTA blood sample into 10mL Leucosep™ tube. 
2) Centrifugate at room temperature for 30 minutes at 900 x g using a swinging bucket rotor. 
Switch off brakes of the centrifuge. 3) After centrifugation, the sequence of layers occurs as 
follows a) PBS-diluted plasma, b) interface layer (consisting of lymphocytes / PBMCs), c) Ficoll-
premium (1.077g/mL) separation medium, d) porous barrier, e) Ficoll-premium (1.077g/mL) 
separation medium and f) pellet (erythrocytes and granulocytes). 4) Harvest the interface 
layer containing PBMCs by a Pasteur pipette into new a sterile 15 mL polypropylene centrifuge 
tube. Cited from greinerbio one Catalogue 2017. 
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2.4.3 Sample Storage 
Prior to being frozen for storage at -80C, all aliquots of serum, plasma and PBMC cell pellets 
were labelled, anonymously, with their unique identification numbers, their specimen types, 
date of processing. 
2.5 RNA Extraction 
2.5.1 Isolation and purification of RNA from serum and plasma 
Isolation of small RNA was achieved by using a combination of TRIzol® LS reagent and a 
QIAGEN miRNeasy Mini Kit. Generally, 400 µL aliquots of serum or plasma was added into a 
2.0mL Ultra High Recovery (UHR) microcentrifuge tube containing 1200 µL TRIzol® LS reagent. 
The tube was vortexed at the highest speed (Vortex-Genies2) for 30-60 seconds and 
incubated at room temperature for 15-30 minutes. Then 2.4 µL of glycogen (10 mg/mL)) were 
added to improve the yield of RNA and 5 µL of 5nM synthetic miRNA-39 from Caenorhabditis 
elegans (Sysn-cel-miR-39) (QIAGEN) was added as a spike-in control. After adding 320 µL 
chloroform (99.5%), the mixture was vortexed vigorously for 30 seconds, incubated on ice for 
10 minutes and centrifuged for 30 minutes at 14,000 x g at 4°C (Thermo IEC Microcentrifuge). 
The clear upper aqueous solution containing RNA was transferred into a sterile 2.0mL 
microcentrifuge tube. RNA was precipitated by adding 1.5 volume of 100% ethanol and 
vortexed at medium speed. Purification of extracted total RNA was performed using 
miRNeasy columns (QIAGEN) according to the manufacturer’s recommendation. Briefly, up 
to 700 µL of the sample was pipetted into an miRNeasy Mini spin column in a 2 mL collection 
tube, centrifuged at ≥ 8000 x g for 15 seconds at room temperature and the flow-through was 
discarded. The step was repeated for the remaining ethanol’s precipitated sample. Followed 
by two washing steps using 700 µL of RNeasy RWT and 500 µL x2 RPE Buffers. RNA was eluted 
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from the Mini spin column using 30µL of RNase-free water, followed by 50µL for a second 
elution. The resulting purified RNAs were stored frozen at -80oC until use. 
2.5.2 RNA Concentration and Purity 
RNA concentrations were measured initially using a Thermo Scientific NanoDrop™ 2000 
spectrophotometer. The measurement of RNA concentration was in ng/µL, and the ratio of 
absorbance at 260nm/280nm was used to assess the purity of nucleic acids (DNA or RNA) 
from either protein or phenol contaminant, and at 260/230 to measure the nucleic acid purity 
from residual phenol, residual guanidine from the Trizol reagent or glycogen used for 
precipitation of the RNA. 
The assessment of RNA quality and concentration was also carried out in the Centre of 
Genomic Research (CGR), University of Liverpool using Agilent Eukaryote Total RNA Pico chip 
kit and an Agilent 2100 analyser. 2.0 µL of RNA fraction (>8ng/µL) were sent to the Centre of 
Genomic Research (CGR), University of Liverpool for RNA quality check.  
2.6 Real-Time Quantitative PCR (RT-qPCR) 
2.6.1 RNA Reverse Transcription 
RNA reverse transcription was carried out on total RNA isolated from serum and plasma 
samples. 100 ng of purified RNA was mixed with 4 µL of 5x QIAGEN miScript HiSpec Buffer, 2 
µL of 10x QIAGEN miScript Nucleics Mix (dNTPs, rATP, oligo-dT primers, and an internal 
synthetic RNA control [miRTC]) and 2 µL of QIAGEN miScript Reverse Transcriptase Mix 
(poly(A) polymerase & reverse transcriptase) (Table 2-2). Reverse Transcriptase (RT) was 
replaced by RNase-free water for the no-RT control preparation. The RNA reverse 
transcription reaction mixtures, of final volumes of 20 µL, were incubated in a Bio-Rad T100 
thermal cycler (Chapter 2: Materials and Methods Error! Reference source not found.) at 
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37oC for 60 minutes, then at 95oC for 5 minutes to inactivate the reverse transcriptase enzyme 
and held at 4 oC. The resulting reverse transcription products were stored frozen at -20 oC and 
were used as a template for RT-qPCR amplification. 
Table 2-2: Reverse transcription reaction components 
Component RT-master mix (1x) No-RT control 
1. RNase-free water µL Variable µL Variable 
2. 5x miScript HiSpec Buffer 4 µL 4 µL 
3. 10x miScript Nucleics Mix 2 µL 2 µL 
4. Total RNA containing miRNA µL Variable (100ng) µL Variable (100ng) 
5. miScript Reverse Transcriptase Mix 2 µL no 
Total Volume 20 µL 20 µL 
 
2.6.2 Real time -Quantitative Polymerase chain reaction (RT-qPCR) 
RT-qPCR was performed by adding 1µL of 1:3 diluted RNA reverse transcription products to 
5µL of 2x QIAGEN QuantiTect SYBR Green PCR Master Mix (HotStarTaq® DNA Polymerase, 
QuantiTect SYBR Green PCR Buffer, dNTP mix, including dUTP, SYBR Green I, ROX™ passive 
reference dye and 5 mM MgCl2), 1µL of 10x miScript Universal Primer (reverse primer), and 1 
µL of 10x Primer Mix (forward miScript primer, Table 2-3) with a final volume of 10µL.   The 
RT-qPCR mixtures were incubated in 96 well plates at 95oC for 15 min as per manufacturer’s 
recommendation, to activate the DNA polymerase, followed by 45 cycles of the following 3 
steps: denaturation at 94oC for 15s, annealing at 55oC for 30s and extension at 70oC for 30s, 
followed by, melting steps of 95oC for 10s, 65oC for 60s and 97oC for 1s Continuous Mode), 
and final cooling step of 37oC for 30s. All RT-qPCR reactions were performed in duplicate and 
a No-Reverse Transcriptase (NRT) control was included. RT-qPCR amplification was performed 
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using a Roche Lightcycler 96® real-time PCR system. All primers used for RT-qPCR in this study 
were from QIAGEN as shown in Table 2-3. 
Table 2-3: A list of miScript miRNA Primers used for RT-qPCR 
NO. miRNA miRBase miRNA database/Forward Primer 
Sequence 
QIAGEN 
miScript 
Catalog 
1.  hsa-miR-1193 MIMAT0015049: 
5'GGGAUGGUAGACCGGUGACGUGC 
MS00020265 
2.  hsa-miR-1281 MIMAT0005939: 5'UCGCCUCCUCCUCUCCC MS00014455 
3.  hsa-miR-3923 MIMAT0018198: 
5'AACUAGUAAUGUUGGAUUAGGG 
MS00023611 
4.  hsa-miR-485-5p MIMAT0002175: 
5'AGAGGCUGGCCGUGAUGAAUUC 
MS00006972 
5.  hsa-miR-4258 MIMAT0016879: 5'CCCCGCCACCGCCUUGG MS00021175 
6.  hsa-miR-4274 MIMAT0005828: 
5'CACUGUAGGUGAUGGUGAGAGUGGGCA 
MS00014105 
7.  hsa-miR-3911 MIMAT0018185: 
5'UGUGUGGAUCCUGGAGGAGGCA 
MS00023527 
8.  hsa-miR-1290 MIMAT0005880: 
5'UGGAUUUUUGGAUCAGGGA 
MS00014518 
9.  hsa-miR-143-3p MIMAT0000435: 
5'UGAGAUGAAGCACUGUAGCUC 
MS00003514 
10.  hsa-miR-4516 MIMAT0019053: 5'GGGAGAAGGGUCGGGGC MS00037555 
11.  hsa-miR-4306 MIMAT0016858: 5'UGGAGAGAAAGGCAGUA MS00021511 
12.  hsa-miR-548e-3p MIMAT0005874: 
5'AAAAACUGAGACUACUUUUGCA 
MS00014735 
13.  hsa-miR-100-5p MIMAT0000098: 
5'AACCCGUAGAUCCGAACUUGUG 
MS00003388 
14.  hsa-miR-122-5p MIMAT0000421: 
5'UGGAGUGUGACAAUGGUGUUUG 
MS00003416 
15.  hsa-miR-215-5p MIMAT0000272: 
5'AUGACCUAUGAAUUGACAGAC 
MS00003829 
16.  hsa-miR-548d-5p MIMAT0004812: 
5'AAAAGUAAUUGUGGUUUUUGCC 
MS00010136 
17.  hsa-miR-450a-5p MIMAT0001545: 
5'UUUUGCGAUGUGUUCCUAAUAU 
MS00006937 
18.  hsa-miR-373-5p MIMAT0000725: 
5'ACUCAAAAUGGGGGCGCUUUCC 
MS00006867 
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NO. miRNA miRBase miRNA database/Forward Primer 
Sequence 
QIAGEN 
miScript 
Catalog 
19.  hsa-miR-375 MIMAT0000728: 
5'UUUGUUCGUUCGGCUCGCGUGA 
MS00004088 
20.  hsa-miR-99a-5p MIMAT0000097: 
5'AACCCGUAGAUCCGAUCUUGUG 
MS00003374 
21.  hsa-miR-145-3p MIMAT0004601: 
5'GGAUUCCUGGAAAUACUGUUCU 
MS00008708 
22.  hsa-miR-206 MIMAT0000462: 
5'UGGAAUGUAAGGAAGUGUGUGG 
MS00003787 
23.  hsa-SNORD96A CCTGGTGATG ACAGATGGCA TTGTCAGCCA 
ATCCCCAAGT GGGAGTGAGG ACATGTCCTG 
CAATTCTGAA GG  
MS00033733  
24.  hsa-RNU6-6P GTGCTCGCTT CGGCAGCACA TATACTAAAA 
TTGGAACGAT ACAGAGAAGA TTAGCATGGC  
MS00033740  
 
Data was analysed using Roche Light cycler 96® software which enables the comparison of 
the signal obtained for the target miRNA of interest with that of a reference control gene. 
Relative quantities of miRNA were calculated using the Ct methods after normalization to 
the control. Both hsa-SNORD96A (homo sapiens small nucleolar RNA, C/D box 96A) and hsa-
RNU6-6P (homo sapiens small nuclear 6, pseudogene) were used as RT-qPCR normalization 
control. The expression levels of miRNA between the osteopenia, osteoporosis and non-
osteoporosis control groups was calculated using the Ct equation (Equation 2-2) as well as 
the fold change (2-CT) for each miRNA (Equation 2-3) (Bustin et al., 2009). Since Ct values 
greater than 35 were considered to be below the detection level of the reaction, (indicated 
as N/A, not detected), all miRNA RT-qPCR reactions with Ct > 35 were included in the analysis 
as undetected and assigned the Ct values of 35. 
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Equation 2-1: Pathway-focused gene Ct 
∆𝐶𝑡 = (𝐶𝑡 𝐺𝑒𝑛𝑒 𝑜𝑓 𝐼𝑛𝑡𝑒𝑟𝑒𝑠𝑡) − (𝐶𝑡 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝐻𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝐺𝑒𝑛𝑒) 
Equation 2-2: Gene Expression across two groups Ct 
∆∆𝐶𝑡 = ∆𝐶𝑡(𝑇𝑎𝑟𝑔𝑒𝑡 𝐺𝑟𝑜𝑢𝑝) −  ∆𝐶𝑡 (𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐺𝑟𝑜𝑢𝑝) 
Equation 2-3: Fold Change Expression  
𝐹𝑜𝑙𝑑 𝐶ℎ𝑎𝑛𝑔𝑒 = 2−(𝐶𝑡)  
2.7 miRNAs Array Analysis 
The expression level of miRNA in four pooled serum groups including a pool of 6 non-
osteoporotic male samples (NOPMP1), a pool of 4 non-osteoporotic female samples 
(NOPFP1), a pool of 8 osteopenia female samples (OPAFP3) and a pool of 9 osteoporosis 
female samples (OPFP4) (Table 2-4) were profiled using Human Serum & Plasma miRNA PCR 
Array MIHS‐3106Z (QIAGEN), which represented 370 mature miRNAs and six reference genes, 
including SNORD61, SNORD68, SNORD72, SNORD95. SNORD96A and RNU6-6P and two RNA 
and PCR quality controls including Reverse Transcription control [miRTC] and positive PCR 
Control [PPC]).  
Each pool contained 50 ng of purified RNA from individual serum samples. RT-qPCR based 
miRNA array analysis were carried out by QIAGEN.  
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Table 2-4: Serum RNA Pools for QIAGEN miRNA PCR Array 
No. Category ID No (no. of Samples) Total RNA (ng) 
1.  non-osteoporotic male pool 
1 (NOPMP1) 
NOPMP1 (6) 300 
2.  non-osteoporotic female 
Pool 2 (NOPFP2) 
NOPFP2 (4) 400 
3.  Osteopenia, Female Pool 3 
(OPAFP3) 
OPAFP3 (8) 400 
4.  Osteoporosis, Female, Pool 
4 (OPFP4) 
OPFP4 (9) 450 
 
Briefly, miRNAs were converted to cDNA by miScript Reverse Transcription (RT) and pre-
amplified using QIAGEN preamplification mix and QIAGEN miScript PreAMP PCR kit. The 
amplified cDNA was combined with QuantiTect SYBR green PCR master mix and mixtures 
were aliquoted across miScript PCR array Plate (See Figure 2-6). Levels of miRNAs were 
determined via real time PCR (RT-PCR). All reported Ct value greater than 30 or as N/A (not 
detected) were reported as 30 and considered not significant and the Ct values were excluded 
(as described in 2.6.2).  
Data were normalized to the average of the two control small RNA molecules, SNORD96A and 
RNU6-6P, using the fold change (2-CT) method (refer to 2.6.2). 
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Figure 2-6: RT-qPCR Array Protocol. 
Cited from QIAGEN miRNesy mini kit Handbook. 
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2.8 Bioinformatics Data Analysis  
To calculate the fold change in miRNA levels between serum RNA pools, data analysis web-
based portal software (http://www.sabiosciences.com/mirnaArrayDataAnalysis.php) from 
QIAGEN was used.  
miRWalk 2.0 (Dweep and Gretz, 2015) was used for predicted miRNA gene targets. Gene 
ontology annotation (Carbon et al., 2009, The Gene Ontology, 2015), Enrichr database 
(Kuleshov et al., 2016) and DAVID Bioinformatics Resources ver. 6.8: Oct. 2016 (Huang da et 
al., 2009) were used for gene functional annotation. InteractiVenn: web-based Venn diagram 
tool (Heberle et al., 2015) was used to cluster genes associated with miRNA and osteoporosis 
disease. String software (Szklarczyk et al., 2017) was used to generate protein to protein 
signalling interaction diagrams. 
2.9 Statistical Analyses 
A variety of statistical tools have been used to measure the numerical analytical data, 
including IBM SPSS Statistic 22.0 (UK Head Office IBM United Kingdom Limited PO Box 41, 
North Harbour Portsmouth Hampshire, PO6 3AU) and GraphPad Prism version 7 (GraphPad 
Software, Inc. 7825 Fay Avenue, Suite 230 La Jolla, CA 92037 USA). 
RT-PCR 2^-Ct results were transformed to logarithmic data in an Excel spreadsheet, and 
analysed in GraphPad Prism by One-way ANOVA with post hoc ‘Bonferroni's multiple 
comparisons test’ and by Mann Whitney test (two-tail) statistical tests. Comparisons were 
made between non-osteoporotic, osteopenia and osteoporotic groups to determine any 
significance of differentially expressed results between these groups. Results were displayed 
as ‘Box-and-Whisker’ plots with the 25th, middle and 75th percentiles, and minimum to 
maximum ranges (error bars).  
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SPSS Ver. 22.0 was used to calculate the AUC (ROC) diagnostic value of miRNAs. The cut‐off 
points with the highest sensitivity and specificity were determined. The minimum level of 
significance was p<0.05.  
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3 Chapter 3: Identification of Differentially Expressed 
Circulating miRNAs in Osteoporosis 
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3.1 Introduction 
Osteoporosis is an age related skeletal disorder, caused by a relative increase of bone 
resorption over bone formation, is characterised by decreased bone mass and bone 
strength predisposing to fracture (Kanis et al., 2013). Osteoporosis is normally non-
symptomatic until a fracture occurs.  
Current diagnosis for osteoporosis is mainly based on bone mineral density (BMD) 
using Dual-Energy-X-ray (DEXA) scanning, the assessment of clinical risk factors using 
WHO Fracture Risk Assessment Tool (FRAX) and different bone turnover markers 
(BTM)(Silva and Bilezikian, 2011).  
Despite the fact that the risk of fracture increases with decreasing levels of BMD, 
many patients with osteoporosis do not go on to have a fracture and that most 
fracture in the general population occur in patients without osteoporosis (Das and 
Crockett, 2013, Marshall et al., 1996, Richards et al., 2012). Even with the use of 
current bone turnover markers (BTMs) such as serum Procollagen I Intact N-Terminal 
propeptide (s-PINP), a bone formation marker or C-terminal collagen crosslinks (s-
CTX), a bone resorption marker(Bauer et al., 2012), as a diagnostic tool remains a 
challenge, due to their analytical and biological variability (Sandhu and Hampson, 
2011), inadequate quality control and lack of reference population databases (Bauer 
et al., 2012).  
Circulating miRNAs (miRNA) which are small non-coding RNAs of 18–22 nucleotides 
(Rodriguez et al., 2004), that control gene expression and participate in many 
pathological disorders could be used as novel biomarkers to assess the health status 
and progression of disease (Guay and Regazzi, 2013).  
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Several studies have shown that miRNAs play a significant role in skeletal 
development where Dicer enzyme found to be an essential component for 
biogenesis of miRNAs in which dicer was knocked down resulted in altered 
chondrocyte proliferation and differentiation in Col2-:Dicerfl/fl transgenic mice 
compared to wildtype mice (Kobayashi et al., 2008), delayed perinatal osteoblast 
differentiation and a dramatic increase in postnatal bone mass in targeted deletion 
of Dicer in mature osteoblasts (DicerΔoc/Δoc) mice compared to conditional deletion of 
Dicer (Dicerc/c) control mice (Gaur et al., 2010), and reduced bone remodelling in 
mice with Dicer deficiency in osteoclasts (cKO mutant) compared to wildtype mice 
(Mizoguchi et al., 2010).  
Although a few pilot studies have shown miRNAs in blood samples could be 
associated with  osteoporotic fractures in very small numbers of patients (Panach et 
al., 2015, Seeliger et al., 2014, Weilner et al., 2015), or in low bone mineral density 
(BMD) patients versus normal BMD control (Li et al., 2014), more clinical research is 
needed to investigate whether circulating miRNA could be used as a routine 
diagnostic application in osteoporosis. 
The aim of the research is to identify differentially-expressed circulating miRNA as 
potential osteoporotic biomarkers in clinical specimens using micro RNA PCR array. 
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3.2 Results 
After obtaining ethical approval and patient consent, blood samples were drawn 
from osteoporotic (study), and non-osteoporosis (control) subjects. Patients were 
categorised into four osteoporotic groups, based on their BMD T-score and fragility 
fracture history (Materials & Methods 2.3.1). Group A for osteopenia patients 
without fracture (BMD T score <-1.0 and >-2.5), group B for osteoporosis patients (T 
score ≤ -2.5), group C for osteoporosis with fracture (BMD T score ≤-2.5) and finally 
group D for osteopenia patients with fragility fracture (T score <-1.0 & >-2.5). 
A total number of sixty-one osteoporotic and non-osteoporotic participants were 
recruited (Table 3-1). Twenty-five percent of the recruits were healthy non-
osteoporotic adults (7 male & 8 Female), however BMD’s T-Score (T-S) were not 
available for this group. Twenty-four percent were osteopenia (with and without 
fracture) with average BMD T-Score of -2.0 ± 0.3 and the remaining 51% were 
osteoporosis patients (average BMD T-Score = -3.2 ± 0.7). There was no significant 
difference in mean age between the four osteoporotic study groups (Figure 3-1). 
Indeed, 89% of the Osteoporotic participants were females (Figure 3-2). 
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Table 3-1: Total number of Participants recruited between 2012-2013 (Total n=61) 
Participants recruited between 2012-2013 had no BMD (g/cm2) records 
Medical Diagnosis Sex Avg. 
Age ±SD (n) 
Avg.  
T-Score Lumbar 
Spine  
(L2-L4) ±SD 
Non-Osteoporotic F 
M 
T 
33.8 ± 9.9 (n= 8) 
27.9 ± 4.9 (n= 7) 
31 ± 8.3 (n= 15) 
No data 
Osteopenia F 73 ± 5 (n= 8) -1.8 ± 0.5 
Osteopenia with Fracture F 
M 
T 
62.3 ± 8.4 (n= 6) 
86 (n= 1) 
65.7 ± 11.8 (n= 7) 
-1.7 ± 0.7 
-1 ± 
-1.6 ± 0.7 
Osteoporosis F 
M 
T 
64.1 ± 11.9 (n= 10) 
68.5 ± 21.9 (n= 2) 
64.8 ± 12.8 (n= 12) 
-2.9 ± 1 
-3 ± 1.3 
-2.9 ± 1 
Osteoporosis with Fracture F 
M 
T 
69.5 ± 11.5 (n= 17) 
57.5 ± 19.1 (n= 2) 
68.3 ± 12.3 (n= 19) 
-2.8 ± 1.1 
-3.4 ± 0.2 
-2.9 ± 1 
Grand Total 61   
F= Female, M= Male and T= Total 
 
 
Figure 3-1: Ages of patients between experimental groups. 
Plot shows average age between non-Osteoporosis, osteopenia, osteopenia with 
fracture, osteoporosis, and osteoporosis with fracture. There was significant age 
difference (*P<0.0001) between the low bone mineral density (BMD) groups 
(osteopenia and osteoporosis) and the non-osteoporosis group. 
Chapter3: Identification of Circulating MicroRNAs in Osteoporosis 
64 | P a g e  
 
 
Figure 3-2: Type of Low BMD Patients Recruited in 2012-2013.  
The left side of the figure represents the overall percentages of participants, while 
the right side represents the male subjects. OPN=Osteopenia, OP=Osteoporosis. 
The majority of female patients (n=10) who were >60 years had severe osteoporosis 
with fracture. However, in the case of the osteopenia with fracture group the 
majority of females (n=6) was between 40 and 60 years (Figure 3-3). 
 
Figure 3-3: Number of Osteopenia and Osteoporosis Female Participants based on 
diagnostic category & age.  
Majority of Osteopenia, female was of age 60-70 years (n=5, Grey) and >70 year (n=5, 
Yellow). Osteoporosis, female (n=12) with variable number of 50-59 year (n=5, 
Orange), 60-70 year (n=3, Grey) and > 70 year (n=4, Yellow). Majority of Osteoporosis 
with fracture, female (n=22) were of age: 60-70 year, n=9, grey & > 70 years, n=12, 
yellow. While majority of Osteopenia with fracture female (n=8) were of age 50-59 
years (n=5). One of each osteoporosis with fracture and osteopenia with fracture 
female patients were of age < 50 years. 
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3.2.1 Quality of miRNA Extracted from Serum and Plasma Samples 
3.2.1.1 miRNA Quality Control 
RNAs extracted from participants’ serum and plasma samples were checked for 
purity and concentration using a NanoDrop™ 2000 spectrophotometer (Materials 
and Methods 2.5.1.).  
RNAs were extracted from forty-three serum and thirty-one plasma samples with 
average RNA yields of: 1029.5 ± 642.2 ng and 1273.7 ± 589.3 ng, respectively. In fact, 
the RNAs yield in plasma were relatively higher than those extracted from serum 
samples with lesser variability (Table 3-2). While, both serum and plasma samples 
have relatively similar RNA 260/280 ratio with mean value of 1.33 ± 0.12 and 1.4 ± 
0.13, and RNA 260/230 ratio of RNA 260/230 ratio with mean value of 0.23 ± 0.04 
and 0.28 ± 0.08, respectively (Table 3-2). 
Table 3-2: Summary of quality check of RNA isolated from clinical samples  
Specimen 
Type 
No. of 
Samples 
RNA 260/280 
Optical Density 
Ratio  
Mean ± SD 
RNA 260/230 
Optical Density 
Ratio  
Mean ± SD 
Total RNA (ng)  
Mean ± SD 
Serum 43 1.33 ± 0.12 0.23 ± 0.04 1029.5 ± 642.2 
Plasma  31 1.4 ± 0.13 0.28 ± 0.08 1273.7 ± 589.3 
 
Additional RNA quality assessment was performed using a Eukaryote Total RNA Pico 
chip on Agilent 2100 bioanalyzer (Materials and Methods 2.5.2.). The results were 
analysed by the 2100 Expert Software and visual output confirmed that the isolated 
total small RNA (including miRNA) bands peaked between 25-200nt (Figure 3-4, A-E). 
Total serum RNA concentration for non-osteoporosis (control) was of 915 pg/µL with 
highest fluorescence band peaked of 20 [FU] between 25-200 nucleotide [nt] (Figure 
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3-4, A), 972 pg/µL for osteopenia (Figure 3-4, B), 1,068 pg/µL for osteopenia with 
fracture (Figure 3-4, C), 1,006 pg/µL for osteoporosis (Figure 3-4, D) and 1,505 pg/µL 
for osteoporosis with fracture.  
 
Figure 3-4: Sample of quality checks of total RNA analysis by Agilent 2100 
Bioanalyser 
The gel electropherogram images and fluorescence plots show the total RNA pattern 
performed on serum RNA samples from groups of Non-Osteoporosis (control), SID# 
120425HC05(A), Osteopenia, SID# 120227OP04 (B), Osteopenia with Fracture, SID# 
120206OP05 (C), Osteoporosis, SID# 120206OP04 (D) and Osteoporosis with 
Fracture, SID# 120206OP01 (E). FU= Fluorescence, RIN= RNA Integrity Number, Small 
RNA fractions (including miRNAs) are between 25-200 nucleotide (nt). The gel 
electropherogram images and fluorescence plots were generated using the 2100 
Expert Software.  
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3.2.1.2 Establishment of RNA Pools for RNA Array Analysis  
For cost-efficient sampling strategy, the first step toward the identification of 
circulating miRNA expression in osteoporosis patients was by the PCR array screening 
of 372 circulating miRNAs in four serum RNA pools: Non-Osteoporosis Male Pool1 
(NOPMP1, 6 samples), Non-Osteoporosis Female Pool2 (NOPFP2, 4 samples), 
Osteopenia Female Pool3 (OPAFP3, 8 samples) and Osteoporosis Female Pool4 
(OPFP4, 9 samples) (Materials and Methods 2.7.) (Table 3-3). 
 
Table 3-3: Serum RNA Pool Concentration for QIAGEN miRNA PCR Array  
Samples Sample ID RNA-conc. 
(ng/µL) 
Volume 
[µL] 
(50ng/ 
Sample) 
Total RNA 
[ng]/Pool 
Non-Osteoporosis, 
MalePool 1 
[NOPMP1] 
120425HC04 S1a 9.8 5.1 
 
121212HC02 S1a 12.5 4.0 
121212HC03 S1a 14.0 3.6 
130718HC02 S1a 14.8 3.4 
130930HC02 S1b 12.6 4.0 
131001HC01 S1a 11.2 4.5 
NOPMP1, Total 6 
 
24.5 µL 300 ng 
Non-Osteoporosis, 
FemalePool 2 
[NOPFP2] * 
120425HC01 S1a 42.5 2.4 
 
120425HC08 S1a 11.1 9.0 
120425HC14 S1a 18.7 5.3 
130718HC01 S1a 15.2 6.6 
NOPFP2, Total* 4* 
 
23.3 µL 400 ng* 
Osteopenia, Female 
Pool 3 [OPAFP3] 
120312OP01 S1a 11.22 4.5 
 
120315OP04 S1a 13.6 3.7 
120320OP01 S1a 29.69 1.7 
120416OP01 S1a 27.4 1.8 
120416OP02 S1a 18.4 2.7 
120417OP02 S1a 21.9 2.3 
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Samples Sample ID RNA-conc. 
(ng/µL) 
Volume 
[µL] 
(50ng/ 
Sample) 
Total RNA 
[ng]/Pool 
120508OP02 S1a 18.5 2.7 
121030OP01 S1a 22.8 2.2 
OPAFP3, Total 8 
 
21.5 µL 400 ng 
Osteoporosis, 
Female Pool 4 
[OPFP4] 
130718HC01 S1a 5.0 10.0 
 
120312OP01 S1a 8.4 6.0 
120315OP04 S1a 15.8 3.2 
120320OP01 S1a 4.7 10.6 
120416OP01 S1a 9.0 5.6 
120416OP02 S1a 10.0 5.0 
120417OP02 S1a 9.48 5.3 
120508OP02 S1a 24.2 2.1 
121030OP01 S1a 10.2 4.9 
OPFP4, Total 9 
 
52.6 µL 450 ng 
*(100ng/Sample) 
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RNA pools were checked for RNA quality and yields (Materials and Methods 2.7.). 
The RNA purity at 260nm/280nm was > 1.4 and the concentration between 167 to 
473 ng/pool, which is reasonably acceptable for serum or plasma extracted samples 
(Table 3-4). In addition, miRNA concentration and ratio analysis to the small RNA was 
carried out using Agilent 2100 expert software (Figure 3-5). Individual serum miRNAs 
pool concentration was between 390 and 515 pg/µL (67%-80%) (Table 3-4), with 
miRNA intense peak at 35 nt as shown in the electropherogram (Figure 3-5). 
Table 3-4: Four Serum RNA Pools concentration and integrity by Nanodrop™ 2000 
spectrophotometer, and miRNA concentration by Agilent 2100 Bioanalyser. 
Sample 
ID  
Name RNA 
Conc. 
(ng/pool) 
RNA 
Optical 
Density 
260/280 
Ratio 
RNA 
Optical 
Density 
260/230 
Ratio 
miRNA% miRNA 
conc. 
(pg/μL) 
NOPMP1  Non-
Osteoporosis, 
Male 
363.3 1.45 0.13 80% 514.9 
NOPFP2  Non-
Osteoporosis, 
Female 
169.6 1.56 0.09 78% 517.8 
OPAFP3  Osteopenia, 
Female 
447.8 1.45 0.25 82% 964.2 
OPFP4  Osteoporosis, 
Female 
472.5 1.72 0.17 67% 391.8 
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Figure 3-5: Electropherograms showing RNA Quality Concentration & Integrity for 
four Serum RNA Pools.  
NOPMP1= Non-osteoporosis, male Pool1 (A), NOPFP2 = Non-osteoporosis female 
Pool2 (B), OPAFP3 = Osteopenia, female, Pool3 (C) and OPFP4 = Osteoporosis, 
female, Pool4(D) with miRNA peak displayed at 35nt. Analysis done using Agilent 
2100 Bioanalyser. 
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3.2.2 miRNA PCR Array Data Analysis 
Extracted serum-RNAs pools were reverse transcribed to cDNA. RT-qPCR was 
performed in a single mode run (Materials and Methods 2.7.). Ct data for miRNA, was 
generated by qPCR, and delivered as an Excel Workbook (Ct_Values.xls) (Materials 
and Methods 2.8.). The efficiency of the polymerase chain reaction and the reverse 
transcription reaction, was determined by using positive PCR controls and reverse 
transcription control (Materials and Methods 2.7.). The difference between the 
average Ct reverse transcription control (RTC) and the average PCR positive control 
(PPC) was less than zero (Table 3-5). Therefore, all samples had successful PCR and 
efficient reverse transcription reactions. 
Table 3-5: Quality Check of PCR Array Data  
Array NOPFP1 OPAFP3 OPFP4 NOPMP2 
Average Ct (PPC) 18.54 18.54 18.53 18.53 
ST DEV Ct (PPC) 0.02 0.02 0.11 0.06 
Average Ct (RTC) 16.4 16.53 16.3 16.81 
ST DEV Ct (RTC) 0.03 0.04 0.07 0.1 
Ct (AVG RTC - AVG PPC) -2.14 -2.01 -2.23 -1.72 
RT Efficiency Pass Pass Pass Pass 
Criteria: If Ct (AVG RTC - AVG PPC) <= 0, RT Efficiency reports 'Pass'; otherwise, RT 
Efficiency reports 'Inquiry'. PPC= PCR Positive Control, RTC = Reverse Transcription 
Control, RT = Reverse Transcription, NOPFP1 = Non-Osteoporosis, Female Pool1, 
OPAFP3 = Osteopenia, Female Pool3, OPFP4 = Osteoporosis, Female Pool4 and 
NOPMP2 = Non-osteoporosis, Male Pool2. 
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3.2.2.1 Ct Values Data Distribution Assessment 
A preliminary evaluation study for the Ct value showed that out of 384 miRNAs and 
PCR controls, approximately 48% of the distributed Ct values were below 25, 46% 
between 25-30, and the remaining 5% had late Ct amplification (30-35) or were 
undetectable (Table 3-6). 
Table 3-6: Distribution of Ct Values 
Ct Range NOPFP1 
Distribution of 
Ct Values (%) 
NOPMP2 
Distribution of 
Ct Values (%) 
OPAFP3 
Distribution of 
Ct Values (%) 
OPFP4 
Distribution of 
Ct Values (%) 
<25 188 (48.96%) 180 (46.88%) 201 (52.34%) 170 (44.27%) 
25-30 174 (45.31%) 184 (47.92%) 161 (41.93%) 195 (50.78%) 
30-35 22 (5.73%) 20 (5.21%) 22 (5.73%) 19 (4.95%) 
Absent 
Calls 
0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 
NOPF = Non-Osteoporosis, Female Pool1 (Control), NOPMP2 = Non-Osteoporosis, 
Male Pool2 (Control), OPAFP3= Osteopenia, Female Pool3 andOPFP4=Osteoporosis, 
Female Pool4 and. 
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3.2.2.2 Establishment of PCR Array Threshold Cycle Cut off 
The threshold Ct cut off value for the preamplified miRNAs was set up to 30 cycles. 
Those miRNAs with Ct values greater than 30 or displayed as (N/A) were reported as 
30 and considered as not expressed.  
Out of 372 tested miRNAs, there were 21 targets (hsa-miR-184, hsa-miR-372-3p, hsa-
miR-19b-1-5p, hsa-miR-1286, hsa-miR-138-1-3p, hsa-miR-3655, hsa-miR-373-3p, 
hsa-miR-605-5p, hsa-miR-412-3p, hsa-miR-4267, hsa-miR-133a-3p, hsa-miR-4258, 
hsa-miR-208a-3p, hsa-miR-9-5p, hsa-miR-3689e, hsa-miR-4524a-3p, hsa-miR-2355-
5p, hsa-miR-136-5p, hsa-miR-196b-3p, hsa-miR-1277-3p and hsa-miR-2467-3p) that 
were not expressed and were excluded from the study. The remaining, 185 (48%) 
gave valid Ct value of <25 and 178 (46%) with Ct value between 25-30  
3.2.2.3 Selection of Normalization/Housekeeping Gene 
To select the best normalization control for the miRNA expression in the serum, 
fourteen miRNAs and small nucleolar RNAs (snoRNAs) with no significant Ct value 
mean difference (≤ 2 cycle) between the four serum RNA pools were identified. These 
are 7 miRNAs (hsa-miR-152-3p, hsa-miR-335-5p, hsa-miR-29b-3p, hsa-miR-185-5p, 
hsa-miR-24-3p, hsa-miR-20b-5p and hsa-miR-20a-5p), and six PCR 
normalization/housekeeping genes (SNORD61, SNORD68, SNORD72, SNORD95, 
SNORD96A and RNU6-2) as well as one Spike-in control (cel-miR-39) as shown in 
(Figure 3-6).  
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Figure 3-6: PCR array’s Ct values result from four serum RNA Pools for 14 Genes. 
Circulating serum of: 7 miRNAs; hsa-miR-152-3p, hsa-miR-19b-3p, hsa-miR-20a-5p, 
hsa-miR-185-5p, hsa-miR-24-3p, hsa-miR-335-5p, hsa-miR-20b-5p, 1 spike-in 
Control, cel-miR-39 and 6 small non-coding RNA (normalization Controls); SNORD61, 
SNORD68, SNORD72, SNORD95, SNORD96A & RNU6-2. Dots denote the Ct value of 
each miRNA per group. 
 
Following identification of the RNAs to be used for normalization, the relative 
expression (2-Ct) of miRNA of interest between Osteoporosis and Osteopenia female 
groups were measured using different combination of normalization controls as 
listed in (Table 3-7): two housekeeping genes (HKGs), SNORD96A and RNU6-2; three 
HKGs, SNORD68, SNORD96A and RNU6-2; four HKGs, SNORD68, SNORD95, 
SNORD96A and RNU6-2; 6 HKGs, SNORD61, SNORD68, SNORD72, SNORD95, 
SNORD96A and RNU6-2+ Cel-miR-39 and a set of 7 miRNAs-control group, hsa-miR-
152-3p, hsa-miR-29b-3p, hsa-miR-20a-5p, hsa-miR-185-5p, hsa-miR-24-3p, hsa-miR-
335-5p, hsa-miR-20b-5p and hsa-miR-18a-5p. miRNAs relative expression (2-Ct) of ≥ 
2-fold change upregulation are displayed in red colour, while those downregulated 
by ≤ -2-fold change are displayed in blue (Table 3-7). 
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Table 3-7: miRNA Fold Change Expression between Osteoporosis and Osteopenia 
female groups using different combination of normalization controls.  
No. Mature ID 2HKGs 3HKGs 4HKGs 6HKGs+ 
Cel-miR-39 
miRNAs- 
Control 
Group 
1 hsa-miR-3923 4.1 3.7 3.3 2.8 7.8 
2 hsa-miR-4258 4.0 3.6 3.2 2.7 7.6 
3 hsa-miR-485-5p 2.4 2.2 1.9 1.6 4.5 
4 hsa-miR-196b-3p 2.8 2.5 2.2 1.9 5.3 
5 hsa-miR-1193 2.4 2.1 1.9 1.6 4.5 
6 hsa-miR-1281 2.3 2.1 1.9 1.6 4.4 
7 hsa-miR-4274 2.3 2.0 1.8 1.5 4.3 
8 hsa-miR-100-5p -32.1 -35.4 -40.0 -47.9 -16.9 
9 hsa-miR-4516 -9.1 -10.0 -11.3 -13.6 -4.8 
10 hsa-miR-145-3p -8.8 -9.7 -10.9 -13.1 -4.6 
11 hsa-miR-4306 -7.5 -8.3 -9.4 -11.3 -4.0 
12 hsa-miR-548e-3p -6.4 -7.0 -8.0 -9.5 -3.4 
13 hsa-miR-206 -6.3 -7.0 -7.9 -9.5 -3.3 
14 hsa-miR-215-5p -5.8 -6.4 -7.2 -8.6 -3.1 
15 hsa-miR-122-5p -5.7 -6.3 -7.1 -8.5 -3.0 
16 hsa-miR-3911 -5.2 -5.7 -6.4 -7.7 -2.7 
17 hsa-miR-548d-5p -4.7 -5.2 -5.8 -7.0 -2.5 
18 hsa-miR-373-5p -4.5 -4.9 -5.6 -6.7 -2.4 
19 hsa-miR-99a-5p -4.4 -4.9 -5.5 -6.6 -2.3 
20 hsa-miR-450a-5p -4.2 -4.6 -5.2 -6.2 -2.2 
21 hsa-miR-143-3p -4.0 -4.5 -5.0 -6.0 -2.1 
22 hsa-miR-375 -3.9 -4.3 -4.9 -5.8 -2.1 
2HKGs: Two housekeeping genes (SNORD96A and RNU6-2), 3HKGS; SNORD68, 
SNORD96A and RNU6-2, 4HKGs; SNORD68, SNORD95, SNORD96A and RNU6-2, 
6HKGs; SNORD61, SNORD68, SNORD72, SNORD95, SNORD96A and RNU6-2, Spike-in 
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control: cel-miR-39 and miRNAs-Control Group; hsa-miR-152-3p, hsa-miR-29b-3p, 
hsa-miR-20a-5p, hsa-miR-185-5p, hsa-miR-24-3p, hsa-miR-335-5p, hsa-miR-20b-5p 
and hsa-miR-18a-5p. Red = ≥ 2-fold change upregulated; blue = ≤ -2-fold change 
Downregulated; black = <2 fold-change >-2(no significant up-/down-regulation). 
 
Two PCR control genes; SNORD96A and RNU6-2 had Ct mean value of 24.6 ± 0.4 and 
25.6 ± 0.6 respectively, and the combined Ct means value are 25±0.5 (Figure 3-7).  
 
Figure 3-7: PCR array’s Ct values result from four serum RNA Pools for SNORD96A 
& RNU6-2 (normalization housekeeping genes).  
Dots denote the Ct value of each miRNA per group. 
 
These two genes were selected as normalization controls for miRNA PCR fold change 
(2-CT) expression based on their consistent Ct reading among the control and study 
groups (Table 3-8), as well as acceptable average delta Ct expression (2-Ct). 
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Table 3-8: SNORD96A & RNU6-2 (Housekeeping/Normalization Control) Ct value 
expression in four serum RNA Pools. 
Gene 
Symbol 
Normalization 
Control 
NOPMP1 
(Control) 
NOFPF2 
(Control) 
OPAFP3 
(Group 1) 
OPFP4 
(Group 2) 
SNORD96A  25.15 24.63 24.33 24.32 
RNU6-6P  27.63 26.58 25.85 26.09 
Mean 26.39 25.61 25.09 25.20 
NOPMP1 = Non-Osteoporosis, Male Pool1 (Control), NOPFP2 = Non-Osteoporosis, 
Female Pool2 (Control), OPAFP3= Osteopenia, Female Pool3 and 
OPFP4=Osteoporosis, Female Pool4. 
 
3.2.2.4 Identify Differentially Expressed miRNAs from miRNA array 
3.2.2.4.1 Identify Differentially Expressed miRNAs between Non-Osteoporosis Male and 
Non-Osteoporosis Female using miRNA PCR array 
A differential miRNAs expression analysis between non-osteoporosis male and 
female serum RNA pools was performed using QIAGEN miRNA PCR Array Data 
Analysis Web Portal software (Materials and Methods 2.8.). When the data was 
normalised using two normalising genes; SNORD96A and RNU6-2, out of 372 
circulating miRNAs 91 (24%) were upregulated (≥2-fold change) in the non-
osteoporosis male group, including hsa-miR-3120-3p (8.9-fold change) and hsa-miR-
34c-3p (6.9-fold change). Four miRNAs were downregulated (2.4-fold change) 
including hsa-miR-328-3p and hsa-miR-122-5p (Figure 3-8). 
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Figure 3-8 Scatter Plot of miRNA expression (normalized groups) between Non-
Osteoporosis, Male group (NOPM) vs Non-Osteoporosis, Female group (NOPF). 
Log10 transformed data of all miRNAs expression (2-Ct) in the miScript PCR Array 
were taken to construct this scatter plot. The middle line indicates relative fold 
change (2-Ct) of 1. The left and right lines indicate the fold change in gene expression 
threshold, which was defined as 2-fold. miRNAs upregulated with ≥ 2-fold change are 
depicted in Red circle and those downregulated with ≤ -2-fold change are in Green 
circle by miScript PCR array. 
 
Listed in Table 3-9 summarises the most differentially expressed miRNAs in the non-
osteoporosis, male group compared to non-osteoporosis, female group, eight 
miRNAs: were significantly upregulated by ≥ 4-fold change (highlighted in Red) and 
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three miRNAs were downregulated by ≤-2.4-fold change (highlighted in Blue): hsa-
miR-328-3p, hsa-miR-122-5p and hsa-let-7g-3p.  
The sex of participants could have an influence on the dysregulation expression of 
circulating miRNAs (Dai and Ahmed, 2014, Guo et al., 2017, Ameling et al., 2015). 
Therefore, the non-osteoporosis male control group was excluded from further 
study. 
Table 3-9: Differentially-expressed miRNA between Male and Female Non-
Osteoporosis groups, using the QIAGEN Human Serum & Plasma miRNA PCR Array. 
Red = ≥ 2-fold change upregulated; blue = ≤ -2-fold change Downregulated 
No. Mature ID Fold Regulation 
1.  hsa-miR-3120-3p 8.9 
2.  hsa-miR-34c-3p 6.9 
3.  hsa-miR-15a-3p 4.6 
4.  hsa-miR-485-3p 4.5 
5.  hsa-miR-1-3p 4.5 
6.  hsa-miR-139-3p 4.3 
7.  hsa-miR-138-1-3p 4.3 
8.  hsa-miR-206 4.3 
9.  hsa-miR-328-3p -3.5 
10.  hsa-miR-122-5p -2.6 
11.  hsa-let-7g-3p -2.4 
 
3.2.2.4.2 Identify Differentially Expressed miRNAs Between Osteopenia, Female and Non-
Osteoporosis, Female using miRNA PCR array 
Twenty nine miRNAs (8%) were dysregulated in osteopenia, female pool compared 
to non-osteoporosis female group. 7 miRNAs (2%) were upregulated by (≥2.0 fold 
change) including hsa-miR-3120-3p (≥3.1 fold change) and hsa-miR-4516 (≥2.7 fold 
change (Figure 3-9), and 22 (6%) were downregulated (≤-2.0 fold change) including 
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some which exhibited large differential expression, namely, hsa-miR-3622a-5p (≤-4.3 
fold change) and hsa-miR-122-5p (≤-4.2 fold change). 
 
Figure 3-9: Scatter Plot of miRNA expression (normalized groups) between 
Osteopenia, female group (OPAF) vs Non-Osteoporotic, female group (NOPF). 
Log10 transformed data of all miRNAs expression (2-Ct) in the miScript PCR Array 
were taken to construct this scatter plot. The middle line indicates relative fold 
change (2-Ct) of 1. The left and right lines indicate the fold change in gene expression 
threshold, which was defined as 2-fold. miRNAs upregulated with >2-fold change are 
depicted in Red circle and those downregulated with < -2-fold change are in Green 
circle. 
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Listed in Table 3-10 are the most differentially expressed miRNAs in osteopenia, 
female group compared to the non-osteoporosis female group. five were 
upregulated (> 2.0-fold change) (highlighted in red) and eight miRNAs were 
downregulated by <-2.5-fold change (highlighted in blue).  
Table 3-10: Differentially-expressed miRNA in Osteopenia, Female Group Compared 
with Non-Osteoporosis, Female Group using the QIAGEN Human Serum & Plasma 
miRNA PCR Array. 
No. Mature ID Fold Regulation 
1.  hsa-miR-3120-3p 3.1 
2.  hsa-miR-4516 2.7 
3.  hsa-miR-542-5p 2.5 
4.  hsa-miR-21-3p 2.4 
5.  hsa-miR-3651 2.3 
6.  hsa-miR-3622a-5p -4.3 
7.  hsa-miR-122-5p -4.2 
8.  hsa-miR-4732-3p -2.7 
9.  hsa-miR-1976 -2.7 
10.  hsa-miR-203a-3p -2.6 
11.  hsa-miR-1281 -2.6 
12.  hsa-miR-32-5p -2.5 
13.  hsa-miR-1913 -2.5 
Red = ≥ 2-fold change upregulated; blue = ≤ -2-fold change Downregulated 
3.2.2.4.3 Identify Differentially Expressed miRNAs between Osteoporosis and Non-
Osteoporosis using miRNA PCR array 
Sixty miRNAs (16%) were downregulated (≤ -2-fold change) in the osteoporosis group 
compared to non-osteoporotic, female group, including hsa-miR-122-5p (-24-fold 
change), hsa-miR-100-5p (-38-fold change), hsa-miR-215-5p (-10-fold change) and 
hsa-miR-3911 (-8-fold change). Two miRNAs were upregulated (≥ 2-fold change) (hsa-
miR-21-3 and hsa-miR-1231) as shown in (Figure 3-10).  
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Figure 3-10: Scatter Plot of miRNA expression (normalized groups) between 
Osteoporosis, female group (OPF) vs Non-Osteoporotic, female group (NOPF).  
Log10 transformed data of all miRNAs expression (2-Ct) in the miScript PCR Array 
were taken to construct this scatter plot. The middle line indicates relative fold 
change (2-Ct) of 1. The left and right lines indicate the fold change in gene expression 
threshold, which was defined as 2-fold. miRNAs upregulated with >2-fold change are 
depicted in Red circle and those downregulated with < -2-fold change are in Green 
circle. 
 
Listed in Table 3-11 are the most differentially expressed miRNAs in the osteoporosis 
group compared to non-Osteoporosis, Female group. Two miRNAs: hsa-miR-21-3p 
and hsa-miR-1231 were significantly upregulated by > 2-fold change (highlighted in 
red) and sixteen miRNAs were downregulated by <-2-fold change (highlighted in 
blue): hsa-miR-100-5p, hsa-miR-122-5p, hsa-miR-215-5p, hsa-miR-3911, hsa-miR-
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1290, hsa-miR-32-5p, hsa-miR-194-5p, hsa-miR-145-3p, hsa-let-7a-3p, hsa-miR-
4306, hsa-miR-10b-5p, hsa-miR-365b-3p, hsa-miR-200b-3p and hsa-miR-99a-5p. 
Table 3-11: Differentially-expressed miRNA in Osteoporosis, Female Group 
Compared with Non-Osteoporosis, Female Group using the QIAGEN Human Serum 
& Plasma miRNA PCR Array. 
Red = ≥ 2-fold change upregulated; blue = ≤ -2-fold change Downregulated 
No. Mature ID Fold Change 
1.  hsa-miR-21-3p 2.8 
2.  hsa-miR-1231 2.3 
3.  hsa-miR-100-5p -38.3 
4.  hsa-miR-122-5p -24.1 
5.  hsa-miR-215-5p -9.8 
6.  hsa-miR-3911 -8.3 
7.  hsa-miR-1290 -6.9 
8.  hsa-miR-32-5p -6.8 
9.  hsa-miR-194-5p -6.8 
10.  hsa-miR-192-5p -6.7 
11.  hsa-miR-145-3p -6.5 
12.  hsa-let-7a-3p -6.1 
13.  hsa-miR-4306 -5.8 
14.  hsa-miR-10b-5p -5.5 
15.  hsa-miR-365b-3p -5.4 
16.  hsa-miR-200b-3p -5.1 
17.  hsa-miR-16-2-3p -5.1 
18.  hsa-miR-99a-5p -5.0 
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3.2.2.4.4 Identify differentially expressed miRNAs Between Osteoporosis and Osteopenia 
using miRNA PCR array 
45 (12%) circulating miRNAs were downregulated (≤ -2-fold change) in the 
osteoporosis group compared to the osteopenia group (Figure 3-11), and 8 (2%) were 
upregulated (≥ 2-fold change).  
 
Figure 3-11: Scatter Plot of miRNA expression between Osteoporosis, female group 
(OPF) vs Osteopenia, Female group (OPAF).  
Log10 transformed data of all miRNAs expression (2-Ct) in the miScript PCR Array 
were taken to construct this scatter plot. The middle line indicates relative fold 
change (2-Ct) of 1. The left and right lines indicate the fold change in gene expression 
threshold, which was defined as 2-fold. miRNAs upregulated with ≥ 2-fold change are 
depicted in Red circle and those downregulated with ≤ -2-fold change are in Green 
circle by miScript PCR array. 
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Among them, 24 miRNAs were significantly expressed between osteoporosis and 
osteopenia groups: 8 were upregulated: hsa-miR-1193, hsa-miR-1281, hsa-miR-3923, 
hsa-miR-485-5p, hsa-miR-4274, hsa-miR-4258, SNORD61 and hsa-miR-196b-3p (≥ 2-
fold, Red in display) and 16 were downregulated: hsa-miR-100-5p, hsa-miR-4516, 
hsa-miR-145-3p, hsa-miR-4306, hsa-miR-548e-3p, hsa-miR-206, hsa-miR-215-5p, 
hsa-miR-122-5p, hsa-miR-3911, hsa-miR-548d-5p, hsa-miR-373-5p, hsa-miR-99a-5p, 
hsa-miR-375, hsa-miR-450a-5p and hsa-miR-143-3p (≤ -3-fold change, Blue in display) 
as shown in (Table 3-12) were selected for further individual RT-qPCR screening in 
the low BMD (Osteoporosis, & Osteopenia) and normal BMD (non-osteoporosis) 
subjects. 
Table 3-12: Differentially-expressed miRNA in Osteoporosis, Female Group 
Compared with Osteopenia, Female Group using the QIAGEN Human Serum & 
Plasma miRNA PCR Array. 
Red = ≥ 2-fold change upregulated; blue = ≤ -2-fold change Downregulated 
No. Mature ID Fold Change 
1.  hsa-miR-3923 4.1 
2.  hsa-miR-4258 4.0 
3.  SNORD61 3.3 
4.  hsa-miR-196b-3p 2.8 
5.  hsa-miR-485-5p 2.8 
6.  hsa-miR-1193 2.4 
7.  hsa-miR-2467-3p 2.4 
8.  hsa-miR-1281 2.3 
9.  hsa-miR-4274 2.3 
10.  hsa-miR-100-5p -32.1 
11.  hsa-miR-4516 -9.1 
12.  hsa-miR-145-3p -8.8 
13.  hsa-miR-4306 -7.5 
14.  hsa-miR-548e-3p -6.4 
15.  hsa-miR-206 -6.3 
16.  hsa-miR-215-5p -5.8 
17.  hsa-miR-122-5p -5.7 
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No. Mature ID Fold Change 
18.  hsa-miR-3911 -5.2 
19.  hsa-miR-548d-5p -4.7 
20.  hsa-miR-373-5p -4.5 
21.  hsa-miR-99a-5p -4.4 
22.  hsa-miR-375 -3.9 
23.  hsa-miR-450a-5p -4.2 
24.  hsa-miR-143-3p -4.0 
25.  hsa-miR-1290 -3.6 
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3.2.3 RT-qPCR initial screening 
The expression level of twenty-four miRNAs identified by PCR array were screened 
on individual serum samples using RT-qPCR. 100ng RNA purified from individual 
serum samples including osteopenia and osteoporosis were reverse transcribed first, 
then RT-qPCR was performed in duplicate using QIAGEN miScript miRNA primers 
(Materials and Methods 2.6.2., Table 2-2), and obtained Ct values from each RT-qPCR 
were analysed using two-way ANOVA followed by Bonferroni’ multiple comparisons 
test (Materials and Methods 2.9). 
3.2.3.1 Establish optimized condition for RT-qPCR 
Firstly, to get the appropriate cDNA concentration for individual miRNA expression, 
the optimisation process started on circulating serum hsa-miR-100-5p, which was the 
most significantly downregulated miRNA in the miRNA PCR array (≤-32 fold change), 
on three sets of cDNA diluted samples: 1:10 (10ng), 1:5 (50ng) and 1:3 (33ng) as 
shown in Figure 3-12. 
  
Figure 3-12: Validation of hsa-miR-100-5p Ct value expression between cDNA 
samples diluted 1:10, 1:5 and 1:3.  
miRNA expression of hsa-miRNA-100-5p diluted 1:10 (Green, Osteopenia n=2), 
diluted 1:5 (Yellow, osteopenia n=1 and osteoporosis n= 4) and diluted 1:3 (Orange, 
osteopenia n=2 and osteoporosis=4). 
 
c D N A  1 :1 0  (n = 2 ) c D N A  1 :5  (n = 5 ) c D N A  1 :3  (n = 6 )
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miRNA RT-qPCR Ct mean value for hsa-miR-100-5p (diluted 1:10 and 1:5 and 1:3) 
were ≥ 32 Ct. (Table 3-13). Out of three Osteoporosis with fracture one had a Ct value 
≥40 in both dilutions (1:5 and 1:3), which indicate late RNA amplification or test was 
not detected (Figure 3-12). 
The average miRNA RT-qPCR Ct mean for has-miR-100-5p (cDNA diluted 1:3) were 
lower than has-miR-100-5p (cDNA diluted 1:5) of average Ct mean difference of -1.4 
(Table 3-13), but not when compared with has-miR-100-5p (cDNA diluted 1:10).  
Table 3-13: miRNA RT-qPCR Ct mean value for circulating serum hsa-miR-100-5p in 
cDNA diluted 1:10, 1:5 and 1:3 samples. 
100ng cDNA of osteopenia (with/without fracture) and, osteoporosis (with/without 
fracture) were diluted 1:10 (10ng), 1:5 (20ng) and 1:3 (33ng). 
Clinical 
Category 
Specimen 
type  
(Total no.) 
has-miR-100-5p 
(cDNA 
diluted 1:10) 
Ct Mean ± SD 
(cDNA 
diluted 1:5) 
Ct Mean ± SD 
(cDNA diluted 
1:3) 
Ct Mean ± SD 
Osteopenia 
without 
fracture 
Serum (n=1) 32 ± 0.1 32.8± 0.1 32.4 ± 0.1 
Osteopenia 
with fracture 
Serum (n=1) 31.6 ± 0.2 
 
30.7 ± 0.2 
Osteoporosis 
without 
fracture 
Serum (n=1)  31 ± 0.2 29.7 ± 0.1 
Severe 
osteoporosis 
with fracture 
Serum (n=3)  34.7 ± 5.9 33.6 ± 4.7 
Total Average  31.8 ± 0.2 33.6 ± 4.9 32.2 ± 3.7 
 
Although, there were no significant expression differences between the three cDNA 
dilutions: cDNA diluted 1:5 (10ng), cDNA diluted 1:5 (20ng) and diluted 1:3 (33ng) 
was measured, we decided to use the later one as a dilution protocol for the rest of 
the study. 
Chapter3: Identification of Circulating MicroRNAs in Osteoporosis 
89 | P a g e  
 
3.2.3.2 RT-qPCR screen 
The next step was validating the most down/up-regulated miRNAs identified by PCR 
array, including serum hsa-miR-100-5p (≤-32 fold change), hsa-miR-4516 (-9-fold) 
and hsa-miR-3923 (4.1-fold) in four LBMD study groups: Osteopenia, Osteopenia 
with fracture, Osteoporosis and Osteoporosis with fracture. 
The Ct mean value for the circulating serum has-miR-100-5p and has-miR-4516 of the 
four LBMD subgroups (Figure 3-14) were ranged from 30.9 to 31.6 and 25.6 to 26, 
respectively (Table 3-15), with insignificant Ct mean difference between the four 
LBMD subgroups (Table 3-14). Whereas, the earliest Ct amplification for hsa-miR-
3923 was ≥34 Ct, which indicate late or no RNA amplification (Table 3-15). Therefore, 
hsa-miR-3923 was excluded from any further studies, while hsa-miR-100-5p and hsa-
miR-4516 was kept for further studies. 
The following step was the validation of additional two downregulated miRNAs (by 
PCR array): hsa-miR-122-5p (-5.7-fold) and hsa-miR-373-5p (-4.5-fold) between 
LBMD subgroups: Osteopenia (n=8), Osteopenia with fracture (n=7), Osteoporosis 
(n=17) and Osteoporosis with fracture (n= 14) (Figure 3-14). 
The Ct value expressions for hsa-miR-122-5p and hsa-miR-373-5p of the four LBMD 
study groups (Figure 3-14) were ranged from 25.8 to 27.6 and 32 to 32.7 Ct, 
respectively (Figure 3-14 and Table 3-15). Hsa-miR-122-5p Ct mean difference 
between Osteoporosis with fracture vs. Osteopenia without fracture was up to 2 Ct, 
while for hsa-miR-373-5p there were insignificant Ct mean difference between the 
four LBMD subgroups (Table 3-14). Both miRNAs were kept for further study due to 
their significant expression by PCR array. 
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Furthermore, four downregulated circulating serum miRNAs by PCR array: hsa-miR-
145-3p (-8.8 fold by PCR array), hsa-miR-206 (-6.3-fold change), hsa-miR-4258 (4-fold 
change) and hsa-miR-4306 (-7.5-fold change) were validated for the Ct expression 
and ranged from 29 to 31.2, 30.8 to 34, 32.5 to 35.8 and 30.9 to 34.1 Ct, respectively 
(Figure 3-14) (Table 3-15). But, there were no significant Ct mean difference of these 
four miRNAs between the four LBMD groups. Therefore, these miRNAs were 
excluded from the study.  
Due to limited sample volume and high cost of testing materials, fifteen miRNAs were 
initially validated in only two LBMD individuals: Osteopenia (SID# 120315OP04) 
versus Osteoporosis (SID# 120320OP03) (Figure 3-13). Out of these, five miRNAs 
were upregulated in Osteoporosis by PCR array: hsa-miR-196b-3p (2.8-fold), hsa-miR-
485-5p (2.8-fold), hsa-miR-1193 (2.4-fold), hsa-miR-2467-3p (2.4-fold) and hsa-miR-
4274 (2.3-fold), and the rest were downregulated: hsa-miR-548e-3p (-6.4-fold), hsa-
miR-215-5p (-5.8-fold), hsa-miR-548d-5p (-4.7-fold), hsa-miR-99a-5p (-4.4-fold), hsa-
miR-450a-5p (-4.2-fold), hsa-miR-375 (-3.9-fold), hsa-miR-1290 (-3.6-fold), hsa-miR-
143-3p (-4 fold), hsa-miR-1281 (2.3-fold) and hsa-miR-3911 (-5.2-fold). 
The earliest Ct amplification for 4 miRNAs: hsa-miR-196b-3p, hsa-miR-2467-3p, hsa-
miR-3911 and hsa-miR-485-5p were ≥ 35 Ct (Figure 3-13 and Table 3-15), and were 
excluded from any future study. The Ct value for hsa-miR-375 in both osteopenia and 
osteoporosis subjects was of 22.5 ± 0.1 Ct, with non-significant mean difference of -
0.15, and were kept for further study as a normalisation control. 
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Figure 3-13: Ct expression for 15 circulating serum miRNAs between two LBMD 
Subjects: 
Osteopenia without fracture and Osteoporosis without fracture for 15 Circulating 
serum miRNAs: hsa-miR-99a-5p (28.3 to 33.9), hsa-miR-1193 (33.8 to 45), hsa-miR-
1281 (30.9 to 35.3), hsa-miR-1290 (30.8 to 34), hsa-miR-143-3p (32.2 to 45), hsa-miR-
4274 (25.8 to 38), hsa-miR-196b-3p (35.1 to 41.7), hsa-miR-215-5p (32.4 to 35.1), 
hsa-miR-2467-3p (34.5 to 39.1), hsa-miR-3911 (38.5 to 39.8), hsa-miR-450a-5p (30.8 
to 34), hsa-miR-485-5p (34.6 to 37.6), hsa-miR-548d-5p (33.2 to 37.8), hsa-miR-548e-
3p (33.4 to 36.4) and hsa-miR-375 (22.5 to 22.6). Each bar represents the mean ±SD 
of duplicate run. 
 
Subsequently, hsa-miR-1193, hsa-miR-1281, hsa-miR-1290, hsa-miR-143-3p, hsa-
miR-215-5p, hsa-miR-375, hsa-miR-4274, and hsa-miR-99a-5p were further tested on 
four LBMD subjects and showed no significant Ct mean diff between the four groups 
(Table 3-15). Hsa-miR-215-5p and hsa-miR-99a-5p were kept for future study (Figure 
3-14. 
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Figure 3-14: Ct expression for 17 circulating serum miRNAs between four LBMD 
Subjects: 
Osteopenia without fracture, Osteopenia with fracture, Osteoporosis without 
fracture and Osteoporosis with fracture. hsa-miR-375 (Ct= 21.7 to 22.3), hsa-miR-
4516 (Ct= 25.6 to 26), hsa-miR-122-5p (25.8 to 27.6), hsa-miR-143-3p (26.6 to 29.8), 
hsa-miR-4274 (28.7 to 35.9), hsa-miR-99a-5p (28.2 to 29.6), hsa-miR-1290 (30.1 to 
32), hsa-miR-100-5p (30.9 to 31.6), hsa-miR-1281 (31.1 to 33.5), hsa-miR-145-3p (29 
to 31.2), hsa-miR-373-5p (32 to 32.7), hsa-miR-215-5p (32.4 to 33.2), hsa-miR-1193 
(32 to 32.9), hsa-miR-206 (30.8 to 34), hsa-miR-4306 (30.9 to 34.1), hsa-miR-3923 
(34.9 to 35.4), and hsa-miR-4258 (32.5 to 35.8) . Each bar represents the mean and 
±SD of duplicate run. 
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Table 3-14: Ct mean difference of circulating serum miRNAs between four LBMD 
groups 
Two way Anova with Bonferroni’s multiple comparison test for the Ct mean 
difference between four LBMD groups: Osteopenia, Osteopenia with fracture, 
Osteoporosis and Osteoporosis with fracture showed no significant P value. 
miRNA Test details Mean 
Diff. 
hsa-miR-100-5p Osteopenia with fracture (n= 7) vs. Osteopenia 
without fracture (n= 8) 
0.7 
Osteoporosis without fracture (n= 17) vs. Osteopenia 
without fracture (n= 8) 
0.1 
Osteoporosis with fracture (n= 14) vs. Osteopenia 
without fracture (n= 8) 
0.6 
Osteoporosis without fracture (n= 17) vs. Osteopenia 
with fracture (n= 7) 
-0.6 
Osteoporosis with fracture (n= 14) vs. Osteopenia 
with fracture (n= 7) 
-0.1 
Osteoporosis with fracture (n= 14) vs. Osteoporosis 
without fracture (n= 17) 
0.5 
hsa-miR-4516 Osteopenia with fracture (n= 7) vs. Osteopenia 
without fracture (n= 8) 
0.3 
Osteoporosis without fracture (n= 16) vs. Osteopenia 
without fracture (n= 8) 
0.3 
Osteoporosis with fracture (n= 14) vs. Osteopenia 
without fracture (n= 8) 
-0.1 
Osteoporosis without fracture (n= 16) vs. Osteopenia 
with fracture (n= 7) 
0 
Osteoporosis with fracture (n= 14) vs. Osteopenia 
with fracture (n= 7) 
-0.4 
Osteoporosis with fracture (n= 14) vs. Osteoporosis 
without fracture (n= 16) 
-0.4 
hsa-miR-122-5p Osteopenia with fracture (n= 7) vs. Osteopenia 
without fracture (n= 8) 
0.6 
Osteoporosis without fracture (n= 16) vs. Osteopenia 
without fracture (n= 8) 
0.8 
Osteoporosis with fracture (n= 14) vs. Osteopenia 
without fracture (n= 8) 
1.8 
Osteoporosis without fracture (n= 16) vs. Osteopenia 
with fracture (n= 7) 
0.2 
Osteoporosis with fracture (n= 14) vs. Osteopenia 
with fracture (n= 7) 
1.2 
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miRNA Test details Mean 
Diff. 
Osteoporosis with fracture (n= 14) vs. Osteoporosis 
without fracture (n= 16) 
1 
hsa-miR-373-5p Osteopenia with fracture (n= 7) vs. Osteopenia 
without fracture (n= 7) 
0 
Osteoporosis without fracture (n= 17) vs. Osteopenia 
without fracture (n= 7) 
-0.5 
Osteoporosis with fracture (n= 14) vs. Osteopenia 
without fracture (n= 7) 
0.2 
Osteoporosis without fracture (n= 17) vs. Osteopenia 
with fracture (n= 7) 
-0.5 
Osteoporosis with fracture (n= 14) vs. Osteopenia 
with fracture (n= 7) 
0.2 
Osteoporosis with fracture (n= 14) vs. Osteoporosis 
without fracture (n= 17) 
0.7 
hsa-miR-215-5p Osteopenia with fracture (n= 5) vs. Osteopenia 
without fracture (n= 6) 
0.5 
Osteoporosis without fracture (n= 12) vs. Osteopenia 
without fracture (n= 6) 
-0.3 
Osteoporosis with fracture (n= 8) vs. Osteopenia 
without fracture (n= 6) 
-0.2 
Osteoporosis without fracture (n= 12) vs. Osteopenia 
with fracture (n= 5) 
-0.8 
Osteoporosis with fracture (n= 8) vs. Osteopenia 
with fracture (n= 5) 
-0.7 
Osteoporosis with fracture (n= 8) vs. Osteoporosis 
without fracture (n= 12) 
0.1 
hsa-miR-99a-5p Osteopenia with fracture (n= 4) vs. Osteopenia 
without fracture (n= 5) 
-0.5 
Osteoporosis without fracture (n= 11) vs. Osteopenia 
without fracture (n= 5) 
-1.4 
Osteoporosis with fracture (n= 7) vs. Osteopenia 
without fracture (n= 5) 
-1.4 
Osteoporosis without fracture (n= 11) vs. Osteopenia 
with fracture (n= 4) 
-0.9 
Osteoporosis with fracture (n= 7) vs. Osteopenia 
with fracture (n= 4) 
-0.9 
Osteoporosis with fracture (n= 7) vs. Osteoporosis 
without fracture (n= 11) 
0 
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In summary, the outcomes from RT-qPCR screening process was the selection of 6 
miRNAs: hsa-miR-4516 (26Ct ± 2), hsa-miR-122-5p (27Ct ± 3), hsa-miR-99a-5p (29Ct 
± 2), hsa-miR-373-5p (32Ct ± 2), hsa-miR-215-5p (33Ct ± 2) and hsa-miR-100-5p (31Ct 
± 2) with earliest miRNA expression of 26 Ct and Ct value mean difference between 
the osteopenia and osteoporosis group >2 Ct (Table 3-15). 
Table 3-15: Summary Table for 24 circulating serum miRNAs Average delta Ct value 
in clinical samples 
miRNA Osteopenia  
 
Ct Mean ± SD  
(N) 
Osteopenia 
with fracture 
Ct Mean ± SD  
(N) 
Osteoporosis  
 
Ct Mean ± SD  
(N) 
Osteoporosis 
with fracture 
Mean Ct ± SD  
(N) 
hsa-miR-100-5p 30.9 ± 1.3 
(n=8) 
31.6 ± 1.2 
(n=7) 
31 ± 2 
(n=17) 
31.5 ± 2.8 
(n=14) 
hsa-miR-1193 32.9 ± 0.6 
(n=6) 
32.6 ± 1 
(n=5) 
32.3 ± 1.2 
(n=12) 
32 ± 1.7 
(n=8) 
hsa-miR-122-5p 25.8 ± 1.3 
(n=8) 
26.4 ± 2.3 
(n=7) 
26.6 ± 2.4 
(n=16) 
27.6 ± 3.4 
(n=14) 
hsa-miR-1281 31.1 ± 0.4 
(n=2) 
31.4 ± 0 
(n=1) 
33.5 ± 2.4 
(n=2) 
32.1 ± 0 
(n=1) 
hsa-miR-1290 30.4 ± 0.5 
(n=2) 
30.1 ± 0 
(n=1) 
32 ± 2.8 
(n=2) 
30.3 ± 0 
(n=1) 
hsa-miR-143-3p 26.7 ± 0 
(n=2) 
26.6 ± 0 
(n=1) 
29.8 ± 3.4 
(n=2) 
27 ± 0 
(n=1) 
hsa-miR-145-3p 31.2 ± 0.7 
(n=4) 
30.5 ± 1.8 
(n=4) 
29 ± 0.4 
(n=4) 
30.6 ± 2.5 
(n=4) 
hsa-miR-196b-
3p 
35.1 ± 0.2 
(n=1) 
 41.6 ± 3 
(n=1) 
 
hsa-miR-206 34 ± 1.5 
(n=4) 
33.4 ± 0.6 
(n=4) 
30.8 ± 2 
(n=4) 
33.7 ± 1.4 
(n=4) 
hsa-miR-215-5p 32.7 ± 1.2 
(n=6) 
33.2 ± 1.4 
(n=5) 
32.4 ± 1.4 
(n=12) 
32.5 ± 0.9 
(n=8) 
hsa-miR-2467-
3p 
34.5 ± 0.9 
(n=1) 
 39.1 ± 1 
(n=1) 
 
hsa-miR-373-5p 32.5 ± 0.7 
(n=7) 
32.5 ± 1.2 
(n=7) 
32 ± 2 
(n=17) 
32.7 ± 2.9 
(n=14) 
hsa-miR-375 22.3 ± 0.5 
(n=2) 
21.9 ± 0 
(n=1) 
22.3 ± 0.3 
(n=2) 
21.7 ± 0 
(n=1) 
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miRNA Osteopenia  
 
Ct Mean ± SD  
(N) 
Osteopenia 
with fracture 
Ct Mean ± SD  
(N) 
Osteoporosis  
 
Ct Mean ± SD  
(N) 
Osteoporosis 
with fracture 
Mean Ct ± SD  
(N) 
hsa-miR-3911 39.8 ± 2.4 
(n=1) 
 38.4 ± 0.8 
(n=1) 
 
hsa-miR-3923 35.4 ± 0.2 
(n=2) 
35.3 ± 1.7 
(n=2) 
34.9 ± 0 
(n=1) 
34.9 ± 0.3 
(n=3) 
hsa-miR-4258 35.8 ± 0.9 
(n=4) 
32.5 ± 1.8 
(n=4) 
34.2 ± 0.1 
(n=4) 
33.1 ± 2.1 
(n=4) 
hsa-miR-4274 28.7 ± 4.2 
(n=2) 
32.9 ± 0 
(n=1) 
35.9 ± 2.9 
(n=2) 
31.7 ± 0 
(n=1) 
hsa-miR-4306 34.1 ± 0.8 
(n=4) 
32.2 ± 2.1 
(n=4) 
30.9 ± 0.7 
(n=4) 
33.4 ± 4.5 
(n=4) 
hsa-miR-450a-
5p 
30.8 ± 0.4 
(n=1) 
 33.9 ± 0.2 
(n=1) 
 
hsa-miR-4516 25.7 ± 1.6 
(n=8) 
26 ± 1.4 
(n=7) 
26 ± 1.6 
(n=16) 
25.6 ± 2.4 
(n=14) 
hsa-miR-485-5p 34.6 ± 0.4 
(n=1) 
 37.6 ± 0.6 
(n=1) 
 
hsa-miR-548d-
5p 
33.1 ± 0 
(n=1) 
 37.8 ± 0 
(n=1) 
 
hsa-miR-548e-
3p 
33.4 ± 0.1 
(n=1) 
 36.4 ± 1.2 
(n=1) 
 
hsa-miR-99a-5p 29.6 ± 1.8 
(n=5) 
29.1 ± 1.7 
(n=4) 
28.2 ± 1.2 
(n=11) 
28.2 ± 2.1 
(n=7) 
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3.3 Discussion 
This study was designed to identify circulatory miRNAs associated with the 
progression of osteoporosis in a test group of patients using PCR arrays. Preliminary 
screening for circulating serum miRNAs associated with osteoporosis using miRNA 
PCR array that were capable of detecting more than 300 circulating serum/plasma 
miRNAs per set showed significant changes in the levels of twenty-four miRNAs in 
osteoporotic female patients. Wherein, six miRNAs: hsa-miR-4516, hsa-miR-99a-5p, 
hsa-miR-373-5p, hsa-miR-215-5p, hsa-miR-100-5p and hsa-miR-122-5p were 
remarkably downregulated by > 2-fold in the osteoporosis patient group compared 
to the osteopenia group.  
The study set out to compare the level of secreted miRNAs in certain patterns of low 
bone mass with respect to those from preferably age matched non-osteoporosis 
controls. The levels of 6 miRNAs, hsa-miR-4516, hsa-miR-99a-5p, hsa-miR-373-5p, 
hsa-miR-215-5p, hsa-miR-100-5p and hsa-miR-122-5p, in clinical sample pools were 
screened using RT-qPCR. The results showed that these 6 miRNAs might be 
associated with osteoporosis. Changes in the levels of some of the miRNAs identified 
in the present study have previously been associated with normal and abnormal 
bone development. For example, MiR-99a has been found to regulate early 
chondrogenic differentiation of rat mesenchymal stem cells by targeting the BMPR2 
gene. (Zhou et al., 2016), and to inhibit tumour cell proliferation via targeting of 
TNFAIP8 in osteosarcoma cells. (Xing and Ren, 2016). 
miRNA-100 overexpression was found to inhibits bone morphogenetic protein-
(BMP)-induced osteoblast differentiation by targeting BMPR2 (Zeng et al., 2012b), 
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and by decreasing Smad1 protein levels (Fu et al., 2016). miR-100, and miR-125b 
were reported to be upregulated in osteoporotic fractured patients’ serum and bone 
tissues compared to non-osteoporotic controls. (Seeliger et al., 2014). 
miR-122, which is abundantly detected on hepatocytes (Laterza et al., 2013), was 
found to be upregulated in the serum of patients with osteoporotic fractures 
compared to non-osteoporotic controls (Seeliger et al., 2014, Panach et al., 2015), 
and was found to be under-expressed in osteosarcoma tissues (Xiao et al., 2015). 
However, no effect has been reported in the context of bone metabolism (Weilner 
et al., 2015). 
The levels of miR-4516, miR-215 and MiR-373 in serum/plasma have been found to 
be associated with various pathological processes. For example, miR-215 was 
suggested to be a potential prognostic biomarker in colon cancer (Karaayvaz et al., 
2011), and could contribute to progression of kidney cancer metastasis through 
different biological processes (White et al., 2011). Plasma miR-215 was 
downregulated in Chronic Myeloid Leukaemia (CML) patients undergoing successful 
discontinuation of Imatinib therapy (Ohyashiki et al., 2016). 
MiR-373 functions as an oncogene and targets YOD1 gene in cervical cancer (Wang 
et al., 2015b), and promotes migration and invasion in human oesophageal 
squamous cell carcinoma (ESCC) (Liu et al., 2016). However, there is, so far, no 
published report linking these circulating miRNAs, miR-4516, miR-215 and MiR-373, 
with osteoporosis. Thus, further analysis will be necessary. 
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In conclusion: a number of differentially-expressed miRNAs between osteoporosis 
and osteopenia groups have been identified using miRNA PCR arrays. After initial RT-
qPCR screening, 6 out of 24 miRNAs might be possible candidates associated with 
osteoporosis. Therefore, the next step was to investigate these 6 miRNAs in 
individual clinical serum and plasma samples, to assess their potential diagnostic 
value for osteoporosis. These experiments will be discussed in the next chapter.
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4 Chapter 4 Potential Circulating miRNAs as Diagnostic 
Biomarkers 
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4.1 Introduction 
In the previous chapter, 6 miRNAs were found to be differentially-expressed in serum 
samples from osteoporosis patients. Interestingly, the expression changes of the six 
circulating miRNAs in serum/plasma have been found to be associated with various 
pathological processes. For example, circulating hsa-miR-4516 was found to be 
upregulated in plasma samples of HIV-associated neurocognitive disorder  compared 
to a control group (Asahchop et al., 2016). miR-4516 was also reported to be 
associated with prostate cancer (Bell et al., 2015), cardiovascular (Zhang et al., 2016) 
and skin diseases (Chowdhari and Saini, 2014).  However, there is no published report 
indicating miR-4516 associating with osteoporosis. 
MiR-373 has diverse functions in cancer (Wei et al., 2015). Circulating serum hsa-miR-
373 was significantly upregulated with the progression of breast cancer disease 
(Eichelser et al., 2013), and in epithelial ovarian cancer patients (Meng et al., 2016) 
compared to healthy women. Regarding bone related diseases, miR-373 was 
significantly downregulated in osteoarthritis patients compared to normal controls 
(Iliopoulos et al., 2008). However, until now, there has been no published data 
showing that miR373 is involved in the development of osteoporosis. 
Circulating miR-215 was found to be significantly upregulated in patients with both 
Barrett's esophagus or columnar-lined esophagus compared to esophagitis (Cabibi et 
al., 2016), as well as, in chronic hepatitis and hepatocellular carcinoma compared to 
a control group (Zhang et al., 2014). However, there is no evidence to show that 
miR215 is associated with osteoporosis. 
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Circulating miR-122-5p has been found to be upregulated in the plasma of patients 
with hepatitis B viral infection compared to healthy controls (Zhang et al., 2010), in 
patients with biliary atresia, an idiopathic neonatal liver disease, compared to age 
matched healthy controls (Peng et al., 2016) and in the serum of patients with severe 
acute viral hepatitis with coagulopathy, as compared to patients without 
coagulopathy (Weseslindtner et al., 2016). In the matter of skeletal diseases, hsa-
miR-122-5p was found to be dysregulated in osteosarcoma cells compared to normal 
tissue (Xiao et al., 2015), over-expressed in serum of patients with osteoporotic 
fractures compared to non-osteoporotic (Seeliger et al., 2014) and osteoarthritis 
sufferers (Panach et al., 2015), with significant clinical discrimination value of > 0.7 
during validation (Panach et al., 2015).  
miR-100 upregulation was found to inhibit osteogenic differentiation by targeting 
bone morphogenetic protein receptor type II (BMPR2) (Zeng et al., 2012b) and 
Smad1 protein (Fu et al., 2016). MiR-100 was significantly upregulated in the serum 
and bone tissue of osteoporotic patients (Seeliger et al., 2014). 
MiR-99a-5p was found to play vital role in early chondrogenic differentiation in rat 
(Zhou et al., 2016), was shown to be downregulated in osteosarcoma tissue relative 
to noncancerous bone tissues (Zhao et al., 2016, Gougelet et al., 2011). Circulating 
plasma miR-99a was downregulated in acute myocardial infarction patients 
compared to healthy controls (Yang et al., 2016) and in endometrioid endometrial 
cancer compared to healthy controls (Torres et al., 2012). In contrast, circulating 
serum miR-99a was shown to be upregulated in HBV infected patients compared to 
healthy controls (Li et al., 2010). 
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The purpose of this Chapter is therefore to investigate the association of the panel 
of circulating miRNAs from Chapter 3 (hsa-miR-4516, hsa-miR-373-5p, hsa-miR-122-
5p, hsa-miR-215-5p, hsa-miR-99a-5p and hsa-miR-100-5p) with osteoporosis to 
verify whether these circulating serum/plasma miRNAs could be used in future as 
molecular biomarkers. 
To this end, Real-Time quantitative PCR (RT-qPCR) experiments were performed on 
clinical serum and plasma samples. The relationship between miRNA expression 
changes and BMD index was also examined to investigate their combined association 
with osteoporosis.  
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4.2 Results 
Additional ethical approval for the additional clinical specimens needed was obtained 
from the RLBUHT [Ref No: 15/EE/0051], prior to participants’ recruitment [Materials 
and Methods 2.3.1.]. Clinical samples were obtained from one hundred and sixty-one 
participants after informed consent. 
According to the Bone Mineral Density (BMD) T-Score and the clinical findings, 
samples were classified into 5 groups: Non-osteoporosis control (BMD T-Score >-1, 
n= 30), Osteopenia (-2.5 ≤ BMD T-Score ≤ -1, n= 63), Osteopenia with fracture (-2.5 ≤ 
BMD T-Score ≤ -1, n= 15), Osteoporosis (BMD T-Score ≤ -2.5, n= 34) and Osteoporosis 
with fracture (BMD T-Score ≤ -2.5, n= 19) (Table 4-1). Among those patients with low 
bone mass (BMD T-score < -1), 97 patients were without fractures and 34 patients 
were with fractures. 81% of participants were female. The average age of healthy 
non-osteoporosis control participants was 45 years ± SD 20. The average age of 
osteopenia and osteoporosis patients was 66 years ± SD 10.7 and 68 years ± SD12.6, 
respectively. 18 non-osteoporotic participants were under 40 years old without a 
history of bone fracture. In addition, four Low Bone Mineral Density (LBMD) 
Osteopenia (n=2), Osteoporosis (n=1) and Osteoporosis with fracture (n=1) were 
under 40 years of age (Table 4-1). 
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Table 4-1: Summary of characteristics of clinical samples 
Clinical 
Category 
No. of 
Participants 
Sex 
[Female/
Male] 
Age 
Average 
±SD 
BMD 
Average 
±SD 
(g/cm2) 
T-Score 
(Lumbar 
Spine (L2-
L4) 
Non-
osteoporosis 
control  
30 20/10 45 ± 20 1 ± 0.1 0.6 ± 1.4 
Osteopenia 63 53/10 65 ± 10.3 0.8 ± 0.1 -1.2 ± 0.9 
Osteopenia 
with fracture 
15 13/2 66 ± 11.2 0.9 ± 0.1 -1.1 ± 1.1 
Osteoporosis 34 28/6 67 ± 13 0.7 ± 0.1 -2.8 ± 0.9 
Osteoporosis 
with fracture 
19 17/2 68 ± 12.3 No data -2.9 ± 1 
Total 161  62 ± 13.4 0.9 ± 0.1 -1.5 ± 1.1 
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4.2.1 miRNA quality and yields  
miRNAs were extracted from 161 serum and 142 plasma samples using TRIzol® LS 
reagent and QIAGEN miRNeasy Mini Kit (Materials and Methods 2.5), and were 
checked for purity and concentration using a NanoDrop™ 2000 spectrophotometer 
(Material & Method 2.5.1), with average RNA yields of 1437.1 ± 680.8 ng and 1297 ± 
607 ng, respectively (Table 4-2). Both extracted serum and plasma RNA samples have 
relatively similar RNA concentration (ranging between 700 to 2000 ng/mL), and 
260/280 and 260/230 RNA ratio (Table 4-2). High quality RNAs purified from the 161 
serum and 142 plasma samples were used for RT-qPCR analysis to determine the 
levels of the six miRNAs, hsa-miR-4516, hsa-miR-122-5p, hsa-miR-99a-5p, hsa-miR-
100-5p, hsa-miR-373-5p and hsa-miR-215-5p, as described in the next section.  
Table 4-2: Summary of quality check of RNA isolated from clinical samples  
Specimen 
Type 
No. of 
Samples 
RNA 260/280 
Ratio  
Mean ± SD 
RNA 260/230 
Ratio  
Mean ± SD 
Total RNA Yield 
(ng) Mean ± SD 
Serum 161 1.3 ± 0.05 0.3 ± 0.01 1437.1 ± 680.8 
Plasma  142* 1.2 ± 0.04 0.4 ± 0.16 1297 ± 607 
*No plasma sample were obtained from 19 participants. 
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4.2.2 The levels of miRNA in clinical samples using RT-qPCR  
100 ng of purified RNAs from each serum or plasma sample, in the osteopenia (with 
and without fracture), osteoporosis (with and without fracture) and non-
osteoporosis groups was reverse transcribed to generate first strand cDNA. RT-qPCR 
was performed using diluted first strand cDNA at a ratio of 1:3 in duplicate for each 
sample as described in Material & Methods, 2.6. The Ct value for each sample 
obtained from each RT-qPCR run was normalised using two small RNA molecules, 
SNORD96A and RNU6-2. The relative levels of miRNAs in serum or plasma samples 
were calculated using the 2-Ct methods (Materials and Methods, 3.2.3.3).  
The average levels of miRNA in serum and plasma value (log10 [2-Ct]) for the five 
study groups: non-osteoporotic, osteopenia (with/without fracture) and 
osteoporosis (with/without fracture) are listed in Appendix 8.5. Hsa-miR-215-5p and 
hsa-miR-99a-5p were tested on 161 serum samples, but only 128 and 134 
participants’ plasma samples, respectively and hsa-miR-373-5p was tested on 157 
serum and 136 plasma samples. The reduced number of samples was due to an 
insufficiency of extracted serum/plasma RNA samples for some patients.  All other 
miRNAs were tested on the full number of 161 serum and 142 plasma samples. 
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4.2.3 Identify miRNAs associated with age  
 All members of the panel of miRNA from Chapter 3 were tested for a relationship 
between expression and patient age.  Only three miRNAs showed such a relationship, 
namely hsa-miR-4516, hsa-miR-373-5p and hsa-miR-100-5p. Hsa-miR-4516, hsa-miR-
373-5p showed significant association with increasing age in serum samples (p =< 
0.0001 and 0.023, respectively), but not in plasma samples (p= 0.41 and 0.44, 
respectively) (Figure 4-1 and Figure 4-2), whereas hsa-miR-100-5p significantly 
associated with age in plasma, but not in serum samples (p = 0.0128 and 0.576, 
respectively) (Figure 4-3).  
 
Figure 4-1: The level of circulating hsa-miR-4516 associated with age 
Panel A: The levels of hsa-miR-4516 in serum is significantly associated with age, (p 
(two-tailed) < 0.0001, Pearson r = 0.32 and 95% CI 0.17. to 0.45). Panel B, the levels 
of hsa-miR-4516 in plasma were not associated with age (p = 0.4133, Pearson r= 
0.069 and 95% CI -0.23 to 0.097). Blue line= regression line and Red line= 95% 
prediction band. 
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Figure 4-2: The level of circulating hsa-miR-373-5p associated with Age.  
Panel A, the levels of hsa-miR-373-5p in serum samples significantly increased with 
increasing age (p (two-tailed) = 0.023, Pearson r = 0.18 and 95% CI 0.03 to 0.33). Panel 
B: The levels of hsa-miR-373-5p in plasma samples were not associated with 
increasing age (p (two-tailed) = 0.4396, Pearson r= -0.067 and 95% CI -0.23 to 0.1). 
Blue line= regression line and Red line= 95% prediction band. 
 
 
Figure 4-3: The levels of circulating hsa-miR-100-5p associated with age 
Panel A, the levels of hsa-miR-100-5p in serum samples was not associated with 
participants’ age, (p (two-tailed) = 0.58, Pearson r=-0.044 and 95% CI =-0.2 to 0.11). 
Panel B, the levels of hsa-miR-100-5p in plasma samples were significantly increased.  
with participants ‘age, (p (two-tailed) = 0.0128, Pearson r = 0.21 and 95% CI 0.05 to 
0.36). Blue line= regression line and Red line= 95% prediction band. 
 
These results suggest a possible relationship with age for these three sample, 
although it is not possible to explain the differences between serum and plasma 
samples.  Since participant’s age was a confounding factor in the expression of some 
of the circulating miRNAs (4.2.4). Therefore, those participants under 40 years old 
were not included in the following investigation. 
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4.2.4 Correlation of the levels of miRNA in Plasma Versus Serum  
In order to verify if the levels of circulating miRNA in blood are affected by the 
specimen type, a correlation study for the logarithmically (Log10) transformed 
miRNA qPCR 2^-Ct data was performed between serum and plasma samples for 
participants who are over 40 years of age (n=134). Pearson coefficient correlation 
analysis showed that the levels of both miRNAs, hsa-miR-122-5p and hsa-miR-4516 
in serum correlate with their levels in plasma samples (p (two-tailed) < 0.0001, and 
0.0019, respectively, Figure A & B). Thus, the levels of both miRNAs, hsa-miR-122-5p 
and hsa-miR-4516 are not interfered by the sample types. Therefore, either serum or 
plasma sample type is suitable for the detection of these miRNAs using RT-qPCR. 
The level of hsa-miR-100-5p was much lower in plasma compared to that in serum 
samples as shown in (Figure 4-4, C), (p (two-tailed) = 0.0029, Pearson r =-0.26 and 
95%CI -0.41 to -0.09). The result indicates that the levels of has-miR100-5p is 
proportionally decreased in plasma compared to serum samples.  
The levels of hsa-miR-99a-5p, hsa-miR-373-5p and hsa-miR-215-5p in plasma 
samples were not significant different to those in serum samples. Either serum or 
plasma samples are suitable to detect the level of these three miRNAs. 
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Figure 4-4: Correlation of circulating miRNA expression between serum and plasma 
samples (n=134)  
Panel A: The levels of miR122-5p show strong correlation between plasma and serum 
samples (p (two-tailed) < 0.0001, Pearson r =0.52). Panel B: The levels of hsa-miR-
4516 show strong correlation between serum and plasma samples (p (two-tailed) = 
0.0019, Pearson r =0.27. Panel C: the levels of hsa-miR-100-5p show significant 
reverse correlation between plasma and serum samples (p (two-tailed) = 0.0029, 
Pearson r =-0.26). Blue line= regression line and Red line= 95% prediction band. 
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4.2.5 Differentially expressed circulating miRNAs associated with osteoporosis 
patients 
Six miRNAs were validated on 139 serum samples and 134 plasma samples using RT-
qPCR. One-way ANOVA analysis, with ‘Benferroni’s multiple comparison test’ 
analysis and ‘Box-and-Whisker’ plots were used to identify differentially-expressed 
miRNAs associated with osteoporosis patients (Materials and Methods 2.9). The 
results show that has-miR-373-5p is differentially-expressed between non-
osteoporotic control, osteopenia and osteoporosis patients as shown in Figure 4-5A.  
The levels of hsa-miR-373-5p in serum are lower in osteopenia and osteoporosis 
groups compared to the non-osteoporosis control group (ANOVA p = 0.0003) (Figure 
4-5-A). There was significant down-regulation of hsa-miR-373-5p in osteopenia (with 
& without fracture) and in osteoporosis (with & without fracture) compared to the 
non-osteoporosis control group (p = 0.048 and 0.001, respectively, Bonferroni’s 
correction) (Table 4-3). The levels of hsa-miR-373 were significantly lower in 
osteoporosis (with & without fracture) compared to the osteopenia, group (p= 
0.021). In contrast, there were no significant differences in the levels of hsa-miR-373-
5p in plasma from the same groups of patients (ANOVA p = 0.42) (Figure 4-5). These 
results show that significantly reduced levels of hsa-miR-373-5p in serum, but not 
plasma, were associated with the presence of osteopenia and osteoporosis. 
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Figure 4-5: Differentially expressed has-miR-373-5p associated with Osteoporosis. 
Box plots show the 25th, 50th, and 75th percentiles and minimum to maximum 
ranges of the levels of hsa-miR-373-5p in serum and plasma among non-
osteoporosis, osteopenia and osteoporosis groups. Panel A shows a statistically 
significant correlation of serum hsa-miR-373-5p among the osteoporosis patients 
and the osteopenia patients, compared to the non-osteoporotic control (n=12), 
(ANOVA p< 0.0003). Panel B shows that the level of hsa-miR-373-5p in plasma 
samples was not significantly different among non-osteoporotic control, osteopenia 
patients, and osteoporosis patients, (p=0.4). ns = not significant, *p <0.05 and ***p 
<0.001. The comparison indicated by Bonferroni’s multiple comparisons test (One-
way ANOVA).  
 
Table 4-3: One-way ANOVA multiple comparisons test for hsa-miR-373-5p 
expression level between Non-Osteoporosis, Osteopenia, and Osteoporosis. 
Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's 
p Value 
Serum 
hsa-miR-
373-5p 
0.0003 Osteopenia, (n=74) vs. 
Non-Osteoporotic (n=12) 
-0.32 (-0.641 
to -0.002) 
0.048 
Osteoporosis, (n=50) vs. 
Non-Osteoporotic (n=12) 
-0.53 (-0.859 
to -0.198) 
0.001 
Osteoporosis, (n=50) vs. 
Osteopenia, (n=74) 
-0.21 (-0.39 
to -0.024) 
0.021 
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The level of hsa-miR-122-5p in serum was significantly down-regulated in the 
osteoporosis patients compared to non-osteoporosis control and osteopenia, groups 
(ANOVA p= 0.002) (Figure 4-6), (Bonferroni’s p= 0.008 and 0.021), respectively (Table 
4-4). The level of hsa-miR-122-5p in plasma samples was not significantly changed in 
osteoporosis patients or osteopenia patients compared to control groups (ANOVA p 
value= 0.21) (Figure 4-6B). The results show that serum, but not plasma, hsa-miR-
122-5p might be down-regulated in the development of osteoporosis. 
 
Figure 4-6: Differentially expressed hsa-miR-122-5p associated with Osteoporosis. 
Box Plot shows the 25th, 50th, and 75th percentiles and minimum to maximum 
ranges of the levels of hsa-miR-122-5p among Non-osteoporosis, Osteopenia and 
Osteoporosis groups. Panel A: box plots show a statistically significant correlation of 
hsa-miR-122-5p among the osteoporosis patients (ANOVA p = 0.002) compared to 
the non-Osteoporotic and Osteopenia, p (Bonferroni’s)= 0.008 and p (Bonferroni’s)= 
0.021, respectively. Panel B, box plots show the level of hsa-miR-122-5p in plasma 
samples was not significant among non-osteoporotic control (n=11), osteopenia 
patients and osteoporosis patients. *p <0.05, **p <0.01 and ns = not significant. The 
comparison indicated by Bonferroni’s multiple comparisons test (One-way ANOVA). 
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Table 4-4: One-way ANOVA multiple comparisons test for hsa-miR-122-5p 
expression level between Non-Osteoporosis, Osteopenia and Osteoporosis. 
Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's 
p Value 
Serum 
hsa-miR-
122-5p 
0.002 Osteopenia (n=76) vs. Non-
Osteoporotic (n=12) 
-0.23 (-0.577 
to 0.123) 
0.356 
Osteoporosis (n=51) vs. 
Non-Osteoporotic (n=12) 
-0.46 (-0.818 
to -0.096) 
0.008 
Osteoporosis (n=51) vs. 
Osteopenia (n=76) 
-0.23 (-0.434 
to -0.026) 
0.021 
 
The level of hsa-miR-215-5p in serum in Osteoporosis (Figure 4-7A), but not in 
osteopenia patients, was significantly lower compared to the non-osteoporotic 
control group (ANOVA p = 0.014, p (Bonferroni’s) = 0.013, Table 4-5). There were no 
significant differences in levels of hsa-miR-215-5p in plasma samples between the 
three groups (ANOVA p value= 0.42, Figure 4-7B). The results show that hsa-miR-215-
5p is differentially-expressed in serum, and is associated with Osteoporosis, but not 
osteopenia. 
 
Figure 4-7: Differentially expressed hsa-miR-215-5p associated with Osteoporosis. 
Box Plot shows the 25th, 50th, and 75th percentiles and minimum to maximum 
ranges of the levels of hsa-miR-215-5p among non-osteoporosis, osteopenia and 
osteoporosis groups. Panel A shows a statistically significant correlation of hsa-miR-
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215-5p among the osteoporosis patients (ANOVA p = 0.014) compared to the non-
Osteoporotic p (Bonferroni’s)= 0.013. Panel B shows that the level of hsa-miR-215-
5p in plasma samples was not significantly different among non-osteoporotic control, 
osteopenia patients and osteoporosis patients. ns = not significant and *p <0.05. The 
comparison indicated by Bonferroni’s multiple comparisons test (One-way ANOVA). 
 
Table 4-5: One-way ANOVA multiple comparisons test for hsa-miR-215-5p 
expression level between Non-Osteoporosis, Osteopenia and Osteoporosis 
Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's 
p Value 
Serum hsa-
miR-215-5p  
0.014 Osteopenia (n=72) vs. 
Non-Osteoporotic (n=12) 
-0.23 (-0.508 
to 0.048) 
0.139 
Osteoporosis (n=41) vs. 
Non-Osteoporotic (n=12) 
-0.35 (-0.642 
to -0.059) 
0.013 
Osteoporosis (n=41) vs. 
Osteopenia(n=72) 
-0.12 (-0.295 
to 0.054) 
0.292 
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The levels of circulating hsa-miR-4516 in plasma was significantly lower in the 
osteoporosis patients compared to both non-osteoporotic and osteopenia groups 
(ANOVA p= 0.009, Figure 4-8B), (Benferroni’s p = 0.025, and 0.048 respectively, 
(Table 4-6). The levels of has-miR-4516 did not show difference in serum samples 
(ANOVA P value= 0.15) (Figure 4-8A). The results suggest that hsa-miR-4516 might be 
associated with the development of osteoporosis. 
 
Figure 4-8: Differentially expressed hsa-miR-4516 associated with Osteoporosis. 
Box Plot show the 25th, 50th, and 75th percentiles and minimum to maximum ranges 
of the levels of hsa-miR-4516 among non-osteoporosis, osteopenia and osteoporosis 
groups. Panel A: box plots show the level of hsa-miR-4516 in serum samples was not 
significant among non-osteoporotic control, osteopenia patients and osteoporosis 
patients. Panel B, box plots show a statistically significant correlation of hsa-miR-
4516 among the osteoporosis patients (ANOVA p= 0.009) compared to the non-
Osteoporotic and osteopenic, p (Bonferroni’s)= 0.025 and p (Bonferroni’s)= 0.048. ns 
= not significant and *p <0.05. The comparison indicated by Bonferroni’s multiple 
comparisons test (One-way ANOVA). 
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Table 4-6: One-way ANOVA multiple comparisons test for hsa-miR-4516 expression 
level between Non-Osteoporosis, Osteopenia and Osteoporosis.  
Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's 
p Value 
Plasma 
hsa-miR-
4516 
0.009 Osteopenia (n=76) vs. Non-
Osteoporotic (n=11) 
-0.19 (-0.514 
to 0.142) 
0.516 
Osteoporosis (n=47) vs. 
Non-Osteoporotic (n=11) 
-0.38 (-0.716 
to -0.035) 
0.025 
Osteoporosis (n=47) vs. 
Osteopenia, Total (n=76) 
-0.19 (-0.379 
to -0.001) 
0.048 
 
 
4.2.6 Identify circulating miRNAs associated with osteoporotic fracture 
To find out whether the decrease in bone mineral density associated with or without 
fragility fracture has an influence on the miRNA levels in serum, osteopenia and 
osteoporosis participants (>40-year age) were categorised into four subgroups: 
osteopenia without fracture (n=61), osteopenia with fracture (n=15), osteoporosis 
without fracture (n=33) and osteoporosis with fracture (n=18) (Materials and 
Methods 2.3.1 & 2.3.2) and compared with a non-osteoporotic control group (n=12; 
>40-year age).  
hsa-miR-373-5p. The results show that the levels of hsa-miR-373-5p in serum were 
lower in the osteoporosis patients with fragility fracture compared to the non-
osteoporotic control group, osteopenia group (ANOVA p < 0.0001) (Figure 4-9A). The 
levels of hsa-miR-373-5p in serum samples were lower in osteopenia with fracture 
and osteoporosis without fracture compared to non-osteoporotic (p (Bonferroni’s) 
=0.045 and 0.033, respectively, Table 4-7), and even much lower in the osteoporosis 
patients with fracture compared to Osteopenia and Osteoporosis without fracture 
groups (p (Bonferroni’s) = 0.0004 and 0.05, respectively, Table 4-7).  
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The levels of hsa-miR-373-5p in plasma samples were not significantly different 
between these groups confirming the results in (Figure 4-9B). The results indicate 
that the decreased levels of hsa-miR-373-5p in serum might be associated with 
osteopaenic and osteoporotic fracture. 
 
Figure 4-9: Identification of hsa-miR-373-5p associated with osteoporosis.  
Panel A: Box pots show that the levels of hsa-miR-373-5p in serum were associated 
with osteoporosis patients with fracture (ANOVA p<0.0001) compared to non-
osteoporotic, osteopenia and osteoporosis (p (Bonferroni’s) <0.0001, 0.0004 and 
0.05, respectively). Panel B: Box plots show that the levels of hsa-miR-373-5p in 
plasma were not associated with osteoporosis patients with fracture (ANOVA 
p=0.59). *p <0.05, ***p <0.001 and ****p <0.0001. The comparison indicated by 
Bonferroni’s multiple comparisons test (One-way ANOVA). 
   
Table 4-7: One-way ANOVA multiple comparisons test for hsa-miR-373-5p 
expression level between Non-Osteoporosis, Osteopenia, Osteopenia with 
Fracture, Osteoporosis and Osteoporosis with Fracture 
Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's 
p Value 
Serum 
hsa-miR-
373-5p 
<0.0001 Osteopenia without 
fracture (n=59) vs. Non-
Osteoporotic (n=12) 
-0.29 (-0.659 
to 0.082) 
0.281 
Osteopenia with fracture 
(n=15) vs. Non-
Osteoporotic (n=12) 
-0.45 (-0.901 
to -0.005) 
0.045 
Osteoporosis without 
fracture (n=32) vs. Non-
Osteoporotic (n=12) 
-0.41 (-0.808 
to -0.019) 
0.033 
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Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's 
p Value 
Osteoporosis with 
fracture (18) vs. Non-
Osteoporotic (n=12) 
-0.76 (-1.201 
to -0.317) 
<0.0001 
Osteopenia with fracture 
(n=15) vs. Osteopenia 
without fracture (n=59) 
-0.16 (-0.491 
to 0.161) 
>0.99 
Osteoporosis without 
fracture (n=32) vs. 
Osteopenia without 
fracture (n=59) 
-0.13 (-0.373 
to 0.123) 
>0.99 
Osteoporosis with 
fracture (18) vs. 
Osteopenia without 
fracture (n=59) 
-0.47 (-0.789 
to -0.153) 
0.0004 
Osteoporosis without 
fracture (n=32) vs. 
Osteopenia with fracture 
(n=15) 
0.04 (-0.313 
to 0.393) 
>0.99 
Osteoporosis with 
fracture (18) vs. 
Osteopenia with fracture 
(n=15) 
-0.31 (-0.711 
to 0.1) 
0.332 
Osteoporosis with 
fracture (18) vs. 
Osteoporosis without 
fracture(n=32) 
-0.35 (-0.691 
to 0) 
0.05 
 
hsa-miR-99a-5p. The levels of hsa-miR-99a-5p in serum samples were significantly 
higher in the osteoporosis patients with fracture compared to the osteopenia and 
osteoporosis patients (ANOVA p = 0.0002) (Figure 4-10A), (p (Bonferroni's) <0.0001 
and 0.0007, respectively (Table 4-8). But the levels of hsa-miR-99a-5p in plasma 
samples were not significantly difference compared to the non-osteoporotic control 
group, ANOVA p= 0.3, Figure 4-10B) and (p (Bonferroni's= 0.237) (Table 4-8). The 
results show that the increasing level of hsa-miR-99a-5p in serum might associate 
with the osteoporotic fracture. 
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Figure 4-10: Identification of hsa-miR-99a-5p associated with osteoporosis. 
Panel A: Box pots show that the levels of hsa-miR-99a-5p in serum were associated 
with osteoporosis patients with fracture (ANOVA p= 0.0002) compared to osteopenia 
and osteoporosis (p (Bonferroni’s) < 0.0001 and 0.0007, respectively). Panel B: Box 
plots show that the levels of hsa-miR-99a-5p in plasma were not associated with 
osteoporosis patients with fracture (ANOVA p=0.31). ***p <0.001. The comparison 
indicated by Bonferroni’s multiple comparisons test (One-way ANOVA). 
 
Table 4-8: One-way ANOVA multiple comparisons test for hsa-miR-99a-5p 
expression level between Non-Osteoporosis, Osteopenia, Osteopenia with 
Fracture, Osteoporosis and Osteoporosis with Fracture 
Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's p 
Value 
Serum 
hsa-miR-
99a-5p 
0.0002 Osteopenia without 
fracture (n=59) vs. Non-
Osteoporotic (n=12) 
-0.29 (-0.78 
to 0.21) 
0.969 
Osteopenia with fracture 
(n=13) vs. Non-
Osteoporotic (n=12) 
-0.05 (-0.67 
to 0.58) 
>0.99 
Osteoporosis without 
fracture (n=29) vs. Non-
Osteoporotic (n=12) 
-0.26 (-0.79 
to 0.28) 
>0.99 
Osteoporosis with 
fracture (12) vs. Non-
Osteoporotic (n=12) 
0.51 (-0.13 to 
1.15) 
0.237 
Osteopenia with fracture 
(n=13) vs. Osteopenia 
without fracture (n=59) 
0.24 (-0.24 to 
0.72) 
>0.99 
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Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's p 
Value 
Osteoporosis without 
fracture (n=29) vs. 
Osteopenia without 
fracture (n=59) 
0.03 (-0.32 to 
0.38) 
>0.99 
Osteoporosis with 
fracture (12) vs. 
Osteopenia without 
fracture (n=59) 
0.8 (0.31 to 
1.29) 
<0.0001 
Osteoporosis without 
fracture (n=29) vs. 
Osteopenia with fracture 
(n=13) 
-0.21 (-0.73 
to 0.31) 
>0.99 
Osteoporosis with 
fracture (12) vs. 
Osteopenia with fracture 
(n=13) 
0.56 (-0.07 to 
1.18) 
0.121 
Osteoporosis with 
fracture (12) vs. 
Osteoporosis without 
fracture (n=29) 
0.77 (0.23 to 
1.30) 
0.0007 
 
hsa-miR-122-5p. The levels of hsa-miR-122-5p in serum were significantly lower in 
the osteoporosis patients with fracture compared to the non-osteoporotic and 
osteoporosis without fracture patients (ANOVA p= 0.03, (Figure 4-11A), (p 
(Bonferroni's) = 0.049 and 0.048, respectively (Table 4-9). However, the levels of hsa-
miR-122-5p in plasma did not show significant difference between these groups 
(Figure 4-11B). The results indicate that the decreasing levels of hsa-miR-122-5p in 
serum might is statistically be associated with the osteoporotic fracture.  
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Figure 4-11: Identification of hsa-miR-122-5p associated with osteoporosis. 
Panel A: Box pots show that the levels of hsa-miR-122-5p in serum were associated 
with osteoporosis patients with fracture (ANOVA p= 0.03) compared to non-
osteoporotic and osteoporosis (p (Bonferroni’s)= 0.049, and 0.048, respectively). 
Panel B: Box plots show that the levels of hsa-miR-122-5p in plasma were not 
associated with osteoporosis patients with fracture (ANOVA p=0.228). *p <0.05. The 
comparison indicated by Bonferroni’s multiple comparisons test (One-way ANOVA). 
 
Table 4-9: One-way ANOVA multiple comparisons test for hsa-miR-122-5p 
expression level between Non-Osteoporosis, Osteopenia, Osteopenia with 
Fracture, Osteoporosis and Osteoporosis with Fracture 
Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's p 
Value 
Serum 
hsa-miR-
122-5p 
0.0299 Osteopenia (n=61) vs. 
Non-Osteoporotic (n=12) 
-0.22 (-0.65 
to 0.21) 
>0.99 
Osteopenia with fracture 
(n=15) vs. Non-
Osteoporotic (n=12) 
-0.16 (-0.69 
to 0.36) 
>0.99 
Osteoporosis without 
fracture (n=33) vs. Non-
Osteoporotic (n=12) 
-0.11 (-0.57 
to 0.35) 
>0.99 
Osteoporosis with 
fracture (18) vs. Non-
Osteoporotic (n=12) 
-0.51 (-1.02 
to 0) 
0.049 
Osteopenia with fracture 
(n=15) vs. Osteopenia 
without fracture (n=61) 
0.06 (-0.33 to 
0.45) 
>0.99 
Osteoporosis without 
fracture (n=33) vs. 
Osteopenia without 
fracture (n=61) 
0.11 (-0.18 to 
0.41) 
>0.99 
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Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's p 
Value 
Osteoporosis with 
fracture (18) vs. 
Osteopenia without 
fracture (n=61) 
-0.29 (-0.65 
to 0.08) 
0.266 
Osteoporosis without 
fracture (n=33) vs. 
Osteopenia with fracture 
(n=15) 
0.06 (-0.37 to 
0.48) 
>0.99 
Osteoporosis with 
fracture (18) vs. 
Osteopenia with fracture 
(n=15) 
-0.34 (-0.82 
to 0.13) 
0.41 
Osteoporosis with 
fracture (18) vs. 
Osteoporosis without 
fracture (n=33) 
-0.4 (-0.8 to 
0) 
0.048 
 
hsa-miR-4516. The levels of hsa-miR-4516 in plasma were significantly lower in the 
osteoporosis with fracture patients compared to non-osteoporosis and osteopenia 
without fracture (ANOVA p value= 0.0002, Figure 4-12B), p (Benferroni’s)= 0.004 and 
0.002, respectively) (Table 4-10). Furthermore, the level hsa-miR-4516 in plasma 
were also lower in osteopenia with fracture compared to non-osteoporosis and 
osteopenia without fracture groups with insignificant p (Benferroni’s) of 0.06 and 
0.06, respectively) (Table 4-10). In contrast, the levels of hsa-miR-4516 in serum did 
not show significant differences between groups (Figure 4-12A). The results indicate 
that plasma hsa-miR-4516 might associate with osteoporotic fracture. 
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Figure 4-12: Identification of hsa-miR-4516 associated with osteoporosis. 
Panel A: Box plots show that the levels of hsa-miR-4516 in serum were not associated 
with osteoporosis patients with fracture (ANOVA p=0.140). Panel B: Box plots show 
that the levels of hsa-miR-4516 in plasma were associated with osteoporosis patients 
with fracture (ANOVA p= 0.0002) compared to non-osteoporotic and osteopenia (p 
(Bonferroni’s)= 0.004 and 0.002, respectively. **p <0.01. The comparison indicated 
by Bonferroni’s multiple comparisons test (One-way ANOVA). 
 
Table 4-10: One-way ANOVA multiple comparisons test for hsa-miR-4516 
expression level between Non-Osteoporosis, Osteopenia, Osteopenia with 
Fracture, Osteoporosis and Osteoporosis with Fracture 
Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's 
p Value 
Plasma 
hsa-miR-
4516 
0.0002 Osteopenia without 
fracture (n=61) vs. Non-
Osteoporotic (n=11) 
-0.12 (-0.5 to 
0.25) 
>0.99 
Osteopenia with 
Fracture (n=15) vs. Non-
Osteoporotic (n=11) 
-0.44 (-0.9 to 
0.01) 
0.062 
Osteoporosis without 
fracture (n=33) vs. Non-
Osteoporotic (n=11) 
-0.29 (-0.69 to 
0.11) 
0.43 
Osteoporosis with 
Fracture (n=14) vs. Non-
Osteoporotic (n=11) 
-0.59 (-1.05 to 
-0.12) 
0.004 
Osteopenia with 
Fracture (n=15) vs. 
Osteopenia without 
fracture (n=61) 
-0.32 (-0.65 to 
0.01) 
0.062 
Osteoporosis without 
fracture (n=33) vs. 
-0.16 (-0.41 to 
0.08) 
0.609 
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Data 
analysed 
ANOVA 
p Value 
Bonferroni's multiple 
comparisons test 
Mean Diff. 
(95.00% CI of 
diff.) 
Bonferroni's 
p Value 
Osteopenia without 
fracture (n=61) 
Osteoporosis with 
Fracture (n=14) vs. 
Osteopenia without 
fracture (n=61) 
-0.46 (-0.8 to -
0.12) 
0.002 
Osteoporosis without 
fracture (n=33) vs. 
Osteopenia with 
Fracture (n=15) 
0.16 (-0.2 to 
0.52) 
>0.99 
Osteoporosis with 
Fracture (n=14) vs. 
Osteopenia with 
Fracture (n=15) 
-0.14 (-0.57 to 
0.29) 
>0.99 
Osteoporosis with 
Fracture (n=14) vs. 
Osteoporosis without 
fracture (n=33) 
-0.3 (-0.67 to 
0.07) 
0.212 
 
hsa-miR-215-5p and hsa-miR-100-5p. The levels of circulating miRNAs, hsa-miR-215-
5p and hsa-miR-100-5p in clinical samples did not show significant difference among 
the five groups: Non-Osteoporosis, Osteopenia, Osteopenia without fracture, 
Osteoporosis and Osteoporosis without fracture. 
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4.2.7 miRNA Expression in Low Bone Mineral Density (BMD) Fractured Individuals 
To find out if the fragility fracture rather than the Bone Mineral Density (BMD) 
correlates with the miRNA expression, participants’ serum and plasma miRNA data 
were categorised into three main groups: non-osteoporotic (control group) (T Score 
> -1.0), Low Bone Mineral Density (BMD) without fracture (T Score ≤ -1.0) and low 
BMD with fracture (T Score ≤ -1.0). One-way ANOVA analysis followed by 
’Bonferroni’s multiple comparison test’ were used as before. The results show that 
four miRNAs, hsa-miR-373-5p, hsa-miR-99a-5p, hsa-miR-215-5p and hsa-miR-4516 
were strongly associated with patients’ low BMD and fracture. 
The levels of hsa-miR-373-5p in serum were significantly lower in the low BMD with 
fracture group compared to the non-osteoporosis controls and the low BMD without 
fracture patients (ANOVA p <0.0001, Figure 4-13A) (Bonferroni’s p of <0.0001 and 
0.0030, respectively). The levels of hsa-miR-373-5p in plasma were not significant 
different in the low BMD with fracture patients compared to the non-osteoporosis 
and the low BMD without fracture patients (ANOVA p= 0.64, Figure 4-13B). The 
results indicate that the decreasing levels of hsa-miR-373-5p in serum might be 
associated with low BMD and fragility fracture in these patients.  
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Figure 4-13: Identification of hsa-miR-373-5p associated with Low Bone Mineral 
Density with Fracture.  
Panel A: Box plots show that the levels of hsa-miR-373-5p in serum were significantly 
lower in the low BMD with fracture patients compared to the non-osteoporosis and 
Low BMD without fracture patients (ANOVA p <0.0001). Panel B: Box plots show the 
levels of hsa-miR-373-5p in plasma were not significant different in the low BMD with 
fracture patients compared to the non-osteoporosis and Low BMD without fracture 
patients (ANOVA p=0.64).  *p <0.05 and ***p <0.001. The comparison indicated by 
Bonferroni’s multiple comparisons test (One-way ANOVA). 
The levels of hsa-miR-99a-5p in serum were significantly higher in the low BMD with 
fracture patients compared to the low BMD without fracture patients, (ANOVA p 
<0.0001, Figure 4-14A). The levels of hsa-miR-99a-5p in plasma samples was not 
significant difference between these groups (ANOVA p= 0.26, Figure 4-13B). The 
results indicate that the increasing levels of hsa-miR-99a-5p in serum might 
associated with the fragility fracture in the low BMD with fracture patients. 
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Figure 4-14: Identification of hsa-miR-99a-5p associated with Low Bone Mineral 
Density with Fracture. 
Panel A: Box plots show the levels of hsa-miR-99a-5p in serum were significant lower 
in the low BMD with fracture patients compared to Low BMD without fracture 
patients (ANOVA p <0.0001). Panel B: Box plots show the levels of hsa-miR-99a-5p in 
plasma were not significant different in the low BMD with fracture patients 
compared to the non-osteoporosis and Low BMD without fracture patients (ANOVA 
p= 0.26). ***p <0.001. The comparison indicated by Bonferroni’s multiple 
comparisons test (One-way ANOVA). 
 
The levels of hsa-miR-215-5p in serum samples were lower in the low BMD with 
fracture patients compared to non-osteoporosis controls (ANOVA p = 0.021, Figure 
4-15A). However, the levels of hsa-miR-215-5p in plasma samples were not 
significant among the three group (p =0.768, Figure 4-15B). 
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Figure 4-15: Identification of hsa-miR-215-5p associated with Low Bone Mineral 
Density with Fracture.  
Panel A: Box plots show the levels of hsa-miR-215-5p in serum were significant lower 
in the low BMD with fracture patients compared to the non-osteoporosis (ANOVA p 
=0.021). Panel B: Box plots show the levels of hsa-miR-215-5p in plasma were not 
significant different in the low BMD with fracture patients compared to the non-
osteoporosis and Low BMD without fracture patients (ANOVA p=0.77). *p <0.05. The 
comparison indicated by Bonferroni’s multiple comparisons test (One-way ANOVA). 
The levels of hsa-miR-4516 in serum and plasma samples were much lower in the low 
BMD with fracture patients compared to the non-osteoporosis controls and the low 
BMD without fracture patients (ANOVA p= 0.03 and <0.001, respectively), (Figure 
4-16A & B), Bonferroni’s p= 0.036 and 0.0015, respectively. In addition, the levels of 
hsa-miR-4516 in plasma samples were significantly lower in the low BMD with 
fracture patients compared to LBMD without fracture patients (Bonferroni’ p= 
0.0005). The results suggest that decreased levels of hsa-miR-4516 in clinical samples 
might be associated with osteoporotic fragility fracture in these patients.  
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Figure 4-16: Identification of hsa-miR-4516 associated with Low Bone Mineral 
Density with Fracture.  
Panel A: Box plots show the levels of hsa-miR-4516 in serum were significant lower 
in the low BMD with fracture patients compared to the non-osteoporosis (ANOVA p 
=0.033). Panel B: Box plots show the levels of hsa-miR-4516 in plasma were lower in 
the low BMD with fracture patients compared to the non-osteoporosis and Low BMD 
without fracture patients (ANOVA p=0.0001). *p <0.05, **p <0.01 and ***p <0.001. 
The comparison indicated by Bonferroni’s multiple comparisons test (One-way 
ANOVA). 
 
4.2.8 Identify miRNAs from the panel that are associated with lumbar spine T-Score 
Identification of miRNAs associated with the bone mineral density (BMD) Lumbar 
spine (LS) T-score were conducted to verify if there is a significant association 
between the up-/down- regulation of these miRNAs with lumbar spine T-score. 
The increased levels of hsa-miR-373-5p and hsa-miR-4516 in serum and plasma 
samples were significantly associated with the lumbar spine (L2-L4) T-score as shown 
in (Figure 4-17A & B) and (Figure 4-18A & B). Pearson coefficient correlation analysis 
showed that hsa-miR-373-5p in serum and plasma are strongly associated with 
lumbar spine (L2-4) T-score (p= 0.0002 and 0.0051, respectively) (Figure 4-17A & B).  
The levels of hsa-miR-4516 in serum or plasma samples were significantly associated 
with lumbar spine (L2-L4) T-score (p = 0.031 and 0.0002, respectively) (Figure 4-18A 
& B).  
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The levels of both hsa-miR-122-5p and hsa-miR-215-5p in serum were also 
significantly increased with the lumbar spine (L2-L4) T-score (p = 0.0083 and 0.0435, 
respectively) (Figure 4-19, A & Figure 4-20, A). Nevertheless, the levels of hsa-miR-
122-5p and hsa-miR-215-5p in plasma samples were not significant associated with 
lumbar spine (L2-L4) (Figure 4-19B and Figure 4-20B).  
 
Figure 4-17: Correlation of the levels of hsa-miR-373-5p in clinical samples with the 
lumbar spine (L2-L4) T-Score. 
Panel A: The levels of hsa-miR-373-5p in serum significantly increased with increasing 
lumbar spine (L2-L4) T-score of the subject (p (two-tailed) = 0.0002). Panel B: The 
levels of hsa-miR-373-5p in plasma samples significantly increased with increasing 
lumbar spine (L2-L4) of the subject (p (two-tailed) = 0.0051). Blue line= regression 
line and Red line= 95% prediction band. 
 
 
Figure 4-18: Correlation of the levels of hsa-miR-4516 in clinical samples with the 
lumbar spine (L2-L4) T-Score. 
Panel A: The levels of hsa-miR-4516 in serum significantly increased with increasing 
lumbar spine (L2-L4) of the subject (p (two-tailed) = 0.031). Panel B: The levels of hsa-
miR-4516 in plasma samples significantly increased with increasing lumbar spine (L2-
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L4) of the subject (p (two-tailed) = 0.0002). Blue line= regression line and Red line= 
95% prediction band. 
 
 
Figure 4-19: Correlation of the levels of hsa-miR-122-5p in clinical samples with the 
lumbar spine (L2-L4) T-Score. 
Panel A: The levels of hsa-miR-122-5p in serum significantly increased with increasing 
lumbar spine (L2-L4) of the subject (p (two-tailed) = 0.008). Panel B: The levels of hsa-
miR-122-5p in plasma samples was not significant associated with the lumbar spine 
(L2-L4) of the subject (p (two-tailed) = 0.28). Blue line= regression line and Red line= 
95% prediction band. 
 
Figure 4-20: Correlation of the levels of hsa-miR-215-5p in clinical samples with the 
lumbar spine (L2-L4) T-Score. 
Panel A: The levels of hsa-miR-215-5p in serum significantly increased with increasing 
lumbar spine (L2-L4) of the subject (p (two-tailed) = 0.043). Panel B: The levels of hsa-
miR-215-5p in plasma samples was not significant associated with lumbar spine (L2-
L4) of the subject (p (two-tailed) = 0.21). Blue line= regression line and Red line= 95% 
prediction band.  
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4.2.9 Correlation Among Three Serum miRNAs Expression 
To verify if combining the downregulation of the three serum miRNAs, hsa-miR-373-
5p, hsa-miR-122-5p and hsa-miR-215-5p, has a significant clinical empowerment on 
the diagnosis of osteoporosis, a correlation study for the mixed level of these three 
miRNAs was performed. 
All the three circulating serum miRNAs have relatively similar expression among the 
three main groups: non-osteoporosis control and osteopenia (with/without fracture) 
and Osteoporosis (with/without fracture) groups, between hsa-miR-373-5p and hsa-
miR-122-5p with p value of 0.021 (Pearson’s r= 0.2), between hsa-miR-373-5p and 
hsa-miR-215-5p with p value of 0.01 (Pearson’s r= 0.23) and between hsa-miR-122-
5p and hsa-miR-215-5p with p value <0.0001 (Pearson’s r= 0.23). However, there 
were no distinct up/or down regulation populations of the three main study groups: 
Non-Osteoporosis (colour= green) Osteopenia (colour= yellow/blue/or brown) and 
Osteoporosis groups (colour= olive green/navy blue/or dark brown) (Figure 4-21). 
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Figure 4-21: Correlation of miRNA expression between three circulating serum 
miRNAs 
Pearson coefficient correlation analysis showed that the expression level of the three 
circulating serum correlates to each other: hsa-miR-373-5p vs. hsa-miR-122-5p with 
p value =0.021 (A) hsa-miR-373-5p vs. hsa-miR-215-5p with p value =0.011 (B) and 
hsa-miR-122-5p vs. hsa-miR-215-5p with p value <0.0001. Colour: Green for Non-
osteoporosis, Yellow/blue/or Brown= Osteopenia (with/out fracture) and Olive 
green/navy blue/or dark Brown = Osteoporosis (with/out fracture). 
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4.2.10 Diagnostic Value of miRNAs for osteoporosis 
The assessment of potential diagnostic value of the four miRNAs in serum and plasma 
for osteoporosis was performed using a receiver operating characteristic (ROC) 
curve. The associated area under the curve (AUC) for the relative expression of these 
miRNAs (hsa-miR-373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-4516) was 
used to confirm the diagnostic value of each miRNA (Table 4-11).  
There are acceptable diagnostic values for the levels of hsa-miR-373-5p in serum and 
the levels of hsa-miR-4516 in plasma for osteoporosis patients (AUC= of 0.717, p 
=0.013) and (AUC= 0.727, p =0.023), respectively) (Figure 4-22A & B). This indicates 
that both miRNAs have the potential to be used as a diagnostic marker for 
osteoporosis. 
The AUC discrimination accuracy for serum for the remaining two miRNAs: hsa-miR-
215-5p and hsa-miR-122-5p were low (0. 6≤ AUC <0.7) as shown (Table 4-11). AUC 
was 0.67 for both serum hsa-miR-215-5p and hsa-miR-122-5p (P value=0.056 and 
0.058, respectively) (Figure 4-22C & D). 
Table 4-11: Diagnostic value of serum and plasma miRNAs for Osteoporosis 
Data analysed Specimen AUC (95% CI) p value 
hsa-miR-373-5p Serum 0.717 (0.568 to 0.865) 0.013 
hsa-miR-4516 Plasma 0.727 (0.613 to 0.841) 0.023 
hsa-miR-215-5p Serum 0.668 (0.507 to 0.829) 0.056 
hsa-miR-122-5p Serum 0.666 (0.512 to 0.820) 0.058 
p value <0.05 is significant. 
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The sensitivity and specificity associated with the optimal cut‐off points for the 4 
circulating miRNAs in clinical samples from osteoporosis patients are listed in Table 
4-12. The sensitivity and specificity for hsa-miR-373-5p is 66.1% and 75.0%, and 
68.8% and 66.7% for hsa-miR-4516. While the remaining miRNAs had variable 
sensitivity with low specificity of 58.3% for the optimal cut off point.  
Table 4-12: Sensitivity and Specificity of the miRNAs in clinical samples from 
osteoporosis patients 
miRNA Specimen 
Type 
Sensitivity (%) Specificity (%) 
hsa-miR-373-5p Serum 66.1% 75.0% 
hsa-miR-4516 Plasma 68.8% 66.7% 
hsa-miR-122-5p  Serum 66.1% 58.3% 
hsa-miR-215-5p  Serum 56.6% 58.3% 
Data were evaluated via a cut-off point which jointly maximises both sensitivity and 
specificity. If the cut-off point is raised, there are fewer false positives but more false 
negatives the test is highly specific but not very sensitive. 
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Figure 4-22: Diagnostic value of circulating miRNAs for osteoporosis.  
ROC curves show acceptable AUC for hsa-miR-373-5p in serum samples (A) and hsa-
miR-4516 in plasma samples (B) from osteoporosis patients, [AUC= 0.717 and 0.727] 
and p (two-tailed) = 0.013 and 0.023, respectively. ROC curves show fair AUC for hsa-
miR-215-5p (C) and hsa-miR-122-5p (D) in serum samples from osteoporosis patients 
[AUC= 0.668 and 0.666] and p (two-tailed) = 0.056 and 0.058, respectively. AUC = 
Area Under the Curve. a fair AUC for hsa-miR-122-5p in serum samples from 
osteoporosis patients [AUC= 0.666,95% CI = 0.512 to 0.820, p = 0.058]. CI = 
Confidence interval. AUC <0.6 fail (discrimination no better than chance), 0. 6≤ AUC 
<0.7 low accuracy, 0.7 ≤ AUC < 0.9 moderate accuracy and AUC ≥ 0.9 high accuracy 
(Akobeng, 2007). 
 
AUC discrimination was performed for the combined level of the three miRNAs: hsa-
miR-373-5p, hsa-miR-122-5p and hsa-miR-122-5p in serum and hsa-miR-4516 in 
plasma of osteoporosis patients to find out if the combined analytical data have a 
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more powerful AUC diagnostic value (Figure 4-23). The ROC curve for these four 
miRNAs together for osteoporosis patients showed an improved AUC value of 0.774 
(p value=0.007).  
 
Figure 4-23: Diagnostic value of four combined circulating miRNAs for osteoporosis. 
ROC curve show an acceptable AUC for the three miRNAs: hsa-miR-373-5p, hsa-miR-
122-5p and hsa-miR-215-5p in serum and hsa-miR-4516 in plasma samples from 
osteoporosis patients [AUC= 0.774 and p=0.002]. AUC = Area Under Cover. AUC <0.06 
fail (discrimination no better than chance), 0. 6≤ AUC <0.7 low accuracy, 0.7 ≤ AUC < 
0.9 moderate accuracy and AUC ≥ 0.9 high accuracy.  
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4.2.11 Diagnostic Value Assessment Based on Serum/Plasma miRNA Expression and 
T-Score 
The potential diagnostic value of the significantly regulated miRNAs with the 
association of Lumbar Spine T-Score (LS2-LS4) record was performed using a receiver 
operating characteristic (ROC) curve. The relative expression of the four circulating 
miRNAs:  hsa-miR-373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-4516 from 
the participants’ serum and plasma samples were logarithmically (Log10) 
transformed, and the associated area under the curve (AUC) was used to identify any 
diagnostic value of each miRNA.  
Hsa-miR-373-5p, hsa-miR-215-5p and hsa-miR-122-5p associated with a Lumbar 
Spine (LS) T-Score in the serum of osteoporosis patients have an AUC of 0.921, 0.940 
and 0.933, respectively with (p (two-tailed) <0.001) (Figure 4-24A, C & D). Hsa-miR-
4516 in plasma with the association of LS T-score have an AUC of 0.918 (p (two-tailed) 
< 0.001) (Figure 4-24B). This indicates that these miRNAs: hsa-miR-373-5p, miR-215-
5p, hsa-miR-122-5p and hsa-miR-4516 have an improved diagnostic AUC accuracy 
when associated with BMD T-score.  
The sensitivity and specificity associated with the optimal cut‐off points related to 
the four circulating miRNAs are listed in Table 4-13. Circulating serum hsa-miR-215-
5p has the highest sensitivity and specificity for the optimal cut off point of 86.6% 
and 83.3% respectively, and sensitivity of 89.9% and specificity of 83.3%. for serum 
hsa-miR-373-5p. Both hsa-miR-4516 in plasma and hsa-miR-122-5p in serum of 
osteoporosis patients have an improved sensitivity of 85% and specificity of 83.3% 
when associated with BMD T-Score.  
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Table 4-13: Sensitivity and Specificity of the Regulated miRNAs in the serum and 
plasma of Osteoporotic and Non-Osteoporotic Participants associated with Lumbar 
Spine (LS2-4) T-score. 
miRNA Specimen 
Type 
Sensitivity (%) Specificity (%) 
hsa-miR-215-5p Serum 89.80% 83.30% 
hsa-miR-373-5p Serum 86.60% 83.30% 
hsa-miR-4516 Plasma 85.00% 83.30% 
hsa-miR-122-5p Serum 85.80% 83.30% 
Data were evaluated via a cut-off point which jointly maximises both sensitivity and 
specificity. 
 
Figure 4-24: Diagnostic value of circulating miRNAs with Lumbar Spine T-Score for 
osteoporosis.  
ROC curve show acceptable AUC for hsa-miR-373-5p, hsa-miR-215-5p and hsa-miR-
122-5p in serum (Panel A, C and D, respectively) and hsa-miR-4516 in plasma (Panel 
B) with a Lumbar Spine (LS2-LS4) T-Score from osteoporosis patients [AUC= 0.921, 
0.94, 0.933 and 0.918, with p value< 0.001]. AUC = Area Under Cover. AUC <0.06 fail 
(discrimination no better than chance), 0. 6≤ AUC <0.7 low accuracy, 0.7 ≤ AUC < 0.9 
moderate accuracy and AUC ≥ 0.9 high accuracy. 
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4.3 Discussion 
In this study, circulating miRNAs in osteoporotic fractured and non-fractured 
patients’ sera and plasma were compared to age matched non-osteoporotic controls. 
Three circulating serum miRNAs: hsa-miR-373-5p, hsa-miR-122-5p and hsa-miR-215-
5p and plasma hsa-4516 were significantly downregulated in the osteoporosis 
patients. Indeed, the downregulation of these circulating miRNAs were consistent 
with the progression of the osteoporotic fragility fracture, and their expressions level 
correlate with the BMD Lumbar Spine T-score. Therefore, downregulation of these 
miRNAs could contribute in the progression of osteoporosis. ROC analysis showed 
that serum hsa-miR-373-5p and plasma hsa-miR-4516 miRNAs were potent 
diagnostic value in discriminating osteoporotic fractured patients from non-
osteoporosis control group, and could be pursued to validate the results on a 
separate cohort of patients. On the other hand, hsa-miR-99a-5p was significantly 
upregulated in Low BMD with fracture compared to LBMD without fracture, but it 
did not significantly correlate with the non-osteoporotic control group. Indeed, both 
miRNAs: hsa-miR-99a-5p and hsa-miR-100-5p showed no overall significant 
dysregulation expression in osteoporosis patients. 
Interestingly, the downregulation of hsa-miR-373-5p in the cartilage of osteoarthritis 
patients compared to normal control (Iliopoulos et al., 2008) was shown to correlate 
with our finding in the osteoporosis subjects. So far, no published data relating the 
biological function of mir-373-5p in any bone related diseases has been reported. 
The miRNA hsa-miR-122-5p has been shown in the present study to be associated 
with osteoporosis (Seeliger et al., 2014, Panach et al., 2015). Contrary to our study, 
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hsa-miR-122-5p was shown to be upregulated in osteoporotic fractured (hip fracture) 
serum and plasma samples compared to osteoarthritic group (Panach et al., 2015, 
Seeliger et al., 2014). In addition, miR-122 was significantly downregulated in 
osteosarcoma cell lines compared to normal fibroblast cell lines (Xiao et al., 2015). 
However, our findings showed that there was a significant downregulation of 
circulating serum miR-122-5p in osteoporotic individuals, which was consistent with 
the preliminary miRNA PCR array testing. 
As far as for miR-4516 and miR-215-5p, even though, hsa-miR-215-5p was found by 
others to be decreased in osteosarcoma patients (Wang et al., 2015c), up to date 
there have been no published data correlating the regulation of these circulating 
miRNAs with osteoporosis disease. Therefore, this study is the first to highlight the 
correlation between these circulating miRNAs and osteoporosis. 
miR-100 overexpression was observed previously in the serum and bone tissue of 
osteoporotic fractured patients (Seeliger et al., 2014), and under-expressed in 
osteosarcoma tumour samples (Maire et al., 2011, Huang et al., 2014). While, it was 
not differentially expressed in our study, and there is no clear evidence about why 
this variation happened. 
MiR-99a has been found by others to be up-regulated in the osteosarcoma cell line 
MG-63 compared to human osteoblast (HOB) cell lines (Hu et al., 2012), and its 
overexpression regulates early chondrogenic differentiation of rat mesenchymal 
stem cells (rMSCs) by reducing the levels of bone morphogenetic protein (BMP) 
receptor type 2 (BMPR2) (Zhou et al., 2016). Whereas, it was found to be 
downregulated in bone tissue of osteosarcoma patients with increased level of its 
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target gene mammalian target of rapamycin (mTOR) (Zhao et al., 2016). Our findings, 
showed that serum miR-99a was significantly up-regulated in the serum of 
osteoporotic fractured participants, suggesting that this up-regulation is mainly due 
to the fragility fracture associated with LBMD.  
Our observations showed that the expression of hsa-miR-373-5p, hsa-miR-215-5p 
and hsa-miR-99a-5p in plasma did not match with serum among the study groups, 
and there was a significantly decreased level of has-miR100-5p in plasma compared 
to the serum. In contrast, relatively similar expression of hsa-miR-122-5p and hsa-
miR-4516 between serum and plasma was observed. This poor correlation could be 
due to the release of additional RNA from platelets during the coagulation process 
(Wang et al., 2012b) or could be due interfering substances, such as the collection 
tube components and test sample additives (Dimeski, 2008). However, it is not 
possible presently to identify the cause of this analytical discrepancy. 
In conclusion three circulating serum miRNAs: hsa-miR-373-5p, hsa-miR-122-5p and 
hsa-miR-215-5p, as well as one plasma miRNA (miR-4516) were significantly 
downregulated in osteoporosis patients. Both hsa-miR-373-5p and hsa-miR-4516 
have an AUC of moderate accuracy of 0.72 and 0.73, respectively. The dysregulation 
of these miRNAs in LBMD patients positively correlates with their BMD (LS) T-Score. 
While, there was a significant upregulation of serum miR-99a in osteoporotic 
fractured subjects, the expression of circulating serum and plasma hsa-miR-99a did 
not correlate with the individuals’ BMD (LS) T-Score. 
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The next step will focus on the potential target genes that are post-transcriptionally 
regulated be these 6 circulating miRNAs and their role in normal bone haemostasis 
and in osteoporosis.
 146 | P a g e  
 
5 Chapter 5 miRNA Predicted Gene targets in Osteoporosis 
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5.1 Introduction 
miRNAs play an important role as post-transcriptional regulators for up to 60% of 
human protein-coding genes (Friedman et al., 2009). They also play critical roles in 
bone cell growth and development (Bakhshandeh et al., 2012, Eguchi et al., 2013), 
bone remodelling processes (Lian et al., 2012) and there is a correlation of miRNAs 
dysfunction with bone diseases (van Wijnen et al., 2013).  
Following the validation process for the identification of novel miRNAs associated 
with osteoporosis described in Chapter 4, four circulating miRNAs (hsa-miR-373-5p, 
hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-4516) were found to be differentially-
expressed in clinical samples (serum or plasma) in the osteoporosis patients 
compared to the osteopenia patients and non-osteoporotic controls. The results 
suggest that these four differently-expressed miRNAs in clinical samples might 
associate with osteoporosis. Changes in serum/ plasma miRNAs may reflect 
underlying changes in cells associated with bone fragility. It is important to identify 
putative gene targets for theses 4 miRNAs that might be potentially involved in 
osteoporosis. 
The aim of this Chapter is to identify potential miRNA gene targets that are involved 
in bone remodeling and osteoporosis, using computational prediction algorithms, 
and understanding their biological functions in osteoporosis using bioinformatic 
analysis.  
miRNA gene targets were predicted by identifying mRNAs with conserved pairing to 
the 5' region of the miRNA, known as the miRNA seed region, by searching for perfect 
Watson-Crick complementarity over conserved 6–8mer seed matches to miRNA seed 
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region (Lewis et al., 2003). The identification was achieved using the miRWalk 2.0 
database (Dweep and Gretz, 2015) that uses four putative target algorithms 
(miRWalk, miRanda, RNA22 and Targetscan) (Materials & Methods 2.8).  
In addition, String, version 10.5 database was used to identify direct (physical) and 
indirect (predicted) protein-protein interaction (Szklarczyk et al., 2017), between 
these target gene products that are involved in bone remodeling and bone diseases. 
5.2 Results 
5.2.1 Characteristics of miRNAs and functions 
Initially, using literature databases, associations of changes in circulating hsa-miR-
373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-4516 with human disease 
states were reviewed. Circulating serum miR-373 level has been shown to be 
increased in breast cancer patients compared to healthy controls (Chen et al., 2013, 
Eichelser et al., 2014, Muller et al., 2014), in epithelial ovarian cancer patients 
compared to healthy control (Meng, Muller et al. 2016) and in testicular germ cell 
cancer patients compared to healthy control (Syring et al., 2015). In contrast, 
circulating serum miR-373 level has been shown to be decreased in pancreatic cancer 
patients (PC) compared to healthy control (Hua et al., 2017) and reduced in 
hypertrophic cardiomyopathy (HCM) patients with diffuse myocardial fibrosis 
compared to healthy volunteers (Fang et al., 2015), Table 5-1). 
Circulating serum miR-122 has been shown to be increased in non-alcoholic fatty liver 
disease (NAFLD) patients compared to NAFLD with hepatocellular carcinoma (HCC) 
(Akuta et al., 2016), and in chronic hepatitis C (HCV)-related hepatocellular 
carcinoma patients compared to healthy control (El-Garem et al., 2014). In addition, 
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circulating serum miR-122 level was also Increased in ST-Elevation Myocardial 
Infarction patients (STEMI) compared to non-STEMI controls (Cortez-Dias et al., 
2016). Decreased level of circulating serum miR-122 has been observed in gastric 
cancer with distant metastasis (GC/DM) patients compared to healthy controls (Chen 
et al., 2014b) and in patients with congenital Huntington's disease compared to 
healthy controls (Diez-Planelles et al., 2016), Table 5-1). 
The tissue levels of miR-215-5p miRNA have been reported to be increased in 
Barrett's esophagus tissues compared to normal control (Cabibi et al., 2016), in 
gastric cancer compared to adjacent non-tumour tissues (Deng et al., 2014, Li et al., 
2016a, Xu and Fan, 2015),  in primary gliomas compared to neoplastic brain tissues 
(Tong et al., 2015) and in chronic hepatitis and hepatocellular carcinoma compared 
to healthy control tissues (Zhang et al., 2014). In contrast, miR-215 expression has 
been found to be decreased in colon cancer compared to adjacent normal tissues 
(Chen et al., 2016, Karaayvaz et al., 2011), in nephroblastomas, embryonal renal 
neoplasms, compared to nephrogenic rests (NRs), Wilms' tumour (WT) precursors, 
tissues (Senanayake et al., 2012), in metastatic clear cell renal cell carcinoma (ccRCC) 
compared to adjacent normal tissues (Khella et al., 2013), in metastatic RCC 
compared to primary RCC (White et al., 2011), in epithelial ovarian cancer (EOC) 
compared to non-EOC (other ovarian tumours or ovarian cystadenomas) control 
tissues, in non-small cell lung cancer compared to non-cancerous lung tissues (Hou 
et al., 2015) and in breast cancer compared to  adjacent normal tissues (Zhou et al., 
2014), Table 5-1). 
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MiR-4516 level has been found to be increased in non-invasive follicular thyroid 
neoplasms with papillary-like nuclear features compared to follicular adenomas 
(Borrelli et al., 2017), in the human keratinocyte line, HaCaT cells, with psoralen and 
ultraviolet A (PUVA) treatment compared to HaCaT cells without PUVA treatment 
(Chowdhari and Saini, 2014), and in salvage radiation therapy after radical 
prostatectomy compared to no-recurrence post-salvage radiation therapy (Bell et al., 
2015). Circulating serum miR-4516 has been found to be increased in individuals 
living in a city with moderate air pollution compared to individuals living in a tourist 
city (Li et al., 2016b). In addition, circulating plasma miR-4516 level has been found 
to be increased in HIV-associated neurocognitive disorder (HAND) compared to HIV 
without HAND (Asahchop et al., 2016), Table 5-1). 
However, although it is clear that the four selected miRNAs exhibit changed level in 
disease states, there are so-far no published reports of circulating miR-373, miR-215 
and miR-4516 associated with osteoporosis.  
The next step was to bioinformatically identify biological processes associated with 
the target genes of hsa-miR-373-5p, hsa-miR-215-5p, hsa-miR-122-5p and hsa-miR-
4516. A search of the miRWalk database revealed several genes predicted as targets 
for each of the four identified miRNAs in the serum from osteoporotic patients. The 
analysis of these genes using the Enrichr database (Kuleshov et al., 2016) shows 
biological involvement of these miRNAs in osteoporosis  (Figure 5-1). 
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Table 5-1: Overview of studies on miRNA expression in blood circulation and body 
tissues in the context of human pathogenesis described in the text. 
miRNA Source Disease Specime
n type 
Expression 
level 
Reference 
miR-
373 
Human breast ductal 
carcinoma patients 
with lymph node 
metastasis (n= 35) 
vs. ductal 
carcinoma patients 
without lymph 
node metastasis 
(n= 25) and healthy 
female donors (n= 
10) 
Plasma Increased (Chen et al., 
2013) 
 Human breast cancer 
patients (M0, n= 
120) vs. patients 
with overt 
metastasis (M1, n= 
32) healthy women 
(n= 40) 
Serum Increased (Eichelser 
et al., 2013) 
 Human invasive breast 
cancer (n= 168) vs. 
benign breast 
diseases (n= 19) 
and healthy 
women (n= 28) 
Serum Increased (Eichelser 
et al., 2014) 
 Human epithelial ovarian 
cancer (EOC, n= 60) 
vs. benign ovarian 
diseases (n= 20) 
and healthy 
women (n= 32) 
Serum Increased (Meng et 
al., 2016) 
 Human HER2-postive 
breast cancer after 
neoadjuvant 
therapy (n= 127) 
vs. HER2-postive 
breast cancer 
before therapy (n= 
127) and healthy 
controls (n= 19) 
Serum Increased (Muller et 
al., 2014) 
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miRNA Source Disease Specime
n type 
Expression 
level 
Reference 
 Human patients with 
testicular germ cell 
cancer (n= 30) vs. 
healthy subjects 
(n= 18) 
serum Increased (Syring et 
al., 2015) 
 Human hypertrophic 
cardiomyopathy 
(HCM) with diffuse 
myocardial fibrosis 
(T1< 470 ms, n= 
28) vs. HCM (T1 ≥ 
470 ms, n= 27) 
Plasma Decreased (Fang et al., 
2015) 
 Human pancreatic cancer 
(PC, n= 130) vs. 
benign pancreatic 
tumor (n= 30), 
chronic 
pancreatitis (n= 20) 
and healthy 
volunteers (n= 50) 
Serum Decreased (Hua et al., 
2017) 
miR-
122 
human Non-alcoholic fatty 
liver disease 
(NAFLD) patients 
without 
hepatocellular 
carcinoma (HCC) 
(n=278) vs. 
NAFLD/HCC patients 
(n=27) 
Serum Increased (Akuta et 
al., 2016) 
 human gastric cancer with 
distant metastasis 
(GC/DM, n=12) vs. 
gastric cancer with 
no distant 
metastasis 
(GC/NDM, n=12) 
and healthy controls 
(HCs) 
Plasma Decreased (Chen et al., 
2014b) 
 human HBV/HCV dual 
infection patients 
(n=76) vs. HCV and 
HBV mono-infection 
(n=105 and 39, 
respectively) 
Serum Increased (Cheng et 
al., 2015) 
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miRNA Source Disease Specime
n type 
Expression 
level 
Reference 
 human ST-Elevation 
Myocardial Infarction 
(STEMI, n= 142) vs. 
non-STEMI controls 
(n= 18) 
Serum Increased (Cortez-
Dias et al., 
2016) 
 human ST-Elevation 
Myocardial Infarction 
(STEMI, n= 33) vs. 
healthy donors (n= 
17) 
Plasma decreased (D'Alessand
ra et al., 
2010) 
 human Huntington's disease 
(HD, n= 15) vs. 
Control (n= 7) 
Plasma Decreased (Diez-
Planelles et 
al., 2016) 
 human chronic hepatitis 
C(HCV)-related 
hepatocellular 
carcinoma (HCC, n= 
90) vs. healthy control 
(n=10) 
Serum Increased (El-Garem 
et al., 2014) 
 Human End-stage renal 
disease patients 
(ESRD, n= 17) vs. 
healthy control (n= 
22) 
Plasma decreased (Rivoli et 
al., 2016) 
 Human neoadjuvant 
chemotherapy (NAC) 
for breast cancer 
(n=22) vs. primary 
breast cancer without 
chemotherapy 
treatment (n= 12) 
Plasma Increased (Freres et 
al., 2015) 
miR-
215 
Human 
Bone 
tissue 
and cell 
lines: U-2 
OS, SJSA-
1, HT-29 
bone 
cells and 
A549 
cells 
 
Stage II colon 
cancer tissue vs. 
Colon 
tissue 
decreased Braun, C. J., 
et al. 
(2008). 
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miRNA Source Disease Specime
n type 
Expression 
level 
Reference 
 Human Barrett's 
esophagus (BE, 
n=30) patients vs. 
normal control 
(n=30) 
Esophag
eal 
mucosal 
tissue 
biopsies 
and 
serum 
Increased (Cabibi et 
al., 2016) 
 Human Colon cancer 
specimens (n=44) 
vs. adjacent 
normal tissues 
(n=44) 
Colon 
tissue 
Decreased (Chen et al., 
2016) 
 Human Gastric tumor 
specimens (n= 51) 
vs. and adjacent 
normal tissues (n= 
51) 
Tissue Increased (Deng et al., 
2014) 
 Human Epithelial ovarian 
cancer (EOC, n= 85) 
vs. non-EOC (other 
ovarian tumors or 
ovarian 
cystadenomas) 
control (n= 63) 
Tissue Decreased (Ge et al., 
2016) 
 Human non-small cell lung 
cancer (NSCLC, n= 
115) vs. adjacent 
non-cancerous 
lung tissues (n= 
115) 
Tissue Decreased (Hou et al., 
2015) 
 Human colon cancer (n= 
34) vs. normal 
control (n= 34) 
Tissue Decreased (Karaayvaz 
et al., 2011) 
 Human metastatic clear 
cell renal cell 
carcinoma (ccRCC, 
formalin-fixed n= 
61) 
Tissue Decreased (Khella et 
al., 2013) 
 Human gastric cancer (GC, 
n=77) vs. adjacent 
non-tumor tissues 
(n= 77) 
Tissue Increased (Li et al., 
2016a) 
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miRNA Source Disease Specime
n type 
Expression 
level 
Reference 
 Human Nephroblastomas, 
embryonal renal 
neoplasms vs. 
nephrogenic rests 
(NRs) 
Tissue Decreased (Senanayak
e et al., 
2012) 
  Human primary gliomas 
(n= 179) vs. non-
neoplastic brain 
tissues (n= 10) 
Tissue Increased (Tong et al., 
2015) 
 Human osteosarcoma (n= 
80) vs. adjacent 
noncancerous 
bone tissues (n= 
80) 
Tissue Decreased (Wang et 
al., 2015c) 
 Human acute myeloid 
leukemia (n= 113) 
vs. healthy control 
(n= 25) 
white 
blood 
cell 
(WBC) 
Decreased (Wang et 
al., 2016) 
 Human Metastatic Renal 
cell carcinoma 
(RCC, n= 40) vs. 
primary RCC (n= 
40) 
Tissue Decreased (White et 
al., 2011) 
 Human Gastric cancer (n= 
38) vs. adjacent 
non-malignant 
tissues (n= 38) 
Tissue Increased (Xu and 
Fan, 2015) 
 Human Chronic hepatitis 
(n= 118) and 
Hepatocellular 
carcinoma (HCC, n= 
95) vs. healthy 
control (n= 127) 
Serum Increased (Zhang et 
al., 2014) 
 Human breast cancer vs. 
adjacent non-
malignant tissues 
Tissue Decreased (Zhou et al., 
2014) 
MiR-
4516 
Human salvage radiation 
therapy after 
radical 
prostatectomy 
(n=43)  vs. no 
recurrence post-
salvage radiation 
therapy 
Tissue Increased (Bell et al., 
2015) 
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miRNA Source Disease Specime
n type 
Expression 
level 
Reference 
 Human HIV-associated 
neurocognitive 
disorder (HAND, 
n=22) vs. HIV 
without HAND 
(non-HAND, n= 25) 
Plasma Increased (Asahchop 
et al., 2016) 
 Human Non-invasive 
follicular thyroid 
neoplasms with 
papillary-like 
nuclear features' 
(NIFTPs, n=19) vs. 
follicular 
adenomas (n= 18) 
and infiltrative 
follicular variant of 
papillary thyroid 
carcinomas (n= 17) 
Tissue Increased (Borrelli et 
al., 2017) 
 Human HaCaT cells with 
PUVA treatment 
vs. HaCaT cells 
without PUVA 
treatment 
cultured 
human 
keratino
cytes 
(HaCaT 
cells) 
Increased (Chowdhari 
and Saini, 
2014) 
 Human individuals living in 
a city with 
moderate air 
pollution (n=  120) 
vs. individuals 
living in a tourist 
city (n= 120) 
Serum Increased (Li et al., 
2016b) 
 Human salt-sensitive (SS, 
N = 3) and inverse 
salt-sensitive (ISS, 
N = 3) vs. salt-
resistant (SR, N = 4) 
Urine Increased in 
SS and 
decreased 
in ISS 
(Gildea et 
al., 2013) 
 Human Amyotrophic 
Lateral Sclerosis 
(ALS) (n= 48) vs. 
healthy control (n= 
47) 
Plasma reference 
genes 
(Takahashi 
et al., 2015) 
 Human coronary artery 
disease (CAD, n= 
141) vs. healthy 
control (n= 141) 
Plasma reference 
genes 
(Zhang et 
al., 2016) 
Chapter5: MiRNA Predicted Gene targets in Osteoporosis 
157 | P a g e  
 
 
Figure 5-1: In silico identification of disease associations of genes regulated by hsa-
miRNAs 373-5p, 122-5p, 215-5p and 4516. 
Disease associations of genes regulated by hsa-miR-373-5p, hsa-miR-122-5p, hsa-
miR-215-5p, and hsa-miR-4516 were identified from OMIM disease annotations 
using the Enrichr database (Kuleshov et al., 2016). 
 
5.2.2 Osteoporosis-related genes and miRNAs: 
In this Section, the osteoporosis associated genes regulated by hsa-miR-373-5p, hsa-
miR-122-5p, hsa-miR-215-5p and hsa-miR-4516 were identified. To achieve this, 
initially, eighty-nine genes associated with osteoporosis were identified using the 
search term ‘Osteoporosis [DOID: 11476]’ from the miRWalk2.0 database. The 3’ 
untranslated regions of the mRNAs encoded by these 89 genes were checked for 
target sequences for hsa-miR-373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-
4516, using 4 different algorithms (miRWalk, miRanda, RNA22 and Targetscan), 
within the miRWalk 2.0 database. Any genes containing miRNA target sequences 
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within the 3’-UTR regions of their mRNAs predicted by at least 2 of the 4 
Osteoporosis-related genes were recorded.  
5.2.2.1 Osteoporosis-related genes and miR-373-5p 
For hsa-miR-373-5p, a total of 9171 predicted gene targets were identified. Out of 
the 89 osteoporosis genes, fifty-two genes contained the hsa-miR-373-5p predicted 
target mRNA binding site within the 3’UTR region (Figure 5-2) with 29 of these 
predicted by two or more algorithms (Table 5-2).  
 
 
Figure 5-2: Venn diagram denoting the overlap between osteoporosis-related 
genes and hsa-miR-373-5p putative gene targets. 
The 52 osteoporosis-related genes which contained has-miR-373-5p target sites 
according to at least one target algorithm were : ABCB1, AHSG, ALDH7A1, ALOX15, 
ANKH, AR, ARHGEF3, BMP2, BMP2K, CA8, CALCR, CD40, CD44, CD47, CNR1, CNR2, 
COL1A1, CST3, CYP19A1, CYP1B1, CYP27B1, CYP3A4, DCAF13, DKK1, ESR1, ESR2, 
FSHB, HGF, IGF1, IGF1R, IL1A, IL1B, IRS2, LRP6, MAPK1, MTHFR, PON1, PTHLH, PTK2B, 
QPCT, RUNX2, SOST, SPARC, STAT1, THBS1, THSD4, THSD7A, TNFRSF11B, TRAF6, 
TWIST1, UGT2B17, VPS13B. Venn Diagram was generated using InteractiVenn 
Software (Heberle et al., 2015). 
Chapter5: MiRNA Predicted Gene targets in Osteoporosis 
159 | P a g e  
 
The 29 genes are: ANKH, CYP1B1, IL1B, LRP6, STAT1, UGT2B17, BMP2K, CA8, CD44, 
CD47, CNR1, CNR2, ESR1, MAPK1, MTHFR, PON1, SOST, SPARC, TRAF6, VPS13B, 
ABCB1, ALDH7A1, AR, COL1A1, FSHB, IGF1R, IRS2, THBS1 and THSD7A.  
Table 5-2: Putative osteoporosis-related genes containing hsa-miR-373-5p target 
sequences within the 3’-UTR regions of their mRNAs 
Predicted by at least 2 of the 4 different algorithms from the miRWalk2.0’s database. 
0= not identified 1 = identified. 
Gene Description 
m
iR
W
al
k 
m
iR
an
d
a 
R
N
A
2
2
 
Ta
rg
et
sc
an
 
Su
m
 
ANKH ANKH inorganic pyrophosphate transport 
regulator 
1 1 1 1 4 
CYP1B1 cytochrome P450 family 1 subfamily B 
member 1 
1 1 1 1 4 
IL1B interleukin 1 beta 1 1 1 1 4 
LRP6 LDL receptor related protein 6 1 1 1 1 4 
STAT1 signal transducer and activator of 
transcription 1 
1 1 1 1 4 
UGT2B1
7 
UDP glucuronosyltransferase family 2 
member B17 
1 1 1 1 4 
BMP2K BMP2 inducible kinase 0 1 1 1 3 
CA8 carbonic anhydrase 8 1 1 0 1 3 
CD44 CD44 molecule (Indian blood group) 1 1 0 1 3 
CD47 CD47 molecule 1 1 0 1 3 
CNR1 cannabinoid receptor 1 1 1 0 1 3 
CNR2 cannabinoid receptor 2 1 1 0 1 3 
ESR1 estrogen receptor 1 1 1 0 1 3 
MAPK1 mitogen-activated protein kinase 1 1 0 1 1 3 
MTHFR methylenetetrahydrofolate reductase 1 1 0 1 3 
PON1 paraoxonase 1 1 1 0 1 3 
SOST sclerostin 0 1 1 1 3 
SPARC secreted protein acidic and cysteine rich 1 1 0 1 3 
TRAF6 TNF receptor associated factor 6 1 1 0 1 3 
VPS13B vacuolar protein sorting 13 homolog B 1 1 0 1 3 
ABCB1 ATP binding cassette subfamily B member 
1 
1 0 1 0 2 
ALDH7A
1 
aldehyde dehydrogenase 7 family 
member A1 
1 0 0 1 2 
AR androgen receptor 1 0 1 0 2 
COL1A1 collagen type I alpha 1 chain 0 1 0 1 2 
FSHB follicle stimulating hormone beta subunit 0 1 0 1 2 
IGF1R insulin like growth factor 1 receptor 1 0 0 1 2 
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Gene Description 
m
iR
W
al
k 
m
iR
an
d
a 
R
N
A
2
2
 
Ta
rg
et
sc
an
 
Su
m
 
IRS2 insulin receptor substrate 2 1 0 1 0 2 
THBS1 thrombospondin 1 1 0 0 1 2 
THSD7A thrombospondin type 1 domain 
containing 7A 
0 1 0 1 2 
Total 29      
 
5.2.2.2 Osteoporosis-related genes and hsa-miR-122-5p 
For hsa-miR-122-5p, a total of 10891 genes contained predicted target sequence 
within the 3’-UTR regions of their mRNAs (miRWalk, miRanda, RNA22 and 
Targetscan). Sixty out of the 89 putative osteoporosis-related genes were identified 
as targets for hsa-miR-122-5p (Figure 5-3).  
  
Figure 5-3: Venn diagram denoting the overlap between osteoporosis-related 
genes and hsa-miR-122-5p putative gene targets. 
The 60 osteoporosis-related genes which contained has-miR-122-5p target sites 
according to at least one target algorithm were: ALDH7A1, ALOX15, ALPL, ANKH, AR, 
ARHGEF3, BMP2K, CA10, CALCR, CD40, CD44, CD47, CNR1, CNR2, COL1A1, CTSK, 
CYP19A1, CYP1A1, CYP1B1, CYP3A4, DKK1, ESR1, FGFBP1, FSHB, GH1, HGF, ICAM1, 
IGF1, IGF1R, IL15, IL1B, IL6, INSL3, IRS2, KIT, LRP6, MAPK1, MTHFR, PDLIM4, PLOD1, 
PTHLH, PTN, QPCT, RUNX2, RXFP2, SLC22A11, SOST, SPARC, STAT1, THBS1, THSD4, 
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TNF, TNFRSF11A, TNFRSF1B, TRAF6, TSC22D3, TWIST1, VDR, VPS13B, WNK4. Venn 
Diagram was generated using InteractiVenn Software 
 
Out of the 60 genes associated with osteoporosis, 21 genes (TNFRSF1B, ALPL, ANKH, 
BMP2K, ESR1, IGF1R, RUNX2, AR, CA10, CD44, CNR2, CYP3A4, FSHB, GH1, INSL3, 
LRP6, MAPK1, PTHLH, SPARC, TSC22D3 and VDR) were predicted by at least two of 
the four algorithms (Table 5-3). 
Table 5-3: Putative osteoporosis-related genes containing hsa-miR-122-5p target 
sequences within the 3’-UTR regions of their mRNAs 
Predicted by at least 2 of the 4 different algorithms from the miRWalk2.0’s database. 
0= not identified 1 = identified. 
Gene Description 
m
iR
W
al
k 
m
iR
an
d
a 
R
N
A
2
2
 
Ta
rg
et
sc
an
 
Su
m
 
TNFRSF
1B 
TNF receptor superfamily member 1B 
1 1 1 1 4 
ALPL alkaline phosphatase, 
liver/bone/kidney 
1 1 0 1 3 
ANKH ANKH inorganic pyrophosphate 
transport regulator 
1 0 1 1 3 
BMP2K BMP2 inducible kinase 1 0 1 1 3 
ESR1 estrogen receptor 1 0 1 1 1 3 
IGF1R insulin like growth factor 1 receptor 1 1 0 1 3 
RUNX2 runt related transcription factor 2 1 1 0 1 3 
AR androgen receptor 1 0 0 0 2 
CA10 carbonic anhydrase 10 1 0 0 1 2 
CD44 CD44 molecule (Indian blood group) 1 0 0 1 2 
CNR2 cannabinoid receptor 2 1 0 0 1 2 
CYP3A4 cytochrome P450 family 3 subfamily A 
member 4 
1 0 0 1 2 
FSHB follicle stimulating hormone beta 
subunit 
1 0 1 0 2 
GH1 growth hormone 1 1 0 0 1 2 
INSL3 insulin like 3 1 0 0 1 2 
LRP6 LDL receptor related protein 6 1 0 1 0 2 
MAPK1 mitogen-activated protein kinase 1 1 0 1 0 2 
PTHLH parathyroid hormone like hormone 1 1 0 1 2 
SPARC secreted protein acidic and cysteine 
rich 
1 0 1 0 2 
TSC22D
3 
TSC22 domain family member 3 
1 0 0 1 2 
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Gene Description 
m
iR
W
al
k 
m
iR
an
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VDR vitamin D (1,25- dihydroxyvitamin D3) 
receptor 
1 0 0 1 2 
Total 21      
 
5.2.2.3  Osteoporosis related genes and Hsa-miR-215-5p 
4762 genes contain hsa-miR-215-5p target sequences within the 3’-UTR regions of 
their mRNAs predicted by one of the 4 algorithms (miRWalk, miRanda, RNA22 and/or 
Targetscan). 33 out of the 89 osteoporosis-related genes were putative targets for 
hsa-miR-215-5p (Figure 5-4).  
 
Figure 5-4: Venn diagram denoting the overlap between osteoporosis-related 
genes and hsa-miR-215-5p putative gene targets. 
The 33 osteoporosis-related genes which contained has-miR-215-5p target sites 
according to at least one target algorithm were: ALDH7A1, ANKH, AR, ARHGEF3, 
BMP2K, CA10, CA8, CD47, CTSK, CYP19A1, CYP1B1, CYP3A4, ESR1, FGFBP1, FSHB, 
HSD11B1, ICAM1, IGF1, IGF1R, IL15, IL1A, IL6, IRS2, ITGA1, MAPK1, PLOD1, PTHLH, 
RUNX2, SPARC, THSD7A, TRAF6, TWIST1, VDR. Venn Diagram was generated using 
InteractiVenn Software. 
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Of these, 33 osteoporosis genes that were predicted targets for hsa-miR-215-5p, 9 
genes, MAPK1, SPARC, CD47, ESR1, TRAF6, BMP2K, CYP1B1, IGF1 and VDR were 
identified by at least 2 of the 4 algorithms (miRWalk, miRanda, RNA22 and 
Targetscan) (Table 5-4).  
Table 5-4: Putative osteoporosis-related genes containing hsa-miR-215-5p target 
sequences within the 3’-UTR regions of their mRNAs 
Predicted by at least 2 of the 4 different algorithms from the miRWalk2.0’s database. 
0= not identified 1 = identified. 
Gene description 
m
iR
W
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k 
m
iR
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2
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MAPK1 mitogen-activated protein kinase 1 1 1 1 1 4 
SPARC secreted protein acidic and cysteine rich 1 1 1 1 4 
CD47 CD47 molecule 1 1 0 1 3 
ESR1 estrogen receptor 1 1 1 0 1 3 
TRAF6 TNF receptor associated factor 6 1 1 0 1 3 
BMP2K BMP2 inducible kinase 0 1 0 1 2 
CYP1B1 cytochrome P450 family 1 subfamily B 
member 1 
1 0 1 0 2 
IGF1 insulin like growth factor 1 0 1 0 1 2 
VDR vitamin D (1,25- dihydroxyvitamin D3) 
receptor 
1 0 0 1 2 
Total 9      
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5.2.2.4  Osteoporosis-related genes and Hsa-miR-4516 
7641 putative genes contain hsa-miR-4516 target sequences within the 3’-UTR 
regions of their mRNAs predicted by one of the 4 algorithms (miRWalk, miRanda, 
RNA22 and Targetscan). 47 osteoporosis-related genes were identified as targets for 
hsa-miR-4516 (Figure 5-5).  
 
Figure 5-5: Venn diagram denoting the overlap between osteoporosis-related 
genes and hsa-miR-4516 putative gene targets. 
The 47 osteoporosis-related genes which contained has-miR-4516 target sites 
according to at least one target algorithm were: ALDH7A1, ALPL, ANKH, AR, 
ARHGEF3, BGLAP, BMP2, BMP2K, CA10, CALCR, CD44, CD47, CNR1, COL1A1, CTSK, 
CYP17A1, CYP19A1, CYP1A1, CYP27B1, FSHB, IGF1, IGF1R, INSL3, ITGA1, KIT, LRP6, 
LTF, MAPK1, MAPK3, MTHFR, PLOD1, PON1, PTHLH, PTK2B, RUNX2, SLC22A11, 
SPARC, STAT1, THBS1, THSD4, THSD7A, TNFRSF11A, TNFRSF1B, TRAF6, TSC22D3, VDR 
and VPS13B. Venn Diagram was generated using InteractiVenn Software. 
 
Of the 47 predicted gene targets associated with osteoporosis, twenty-one genes 
(AR, CYP17A1, CYP19A1, IGF1R, KIT, LTF, MAPK3, PLOD1, RUNX2, SLC22A11, SPARC, 
THBS1, TRAF6, VDR, BMP2K, CD47, CNR1, FSHB, MTHFR, PTHLH and TSC22D3) were 
identified by at least 2 of the 4 algorithms (miRWalk, miRanda, RNA22 and 
Targetscan) (Table 5-5).  
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Table 5-5: Putative osteoporosis-related genes containing hsa-miR-4516 target 
sequences within the 3’-UTR regions of their mRNAs 
Predicted by at least 2 of the 4 different algorithms from the miRWalk2.0’s database. 
0= not identified 1 = identified. 
Gene Description 
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AR androgen receptor 1 1 0 1 3 
CYP17A1 cytochrome P450 family 17 subfamily A 
member 1 
1 1 0 1 3 
CYP19A1 cytochrome P450 family 19 subfamily A 
member 1 
1 1 0 1 3 
IGF1R insulin like growth factor 1 receptor 1 1 0 1 3 
KIT KIT proto-oncogene receptor tyrosine 
kinase 
1 1 0 1 3 
LTF lactotransferrin 1 1 0 1 3 
MAPK3 mitogen-activated protein kinase 3 1 1 0 1 3 
PLOD1 procollagen-lysine,2-oxoglutarate 5-
dioxygenase 1 
1 1 0 1 3 
RUNX2 runt related transcription factor 2 1 1 0 1 3 
SLC22A11 solute carrier family 22 member 11 1 1 0 1 3 
SPARC secreted protein acidic and cysteine rich 1 1 0 1 3 
THBS1 thrombospondin 1 1 1 0 1 3 
TRAF6 TNF receptor associated factor 6 1 1 0 1 3 
VDR vitamin D (1,25- dihydroxyvitamin D3) 
receptor 
1 1 0 1 3 
BMP2K BMP2 inducible kinase 1 0 0 1 2 
CD47 CD47 molecule 0 1 0 1 2 
CNR1 cannabinoid receptor 1 1 0 0 1 2 
FSHB follicle stimulating hormone beta 
subunit 
1 0 0 1 2 
MTHFR methylenetetrahydrofolate reductase 1 0 0 1 2 
PTHLH parathyroid hormone like hormone 1 0 0 1 2 
TSC22D3 TSC22 domain family member 3 0 1 0 1 2 
Total 21      
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5.2.2.5 Common Osteoporosis-related genes among the four miRNAs 
Two genes, BMP2 inducible kinase (BMP2K) and secreted protein acidic and cysteine 
rich (SPARC) contained the recognition sequences for all 4 miRNAs, hsa-miR-122-5p, 
hsa-miR-215-5p, hsa-miR-373-5p and hsa-miR-4516. A total of eight genes contained 
the recognition sequences for three of the miRNAs. Androgen receptor (AR), insulin 
like growth factor 1 receptor (IGF1R) and follicle stimulating hormone beta subunit 
(FSHB) contained hsa-miR-122-5p, hsa-miR-373-5p and hsa-miR-4516 recognition 
sequences. CD47 molecule (CD47) and TNF receptor associated factor 6 (TRAF6) 
contained hsa-miR-215-5p, hsa-miR-373-5p and hsa-miR-4516 recognition 
sequences. Estrogen receptor 1 (ESR1) and mitogen-activated protein kinase 1 
(MAPK1) contained hsa-miR-373-5p, hsa-miR-122-5p and hsa-miR-215-5p 
recognition sequences. Finally, vitamin D (1,25- dihydroxy vitamin D3) receptor (VDR) 
contained recognition sequences for hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-
4516 (Table 5-6).  
Two miRNAs: hsa-miR-122-5p and hsa-miR-373-5p, shared four gene targets: ANKH 
inorganic pyrophosphate transport regulator (ANKH), CD44 molecule (Indian blood 
group, CD44), cannabinoid receptor 2 (CNR2) and LDL receptor related protein 6 
(LRP6). While, hsa-miR-122-5p and hsa-miR-4516 shared three genes: parathyroid 
hormone like hormone (PTHLH), runt related transcription factor 2 (RUNX2) and 
TSC22 domain family member 3 (TSC22D3). Furthermore, hsa-miR-373-5p and hsa-
miR-4516 shared another three genes: cannabinoid receptor 1 (CNR1), 
methylenetetrahydrofolate reductase (MTHFR) and thrombospondin 1 (THBS1). 
Likewise, cytochrome P450 family 1 subfamily B member 1 (CYP1B1) was found to be 
a putative gene for hsa-miR-373-5p and hsa-miR-215-5p (Table 5-6). 
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Moreover, twelve genes were unique targets for hsa-miR-373-5p: ATP binding 
cassette subfamily B member 1 (ABCB1), aldehyde dehydrogenase 7 family member 
A1 (ALDH7A1), carbonic anhydrase 8 (CA8), collagen type I alpha 1 chain (COL1A1), 
interleukin 1 beta (IL1B), insulin receptor substrate 2 (IRS2), paraoxonase 1 (PON1), 
sclerostin (SOST), signal transducer and activator of transcription 1 (STAT1), 
thrombospondin type 1 domain containing 7A (THSD7A), UDP 
glucuronosyltransferase family 2 member B17 (UGT2B17) and vacuolar protein 
sorting 13 homolog (BVPS13B), seven genes for hsa-miR-4516: cytochrome P450 
family 17 subfamily A member 1 (CYP17A1), cytochrome P450 family 19 subfamily A 
member 1 (CYP19A1), KIT proto-oncogene receptor tyrosine kinase (KIT), 
lactotransferrin (LTF), mitogen-activated protein kinase 3 (MAPK3), procollagen-
lysine,2-oxoglutarate 5-dioxygenase 1 (PLOD1) and solute carrier family 22 member 
11 (SLC22A11), 6 genes for hsa-miR-122-5p: alkaline phosphatase, liver/bone/kidney 
(ALPL), carbonic anhydrase 10 (CA10), cytochrome P450 family 3 subfamily A 
member 4 (CYP3A4), growth hormone 1 (GH1), insulin like 3 (INSL3) and TNF receptor 
superfamily member 1B (TNFRSF1B). While, insulin like growth factor 1 (IGF1) (≥ two 
algorithms) was uniquely identified as predicted binding site for hsa-miR-215-5p only 
(Table 5-6). 
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Table 5-6: Osteoporosis-related genes and circulating miRNAs. 
This table show that some genes were targeted by more than one miRNA. 
Gene Description 
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BMP2K BMP2 inducible kinase X X X X 4 
SPARC secreted protein acidic and cysteine 
rich 
X X X X 4 
AR androgen receptor X  X X 3 
IGF1R insulin like growth factor 1 receptor X  X X 3 
FSHB follicle stimulating hormone beta 
subunit 
X  X X 3 
CD47 CD47 molecule  X X X 3 
TRAF6 TNF receptor associated factor 6  X X X 3 
ESR1 estrogen receptor 1 X X X  3 
MAPK1 mitogen-activated protein kinase 1 X X X  3 
VDR vitamin D (1,25- dihydroxy vitamin D3) 
receptor 
X X  X 3 
ANKH ANKH inorganic pyrophosphate 
transport regulator 
X  X  2 
CD44 CD44 molecule (Indian blood group) X  X  2 
CNR2 cannabinoid receptor 2 X  X  2 
LRP6 LDL receptor related protein 6 X  X  2 
PTHLH parathyroid hormone like hormone X   X 2 
RUNX2 runt related transcription factor 2 X   X 2 
TSC22D3 TSC22 domain family member 3 X   X 2 
CNR1 cannabinoid receptor 1   X X 2 
MTHFR methylenetetrahydrofolate reductase   X X 2 
THBS1 thrombospondin 1   X X 2 
CYP1B1 cytochrome P450 family 1 subfamily B 
member 1 
 X X  2 
ALPL alkaline phosphatase, 
liver/bone/kidney 
X    1 
CA10 carbonic anhydrase 10 X    1 
CYP3A4 cytochrome P450 family 3 subfamily A 
member 4 
X    1 
GH1 growth hormone 1 X    1 
INSL3 insulin like 3 X    1 
TNFRSF1B TNF receptor superfamily member 1B X    1 
IGF1 insulin like growth factor 1  X   1 
ABCB1 ATP binding cassette subfamily B 
member 1 
  X  1 
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Gene Description 
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ALDH7A1 aldehyde dehydrogenase 7 family 
member A1 
  X  1 
CA8 carbonic anhydrase 8   X  1 
COL1A1 collagen type I alpha 1 chain   X  1 
IL1B interleukin 1 beta   X  1 
IRS2 insulin receptor substrate 2   X  1 
PON1 paraoxonase 1   X  1 
SOST sclerostin   X  1 
STAT1 signal transducer and activator of 
transcription 1 
  X  1 
THSD7A thrombospondin type 1 domain 
containing 7A 
  X  1 
UGT2B17 UDP glucuronosyltransferase family 2 
member B17 
  X  1 
VPS13B vacuolar protein sorting 13 homolog B   X  1 
CYP17A1 cytochrome P450 family 17 subfamily 
A member 1 
   X 1 
CYP19A1 cytochrome P450 family 19 subfamily 
A member 1 
   X 1 
KIT KIT proto-oncogene receptor tyrosine 
kinase 
   X 1 
LTF lactotransferrin    X 1 
MAPK3 mitogen-activated protein kinase 3    X 1 
PLOD1 procollagen-lysine,2-oxoglutarate 5-
dioxygenase 1 
   X 1 
SLC22A11 solute carrier family 22 member 11    X 1 
Total 47 21 9 29 21  
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5.2.3 Protein–protein interaction networks within miRNA osteoporosis-related 
target mRNAs. 
Search Tool for the Retrieval of Interacting Genes (String, version 10.5) (Szklarczyk et 
al., 2015) was used to investigate the biological interactions between the 47 miRNA 
predicted osteoporosis–associated gene targets shown in Table 5-6 (5.2.2.5), and 40 
of these genes were shown to be interrelated with at least one other gene (Figure 
5-6) (Table 5-7). 
 
Figure 5-6: Protein-Protein Interaction Network for putative miRNA Gene target 
(n=40). 
Total of 40 predicted gene targets: ABCB1, ALDH7A1, ALPL, AR, CD44, CD47, CNR1, 
CNR2, COL1A1, CYP17A1, CYP19A1, CYP1B1, CYP3A4, ESR1, FSHB, GH1, IGF1, IGF1R, 
IL1B, INSL3, IRS2, KIT, LRP6, MAPK1, MAPK3, MTHFR, PLOD1, PON1, PTHLH, RUNX2, 
SLC22A11, SOST, SPARC, STAT1, THBS1, THSD7A, TNFRSF1B, TRAF6, UGT2B17 and 
VDR for miRNAs: hsa-miR-373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-
4516 were identified. The nodes and edges represent the proteins (genes) and 
interactions, respectively. Image was generated using String version 10.5 Protein-
Protein interaction network (Szklarczyk et al., 2015). 
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Interestingly, insulin like growth factor 1 (IGF1) was the node with the highest 
number of interacting genes (n= 20), which means that interactions must pass 
through this node to reach other portions of the network; there were 17 interacting 
genes for the nodes, estrogen receptor 1 (ESR1) and mitogen-activated protein 
kinase 3 (MAPK1), 16 for MAPK3, then 14 for the androgen receptor (AR) node and 
13 for both CD44 and runt related transcription factor 2 (RUNX2). In addition, 12 
genes interacted with insulin like growth factor 1 receptor (IGF1R) and interleukin 1 
beta (IL1B), respectively and 11 for collagen type I alpha 1 chain (COL1A1) and 
cytochrome P450 family 19 subfamily A member 1 (CYP19A1), respectively. Likewise, 
9 genes interacted with KIT proto-oncogene receptor tyrosine kinase (KIT), as well as 
for signal transducer and activator of transcription 1 (STAT1). In the same fashion, 
eight genes were interrelated with cytochrome P450 family 3 subfamily A member 4 
(CYP3A4), parathyroid hormone like hormone (PTHLH), thrombospondin 1 (THBS1) 
and TNF receptor associated factor 6 (TRAF6), seven for growth hormone 1 (GH1), 
then 6 genes for cytochrome P450 family 17 subfamily A member 1 (CYP17A1), 
insulin receptor substrate 2 (IRS2) and secreted protein acidic and cysteine rich 
(SPARC), insulin like 3 (INSL3, n=5); ATP binding cassette subfamily B member 1 
(ABCB1), CD47, follicle stimulating hormone beta subunit (FSHB), sclerostin (SOST), 
TNFRSF1B and UGT2B17 (n= 4, each), and finally, 2 for each of cannabinoid receptor 
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1 (CNR1), cytochrome P450 family 1 subfamily B member 1 (CYP1B1) and LDL 
receptor related protein 6 (LRP6) (Table 5-7).  
Table 5-7: Protein-Protein Interaction for four miRNAs predicted gene target. 
Data was generated using String protein-protein interaction network software 
(Ver.10) (Szklarczyk et al., 2015). 
Gene 
(node) 
Interrelated Genes No. of 
Genes 
IGF1 AR, CD44, CD47, COL1A1, CYP17A1, CYP19A1, ESR1, GH1, 
IGF1R, IL1B, IRS2, KIT, MAPK1, MAPK3, PTHLH, RUNX2, 
SPARC, STAT1, THBS1 and VDR 
20 
ESR1 AR, CD44, CYP17A1, CYP19A1, CYP1B1, CYP3A4, GH1, 
IGF1, IGF1R, IL1B, IRS2, KIT, MAPK1, MAPK3, RUNX2, 
STAT1 and TRAF6 
17 
MAPK3 ALPL, AR, CD44, CYP19A1, ESR1, GH1, IGF1, IGF1R, IL1B, 
IRS2, KIT, MAPK1, RUNX2, STAT1, THBS1, TRAF6 and VDR 
17 
MAPK1 ALDH7A1, AR, CD44, ESR1, GH1, IGF1, IGF1R, IL1B, IRS2, 
KIT, LRP6, MAPK3, RUNX2, STAT1, TRAF6 and VDR 
16 
AR CD44, CYP17A1, CYP19A1, CYP3A4, ESR1, FSHB, IGF1, 
IGF1R, INSL3, KIT, MAPK1, MAPK3, RUNX2 and UGT2B17 
14 
CD44 ABCB1, AR, CD47, COL1A1, ESR1, IGF1, IL1B, KIT, MAPK1, 
MAPK3, RUNX2, SPARC and THBS1 
13 
RUNX2 ALPL, AR, CD44, COL1A1, ESR1, IGF1, IL1B, MAPK1, 
MAPK3, PTHLH, SOST, SPARC and VDR 
13 
IGF1R AR, CYP19A1, CYP3A4, ESR1, GH1, IGF1, IL1B, IRS2, 
MAPK1, MAPK3, TRAF6 and VDR 
12 
IL1B CD44, CD47, ESR1, IGF1, IGF1R, MAPK1, MAPK3, PTHLH, 
RUNX2, STAT1, TNFRSF1B and TRAF6 
12 
COL1A1 ALPL, CD44, CNR1, GH1, IGF1, PLOD1, RUNX2, SOST, 
SPARC, THBS1 and VDR 
11 
CYP19A1 AR, CYP17A1, CYP3A4, ESR1, FSHB, IGF1, IGF1R, INSL3, 
MAPK3, UGT2B17 and VDR 
11 
VDR COL1A1, CYP19A1, CYP3A4, IGF1, IGF1R, MAPK1, MAPK3, 
PTHLH, RUNX2 and STAT1 
10 
KIT ABCB1, AR, CD44, ESR1, IGF1, MAPK1, MAPK3, STAT1 and 
TRAF6 
9 
STAT1 ESR1, IGF1, IL1B, KIT, MAPK1, MAPK3, TNFRSF1B, TRAF6 
and VDR 
9 
CYP3A4 ABCB1, AR, CYP17A1, CYP19A1, ESR1, IGF1R, UGT2B17 
and VDR 
8 
PTHLH FSHB, IGF1, IL1B, INSL3, RUNX2, SOST, SPARC and VDR 8 
THBS1 CD44, CD47, COL1A1, IGF1, MAPK3, SPARC, THSD7A and 
TNFRSF1B 
8 
TRAF6 ESR1, IGF1R, IL1B, KIT, MAPK1, MAPK3, STAT1 and 
TNFRSF1B 
8 
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Gene 
(node) 
Interrelated Genes No. of 
Genes 
GH1 COL1A1, ESR1, IGF1, IGF1R, IRS2, MAPK1 and MAPK3 7 
CYP17A1 AR, CYP19A1, CYP3A4, ESR1, IGF1 and INSL3 6 
IRS2 ESR1, GH1, IGF1, IGF1R, MAPK1 and MAPK3 6 
SPARC CD44, COL1A1, IGF1, PTHLH, RUNX2 and THBS1 6 
INSL3 AR, CYP17A1, CYP19A1, FSHB and PTHLH 5 
ABCB1 CD44, CYP3A4, KIT and SLC22A11 4 
CD47 CD44, IGF1, IL1B and THBS1 4 
FSHB AR, CYP19A1, INSL3 and PTHLH 4 
SOST COL1A1, LRP6, PTHLH and RUNX2 4 
TNFRSF1B IL1B, STAT1, THBS1 and TRAF6 4 
UGT2B17 AR, CYP19A1, CYP1B1 and CYP3A4 4 
ALPL COL1A1, MAPK3 and RUNX2 3 
CNR1 CNR2 and COL1A1 2 
CYP1B1 ESR1 and UGT2B17 2 
LRP6 MAPK1 and SOST 2 
ALDH7A1 MAPK1 1 
CNR2 CNR1 1 
MTHFR PON1 1 
PLOD1 COL1A1 1 
PON1 MTHFR 1 
SLC22A11 ABCB1 1 
THSD7A THBS1 1 
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5.2.4 Signalling Pathways 
5.2.4.1 Bone remodelling 
Out of the 40 osteoporosis-related genes with target sequences for miRNAs hsa-miR-
373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-4516 related by the String 
network (refer to 5.2.3), Eleven genes were involved in skeletal system development 
(GO:0001501) as shown in Figure 5-7. 
 
Figure 5-7: Protein-Protein Interaction Network for putative miRNA Gene target 
involved in skeletal system development. 
11 predicted gene targets: ANKH, CD44, GH1, IGF1, KIT, LRP6, LTF, MAPK3, SPARC, 
THBS1 and VDR were identified as being associated with skeletal system 
development. The nodes and edges represent the proteins (genes) and interactions, 
respectively. Image was generated using String version 10.5 Protein-Protein 
interaction network. 
 
 
Ten genes were involved in bone development (GO:0060348), seven genes in the 
ossification process (GO:0001503) COL1A1, IGF1, LTF, PTHLH, SOST, SPARC and 
TRAF6, with six genes involved in ossification regulation  (GO:0030278) ANKH, 
BMP2K, IGF1, LTF, RUNX2 and SOST and six genes: ALPL, COL1A1, LTF, PTHLH, RUNX2 
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and THBS1 in bone morphogenesis (GO:0060349) as well as in skeletal system 
morphogenesis (GO:0048705), (Figure 5-8).  
 
Figure 5-8: Numbers of Gene from the 40 gene String network s involved in Bone 
Remodelling.  
 
The most common genes involved in bone development, morphogenesis and 
osteoblast differentiation are:  ALPL, COL1A1, IGF1, LTF, PTHLH, RUNX2 and THBS1. 
In contrast, the most common genes involved in bone remodeling signalling pathway 
and osteoclast differentiation were FSHB, SOST and TRAF6. Indeed, TRAF6 shown to 
be involved in bone resorption (GO:0045453), osteoclast differentiation 
(GO:0030316) and positive regulation of osteoclast differentiation (GO:0045672), 
while SOST was involved in negative regulation of BMP signalling pathway 
(GO:0030514) and in the negative regulation of ossification (GO:0030279) (Table 
5-6). 
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Table 5-8: Genes involved in Bone Remodelling and their Biological Process (GO id) 
Genes Biological Process (GO ID) 
ANKH, CD44, GH1, IGF1, KIT, LRP6, 
LTF, MAPK3, SPARC, THBS1 and 
VDR 
skeletal system development (GO:0001501) 
ALPL, COL1A1, GH1, IGF1, KIT, LTF, 
PTHLH, RUNX2, SPARC and THBS1 
bone development (GO:0060348) 
COL1A1, IGF1, LTF, PTHLH, SOST, 
SPARC and TRAF6 
ossification (GO:0001503) 
ALPL, COL1A1, LTF, PTHLH, RUNX2 
and THBS1 
bone morphogenesis (GO:0060349, 
GO:0048705) 
ANKH, BMP2K, IGF1, LTF, RUNX2 
and SOST 
regulation of ossification (GO:0030278) 
ALPL, COL1A1, PTHLH, RUNX2 and 
THBS1 
endochondral bone morphogenesis 
(GO:0060350, GO:0001958) 
ALPL, COL1A1 and PTHLH osteoblast differentiation (GO:0001649) 
IGF1, LTF and RUNX2 positive regulation of ossification 
(GO:0045778) and osteoblast 
differentiation (GO:0045669) 
MAPK3 and RUNX2 BMP signalling pathway (GO:0030509) 
GH1 and IGF1 bone maturation (GO:0070977) 
COL1A1 and THBS1 cartilage development involved in 
endochondral bone morphogenesis 
(GO:0060351) 
COL1A1 and CYP1B1 collagen fibril organization (GO:0030199) 
PTHLH and RUNX2 osteoblast development (GO:0002076) 
MAPK1 and MAPK3 regulation of cytoskeleton organization 
(GO:0051493) 
TRAF6 bone resorption (GO:0045453), bone 
remodeling (GO: 0046849), osteoclast 
differentiation (GO: 0030316) and positive 
regulation of osteoclast differentiation (GO: 
0045672) 
COL1A1 bone trabecula formation (GO:0060346) 
and intramembranous ossification 
(GO:0001957) 
SOST negative regulation of ossification 
(GO:0030279) and BMP signalling pathway 
(GO:0030514) 
FSHB positive regulation of bone resorption 
(GO:0045780) 
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5.2.4.2  Wnt Receptor Signalling Pathway  
Wnt signalling pathways are a group of signal transduction pathways that participate 
in the regulation of cell differentiation, proliferation, and apoptosis (Huelsken and 
Birchmeier, 2001), and, through these mechanisms play a key role in bone 
remodeling and disease (Harada and Rodan, 2003, Baron and Kneissel, 2013). Three 
genes, CD44, LRP6 and SOST are involved in regulation of the Wnt signalling pathway 
(GO:0030111) and regulation of canonical Wnt signalling pathway (GO:0060828). 
COL1A1 shown to involved in positive regulation of Wnt signalling pathway 
(GO:0030177), while SOST is involved in the negative regulation of Wnt signalling 
pathway (GO:0030178) negative regulation of canonical Wnt signalling pathway 
(GO:0090090). LRP6 was involved in Wnt Signalling Pathway, including the positive 
and negative regulation of the canonical Wnt signalling pathways, while SOST was 
involved in the negative regulation of canonical Wnt signalling pathway. 
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Table 5-9: Genes involved in Wnt Signalling Pathway and their Biological Process 
(GO) 
Genes Biological Process (GO ID) 
CD44, LRP6 and SOST Wnt signalling pathway (GO:0016055) 
COL1A1, LRP6 and SOST regulation of Wnt (GO:0030111) and 
canonical Wnt (GO:0060828) signalling 
pathways  
COL1A1 and LRP6 positive regulation of Wnt signalling 
pathway (GO:0030177) 
LRP6 and SOST negative regulation of Wnt and canonical 
Wnt (GO:0090090) signalling pathways 
COL1A1 and LRP6 positive regulation of canonical Wnt 
signalling pathway (GO:0090263) 
LRP6 canonical Wnt signalling pathway 
(GO:0060070) involved in regulation of cell 
proliferation (GO:0044340) 
 
5.2.4.3 Insulin, insulin-like growth factor and growth hormone Regulation 
Insulin-like growth factors (IGFs): IGF1 and IGF2 that are produced by bone cells 
regulate specific osteoblastic and osteoclastic functions (Rosen et al., 1994). In total, 
17 genes from the 40 genes in the String network were involved in the ‘Insulin & 
Insulin Like Growth Factor regulation’ signalling pathways.  Eleven genes were 
involved in cellular response to growth factor stimulus (GO:0071363). Five genes, 
GH1, IRS2, MAPK1, MAPK3 and STAT1, were involved in the growth hormone 
receptor signalling pathway (GO:0060396). 4 genes, IGF1R, IRS2, MAPK1 and MAPK3, 
were involved in the insulin receptor signalling pathway (GO:0008286), cellular 
response to insulin stimulus (GO:0032869) and response to insulin (GO:0032868) 
(Figure 5-9). 
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Figure 5-9: Numbers of genes from the 40 member String network involved in 
Insulin & Insulin Like Growth Factor regulation  
 
In addition, CNR1, IL1B and IRS2 were involved in regulation of insulin secretion 
(GO:0050796), while IGF1 and IGF1R were involved in insulin-like growth factor 
receptor signalling pathway (GO:0048009). 
Table 5-10: Genes involved in the insulin and insulin like growth factor signalling 
pathways with their Biological Process (GO id) 
Genes Biological Process (GO ID) 
CD44, COL1A1, FSHB, IRS2, KIT, 
MAPK1, MAPK3, RUNX2, SPARC, 
TNFRSF1B and TRAF6 
cellular response to growth factor stimulus 
(GO:0071363) 
GH1, IRS2, MAPK1, MAPK3 and 
STAT1 
growth hormone receptor signalling 
pathway (GO:0060396) 
IGF1R, IRS2, MAPK1 and MAPK3 insulin receptor signalling pathway 
(GO:0008286), response to insulin 
(GO:0032868) and cellular response to 
insulin stimulus (GO:0032869). 
CNR1, IL1B and IRS2 regulation of insulin secretion 
(GO:0050796) 
IGF1 and IGF1R insulin-like growth factor receptor signalling 
pathway (GO:0048009) 
 
5.2.4.4 MAPK Activity 
Mitogen-activated protein kinases (MAPKs) are part of intracellular signalling 
pathways that play an essential role in cellular proliferation, differentiation (Aouadi 
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et al., 2006), immune responses (Dong et al., 2002) and apoptosis regulation (Wada 
and Penninger, 2004). MAPKs are essential regulators of RANKL-mediated 
osteoclastogenesis that contribute to bone loss (Ge et al., 2007, Boyle et al., 2014). 
Ten genes were involved in positive regulation of MAPK cascade (GO:0043410), 
wherein 8 genes were involved in regulation of MAPK cascade (GO:0043408). Seven 
genes: GH1, IL1B, KIT, MAPK1, MAPK3, THBS1 and TRAF6 were involved in positive 
regulation of MAP kinase activity (GO:0043406) and regulation of MAP kinase activity 
(GO:0043405).  Furthermore, six genes: IL1B, KIT, MAPK1, MAPK3, THBS1 and TRAF6 
were involved in activation of MAPK activity (GO:0000187) (Figure 5-10). 
 
Figure 5-10: Numbers of genes from the 40 member String network involved in 
MAPK and MAPKK activity  
 
Seven genes CD44, GH1, KIT, MAPK1, MAPK3, THBS1 and TRAF6 were associated with 
positive regulation of MAP kinase activity and involved in the regulation of MAPK 
cascade. Additionally, both MAPKs, MAPK1 and MAPK3, were involved in the 
activation of MAPKK activity (GO:0000186) and MAPK import into the nucleus 
(GO:0000189). In contrast, IL1B, IGF1 and IGF1R are involved in both, the negative 
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regulation of MAPK cascade (GO:0043409) and positive regulation of MAPK cascade 
(GO:0043410) (Table 5-11). 
Table 5-11: Genes involved in MAPK activity with their Biological Process (GO id) 
Genes Biological Process (GO) 
CD44, GH1, IGF1, IGF1R, IL1B, KIT, 
MAPK1, MAPK3, THBS1 and TRAF6 
positive regulation of MAPK cascade 
(GO:0043410) 
CD44, GH1, IL1B, KIT, MAPK1, 
MAPK3, THBS1 and TRAF6 
regulation of MAPK cascade (GO:0043408) 
GH1, IL1B, KIT, MAPK1, MAPK3, 
THBS1 and TRAF6 
Positive regulation of MAP kinase activity 
(GO:0043405 GO:0043406) 
IL1B, KIT, MAPK1, MAPK3, THBS1 
and TRAF6 
activation of MAPK activity (GO:0000187) 
IGF1, IL1B, MAPK3 and TRAF6 MAPK cascade (GO:0000165) 
IGF1R, MAPK1, MAPK3 and TRAF6 regulation of stress-activated MAPK 
cascade (GO:0032872) 
IGF1, IGF1R and IL1B negative regulation of MAPK cascade 
(GO:0043409) 
MAPK1, MAPK3 and TRAF6 stress-activated MAPK cascade 
(GO:0051403) 
MAPK1 and MAPK3 activation of MAPKK activity (GO:0000186) 
and MAPK import into nucleus 
(GO:0000189) 
IL1B negative regulation of MAP kinase activity 
(GO:0043407) 
TRAF6 positive regulation of stress-activated MAPK 
cascade (GO:0032874) 
 
5.2.4.5 Steroid hormones associated with osteoporosis 
Gonadal steroid hormones play a vital role in maintaining lifetime bone mass in men, 
women, and children (Harman et al., 2001). Out of 40 predicted osteoporosis-related 
gene targets (refer to 5.2.3), 17 genes were associated with the hormonal regulation 
of osteoporosis, wherein, ten : ALPL, AR, COL1A1, ESR1, GH1, IL1B, MAPK1, SPARC, 
THBS1 and VDR were involved in the  response to steroid hormone (GO:0048545), 7 
genes (CYP17A1, CYP1B1, CYP3A4, ESR1, FSHB, IL1B and UGT2B17) were involved in 
steroid metabolic process (GO:0008202), and 5 genes: COL1A1, ESR1, GH1, IL1B and 
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MAPK1 were involved in response to estrogen (GO:0043627) (Figure 5-11) (Table 
5-12). 
 
Figure 5-11: Numbers of Genes from the 40 gene network involved in Steroid 
hormone regulation. 
 
ESR1 and IL1B were involved in the response to steroid hormone (GO:0048545), 
steroid metabolic process (GO:0008202) and response to estrogen (GO:0043627). In 
addition, ESR1, AR and VDR were involved in steroid hormone mediated signalling 
pathways (GO:0043401). 
Table 5-12: Osteoporosis-related genes involved in steroid hormone activity and 
their Biological Process (GO id) 
Genes Biological Process (GO) 
ALPL, AR, COL1A1, ESR1, 
GH1, IL1B, MAPK1, SPARC, 
THBS1 and VDR 
Response to steroid hormone (GO:0048545) 
CYP17A1, CYP1B1, CYP3A4, 
ESR1, FSHB, IL1B and 
UGT2B17 
steroid metabolic process (GO:0008202) 
COL1A1, ESR1, GH1, IL1B and 
MAPK1 
response to estrogen (GO:0043627) 
CYP17A1, CYP19A1, CYP3A4 
and ESR1 
androgen metabolic process (GO:0008209) 
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Genes Biological Process (GO) 
ALPL, COL1A1, IL1B and 
SPARC 
response to corticosteroid (GO:0031960) 
CYP17A1, CYP19A1, CYP3A4 
and FSHB 
steroid biosynthetic process (GO:0006694) 
CYP19A1, CYP1B1 and IL1B estrogen metabolic process (GO:0008210) 
AR, ESR1 and VDR steroid hormone mediated signalling pathway 
(GO:0043401) 
CYP17A1 and FSHB progesterone metabolic process (GO:0042448) 
AR androgen receptor signalling pathway 
(GO:0030521) 
IGF1 negative regulation of androgen receptor 
signalling pathway (GO:0060766) 
THBS1 response to progesterone (GO:0032570) 
CYP3A4 steroid catabolic process (GO:0006706) 
 
5.2.4.6 Apoptosis Process 
Apoptosis is a genetically programmed cell death (Kerr et al., 1972) that is involved 
in bone remodeling (Xing and Boyce, 2005). Sixteen genes from the 40 genes in the 
String network were shown to be involved in regulation of the apoptotic process 
(GO:0042981), eleven genes were involved in negative regulation of the apoptotic 
process (GO:0043066), eight genes were involved in apoptotic process (GO:0006915) 
and 6 genes were involved in the positive regulation of apoptotic process 
(GO:0043065) (Figure 5-12).  
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Figure 5-12: Number of genes from the 40 gene network involved in the apoptotic 
process. 
 
Eight genes: AR, CD44, IGF1, INSL3, IRS2, LRP6, LTF and TSC22D3 were shown to be 
mainly associated with the negative regulation of the apoptotic process. In contrast, 
three genes: CNR1, CYP1B1 and VDR were shown to be involved mainly in the positive 
regulation of the apoptotic process (GO:0043065). However, IL1B, THBS1 and LRP6 
were shown to be involved in both the positive and negative regulation of the 
apoptotic process.  
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Table 5-13: Genes involved in Apoptosis Process in their Biological Process (GO id) 
Genes Biological Process (GO) 
AR, CD44, CNR1, CYP1B1, ESR1, 
IGF1, IL1B, INSL3, IRS2, LRP6, LTF, 
STAT1, THBS1, TRAF6, TSC22D3 
and VDR 
regulation of apoptotic process 
(GO:0042981) 
AR, CD44, IGF1, IL1B, INSL3, IRS2, 
LRP6, LTF, THBS1, TRAF6 and 
TSC22D3 
negative regulation of apoptotic process 
(GO:0043066) 
CD44, CYP1B1, IGF1, MAPK1, 
MAPK3, STAT1, THBS1, TNFRSF1B 
and TRAF6 
apoptotic process (GO:0006915) 
CNR1, CYP1B1, IL1B, THBS1, TRAF6 
and VDR 
positive regulation of apoptotic process 
(GO:0043065) 
CYP1B1, IGF1, IL1B, TNFRSF1B and 
TRAF6 
apoptotic signalling pathway (GO:0097190) 
AR, CD44, IGF1, IL1B and THBS1 negative regulation of apoptotic signalling 
pathway (GO:2001234) 
AR, IGF1, IL1B and THBS1 negative regulation of extrinsic apoptotic 
signalling pathway (GO:2001237) 
IGF1, IL1B and TNFRSF1B extrinsic apoptotic signalling pathway 
(GO:0097191) 
IGF1, IGF1R and LRP6 negative regulation of muscle cell apoptotic 
process (GO:0010656) 
CD44 and THBS1 negative regulation of cysteine-type 
endopeptidase activity involved in 
apoptotic process (GO:0043154) 
IGF1 and LRP6 negative regulation of smooth muscle cell 
apoptotic process (GO:0034392) 
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5.2.5 Role of miRNAs in Bone Remodeling  
List of genes that are involved in bone remodeling and in bone pathogenesis 
‘Osteoporosis’ were identified (refer to 5.2.4.1). Sclerostin (SOST) a Wnt antagonist 
glycoprotein secreted by osteocytes (van Bezooijen et al., 2004) has been found to 
be a predicted target for circulating serum hsa-miR-373-5p (refer to 0). Binding of 
Sclerostin to its receptors, low-density lipoprotein-related proteins 5/6 (LRP5/6 
receptors), inhibits the Wnt signalling pathway in human embryonic kidney A293T 
cells and mouse osteoblastic MC3T3 cells (Li et al., 2005, Ellies et al., 2006), and 
eventually inhibits osteoblast formation (Poole et al., 2005). LRP6, which is expressed 
in osteoblastic cell (Li et al., 2005) has been found to be a predicted target for both 
hsa-miR-373-5p and hsa-miR-122-5p (Figure 5-13).  
Estrogens and androgen are sex steroid hormones that play an essential role in bone 
development and remodeling, and deficiency of these hormones increases bone 
remodelling with resorption rate exceeding formation leading to osteoporosis 
(Cauley, 2015). Estrogen activity is mediated by binding to ESR1 and ESR2 (Fitzpatrick, 
2006), while the activity of androgens is mediated by binding to the androgen 
receptor (AR) (Beato and Klug, 2000). Both, estrogen receptor 1 (ESR1) and androgen 
receptor (AR) that are expressed in osteoblasts, osteoclasts and their progenitor cells 
(Zallone, 2006, Manolagas et al., 2013, Pederson et al., 1999) are predicted target for 
hsa-miR-373-5p and hsa-miR-122-5p. Therefore, hsa-miR-122-5p and hsa-miR-373-
5p could possibly downregulate ESR1 and AR expression leading to impairment of 
estrogen/ESR1 and androgen/AR signalling pathways, leading to increased bone 
turnover and resorption rate (Figure 5-13).  
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Hsa-miR-373-5p, hsa-miR-215-5p and hsa-miR-4516 were predicted to target CD47 
and tumour necrosis factor receptor-associated factor 6 (TRAF6) (Figure 5-13). CD47 
is a membrane protein belonging to the superfamily of immunoglobulins that have 
been shown to be expressed in all hematopoietic cells, including macrophages 
(Brown et al., 1990), and TRAF6  a transduction factor for RANK binding to RANKL, 
that is expressed in a wide range of tissues including monocytes (Lamothe et al., 
2007) and is involved in the activation of downstream signalling pathways, such as 
nuclear factor of activated T-cells 1 (NFATc1), nuclear factor-kappa B (NF-κB), 
microphthalmia transcription factor (MITF) and c-Fos which are responsible for 
osteoclast differentiation (Kim and Kim, 2014). 
BMP2 inducible kinase (BMP2K) (Salazar et al., 2016) and secreted protein acidic and 
cysteine rich (SPARC) (Delany et al., 2000) are involved in bone development and 
osteoblast differentiation. In addition, hsa-miR-4516 was predicted to target MAPK3 
(Ge et al., 2007) and SPARC genes (Figure 5-13). Therefore, dysregulation of MAPK1, 
MAPK3, BMP2K and SPARC expression by these miRNAs could lead to high bone 
turnover. 
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Figure 5-13: Role of miRNAs in Bone Remodeling. 
 
 
Summary key molecules and functions, refer to Appendix 8.7. 
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5.3 Discussion 
In this chapter, the study set out to assess the post-transcriptional effects of miRNAs 
on genes/mRNAs that are involved in osteoporosis. 
Forty seven protein coding genes were identified as targets for circulating 
serum/plasma miRNAs: hsa-miR-373-5p, hsa-miR-122-5p, and hsa-miR-215-5p and 
hsa-miR-4516 by 2 or more miRNA predicted target algorithms. Some of these genes 
are involved in osteoblastogenesis, while some others are involved in 
osteoclastogenesis according to gene ontology databases. Up to 60% of the predicted 
genes were targets for hsa-miR-373-5p, including Sclerostin SOST gene, 44% for both 
hsa-miR-122-5p and hsa-miR-4516, and 19% for hsa-miR-215-5p. Interestingly, BMP2 
inducible kinase (BMP2K) and secreted protein acidic and cysteine rich (SPARC) were 
the most common gene target for the four circulating miRNAs (hsa-miR-122-5p, hsa-
miR-215-5p, hsa-miR-373-5p and hsa-miR-4516) and nine genes (AR, IGF1R, CD47, 
ESR1, FSHB, MAPK1, SPARC, TRAF6 and VDR) were targets among four circulating 
miRNAs: hsa-miR-373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-4516. 
Sclerostin (SOST), a Wnt antagonist glycoprotein secreted by osteocytes (Winkler et 
al., 2003, van Bezooijen et al., 2004) was shown to be a target for the most 
significantly downregulated circulating serum miRNA, hsa-miR-373-5p in 
osteoporotic fractured patients. Reduced bone mineral density was noticed in 
heterogenous LRP6+/LRP6- mutant mice compared to wild type mice (Holmen et al., 
2004). LRP6 was found to be a common target gene for both hsa-mir-373-5p and hsa-
mir-122-5p.  therefore, hsa-miR-373-5p and miR-122-5p might have a vital role in 
bone haemostasis by downregulating SOST expression and inhibiting its binding to 
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LDL receptor-related protein 5 (LRP5) and LRP6 and halting its negative canonical 
Wnt signalling pathway (Semenov et al., 2005, Li et al., 2005).   
Tumour necrosis factor receptor-associated factor 6 (TRAF6) and CD47 were found 
to be putative target proteins for hsa-miR-373-5p, hsa-miR-215-5p and hsa-miR-
4516. Both CD47 and TRAF6 have been shown to be involved in promoting  cell 
fusions involving mono-nucleated pre-osteoclasts (Kim and Kim, 2014) and the 
activation of downstream signalling pathways, which are responsible for osteoclast 
differentiation (Moller et al., 2017, Han et al., 2000). This might suggest that, 
downregulation of hsa-miR-373-5p, hsa-miR-215-5p and hsa-miR-4516 in LBMD 
subjects could promote the overexpression of CD47 and TRAF6 leading to increased 
bone turnover. 
ESR1 was a predicted target gene for hsa-miR-373-5p, hsa-miR-122-5p and hsa-miR-
215-5p. AR was a predicted target gene for hsa-miR-373-5p, hsa-miR-122-5p and hsa-
miR-4516. Others have shown the deletion of ESR1 in mature osteoblast and 
osteocytes in mice increased osteoblastic apoptosis, while global deletion of AR in 
male mice result in high bone turnover and increased resorption of bone  (Manolagas 
et al., 2013). In addition, ESR1 was found to be downregulated in the peripheral blood 
cells (PBCs) of postmenopausal female osteopenia and osteoporosis patients 
compared to a postmenopausal, non-osteoporotic control group (Chou et al., 2016).  
Follicle stimulating hormone beta subunit (FSHB) a pituitary glycoprotein hormone 
that stimulates the development of ovarian follicles and spermatogenesis in the 
reproductive organs was also a putative target for hsa-miR-373-5p, hsa-miR-122-5p, 
and hsa-miR-4516. FSHB has been found to be expressed in osteoclasts and their 
Chapter5: MiRNA Predicted Gene targets in Osteoporosis 
191 | P a g e  
 
precursors, but not osteoblasts (Martin and Gaddy, 2006). Increased level of 
circulating serum FSH in osteoporosis postmenopausal woman compared to 
postmenopausal woman control group was observed (Wang et al., 2015a). Indeed, 
all the three binding receptors, FSHB, ESR and AR, are putative target proteins for 
hsa-miR-373-5p and hsa-miR-122-5p. Their overexpression could be enhanced by the 
downregulation of hsa-miR-373-5p and hsa-miR-122-5p. However, the dysregulation 
mechanism of these genes (FSHB, ESR and AR) associated with bone remodelling is 
not yet clear. 
In the String analysis, insulin like growth factor 1 (IGF1) was the node with the highest 
number of interacting genes.  Insulin like growth factor 1 (IGF1) is the most abundant 
growth factor in the skeleton, that is crucial for normal bone development and for 
bone remodeling (Rosen and Donahue, 1998, Rosen, 2004), and has been found to 
be significantly decreased in women with low bone mineral density (LBMD), 
compared to normal (Liu et al., 2008). IGF1 binding to its receptor IGF1R has been 
shown to stimulate signalling pathway of the osteoblastic differentiation (Perrini et 
al., 2008, Cornish et al., 2004). Conditional IGF1 knockout mice have an overall 
decreased bone formation compared to control groups (Govoni et al., 2007), while 
IGF1R-knockout mice have reduced bone mass compared to wild type control (Xian 
et al., 2012). In human hepatocellular carcinoma (HCC) cell lines (HepG2, Hep3B, and 
SK-Hep-1) (Bai et al., 2009) and breast cancer (BC) cell lines (MCF-7, T47d, MDA-MB-
231 and BT549 cells), IGF1R was a target gene for miR-122-5p (Wang et al., 2012a),  
as well as a putative target protein for hsa-miR-373-5p and hsa-miR-4516-5p. While 
IGF1 was found to be putative target gene for hsa-miR-215-5p. Therefore, 
downregulation of IGF1 and/or its binding receptor IGF1R by these miRNAs could 
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contributes to the progression of bone turnover leading to osteoporosis. However, 
the mechanism by which the downregulation of circulating miRNAs involved in the 
dysregulation of IGF1 and IGF1R still unknown. 
BMP2K and SPARC have been shown to be putative targets for all four miRNAs 
identified in this study, hsa-miR-373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-
miR-4516. Bone morphogenetic protein2 (BMP2) plays a key role in skeletal 
development and patterning (Kearns et al., 2001). Expression of BMP2-inducible 
kinase (BMP2K), a transmembrane cell surface receptor with serine/threonine 
protein kinase activity is increased during BMP-2 induced differentiation (Kearns et 
al., 2001). Both, BMP2-inducible kinase (BMP2K) and secreted protein acidic and 
cysteine rich (SPARC) are essential for skeletal differentiation and survival (Salazar et 
al., 2016, Kearns et al., 2001, Delany et al., 2000, Li et al., 2009). BMP2K expression 
has been found to be upregulated during osteoblast differentiation (Kearns et al., 
2001), while decreased levels of SPARC in osteonectin-null mice were associated with 
a decreased level of bone remodeling leading to profound osteopenia (Delany et al., 
2000), and mutation of SPARC gene was associated with idiopathic osteoporosis in 
men, compared to age matched control group (Delany et al., 2008). Again, the 
correlation between the downregulated circulating miRNAs, hsa-miR-373-5p, hsa-
miR-122-5p, hsa-miR-215-5p and hsa-miR-4516 and gene expression of BMP2K and 
SPARC in osteoporosis patients is unknown. 
Likewise, Mitogen-activated protein kinase 1 (MAPK1) is a putative target for hsa-
miR-373-5p, hsa-miR-122-5p and hsa-miR-215-5p, while MAPK3 is a putative target 
for hsa-miR-4516. Both MAPK1 and MAPK3 are expressed in osteoblasts, that act in 
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a signalling cascade involved in the regulation of bone mass via the control of 
osteoblast differentiation (Ge et al., 2007, Greenblatt et al., 2010, Zou et al., 2011). 
However, the dysregulation expression of MAPK1 and MAPK3 associated with the 
downregulation of miR-373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-4516 
needs to be verified. 
The present study showed that, VDR is a predicted target for hsa-miR-122-5p, hsa-
miR-215-5p and hsa-miR-4516. VDR is widely distributed in bone cells, chondrocytes, 
osteoblasts, osteocytes, and osteoclasts (Haussler et al., 1998, Bikle, 2012). The 
biologically active metabolite of Vitamin D (1,25-Dihydroxyvitamin D3) and its 
receptor Vitamin D receptor (VDR), together play a vital role in calcium and 
phosphate homeostasis, and skeletal metabolism, and are considered to be 
important candidate genes of osteoporosis (Haussler et al., 1998).  
In summary, in this Chapter, a relationship between osteoporosis-related genes and 
the four miRNAs, hsa-miR-373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-
4516, has been clearly demonstrated. However, for some target genes, the effects 
are opposite to those expected from the known action of intracellular miRNAs. 
Others have shown that the downregulation of circulating miRNAs is not necessarily 
positively correlated with their cellular expression (Waters et al., 2012). Taken 
together the findings in this Chapter, of the downregulation of circulating miRNAs, 
hsa-miR-373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-miR-4516 and their 
associations with osteoporosis-related predicted gene targets might suggest that 
circulating miRNAs could have dual function as negative and positive post-
transcriptional regulators for protein coding genes. 
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6 Chapter 6. Final Discussion and Future Work 
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6.1 Discussion 
Osteoporosis is a silent disease which usually becomes apparent only after a bone 
fracture has occurred. Currently the diagnosis of osteoporosis is primarily based on 
the measurement of bone mineral density (BMD) using DXA scan (Kanis, 1994) and 
the assessment of fragility fracture’s risk factors (Johnell et al., 2005). However, both 
tests have limitation in regard to osteoporotic fragility fracture diagnosis when 
contributing factors such as diabetic osteopathy (Schwartz et al., 2011), aortic 
calcification and soft-tissue calcification (Unnanuntana et al., 2010) are present. 
Furthermore, Changes in BMD occur slowly, and it may take one to two years to 
detect any differences after osteoporosis treatment (Bonnick and Shulman, 2006).  
In addition, the measurement of bone turnover markers (BTMs) in patients’ blood 
and/or urine samples has been used for monitoring treatment and assessment of 
fracture risk (Naylor and Eastell, 2012), but the level of BTM markers in bone 
diseases, such as osteoporosis, are affected by preanalytical (Naylor and Eastell, 
2012) and analytical variabilities (Garnero, 2017), as well as the lack of established 
normal reference population and standardized quality control (Bauer et al., 2012). 
Therefore, due to their diagnostic and therapeutic monitoring limitations, there is a 
demand for reliable non-invasive and cost efficient diagnostic biomarkers for 
osteoporosis. miRNAs are molecular regulators and play an important role in bone 
formation and resorption processes (van Wijnen et al., 2013). Up- or down-expressed 
miRNAs are involved in different physiological and pathological conditions (Velu et 
al., 2012), including bone-related diseases (Hackl et al., 2016). Indeed, circulating 
miRNAs show remarkable stability in body fluids under different storage conditions 
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(Mitchell et al., 2008) and extreme conditions of repeated freeze and thaw cycle and 
exposure low and high pH solutions (Chen et al., 2008). Moreover, miRNAs can be 
detected using conventional RT-qPCR assays that are specific, sensitive and 
reproducible.  
In this study, 49 differentially expressed miRNAs between osteopenia and 
osteoporosis patient groups were identified, initially using miRNA PCR arrays. Six 
miRNAs, miR-215-5p, miR-99a-5p, miR-100, miR-373-5p, miR-4516 and miR-122-5P, 
were significantly differentially-expressed between osteoporosis and osteopenia 
patients by initial RT-qPCR screening. The levels of four of these miRNAs, hsa-miR-
373-5p, hsa-miR-122-5p and hsa-miR-215-5p and hsa-4516 were associated with 
osteoporosis patients, compared to non-osteoporotic participants.  
Noticeably, miRNAs, hsa-miR-373-5p, hsa-miR-122-5p and hsa-miR-215-5p were 
detectable in serum samples, but miR-4516 was detectible in plasma samples, 
suggesting that the clinical specimen sample type seems to influence the detection 
of the miRNAs. The discrepancy of miRNA expression between serum and plasma 
could be due to the association of miRNA released from platelets (Wang et al., 2012b) 
or due to the presence of interfering substances that might be associated with 
collection tube additives (Dimeski, 2008). However, the cause of this analytical 
discrepancy still unknown.   
An important finding in this study was that hsa-miR-373-5p, hsa-miR-122-5p, hsa-
miR-215-5p and hsa-4516 were significantly downregulated in the osteoporosis 
patients compared to non-osteoporotic participants.  Further analysis showed that 
the levels of these circulating miRNAs were associated with fragility fracture and 
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correlated with the low bone mineral density in osteoporosis patients. Both serum 
hsa-miR-373-5p and plasma hsa-miR-4516 in have acceptable diagnostic values of 
AUC= 0.72 and 0.73 respectively in osteoporosis patients. 
Computational analysis for predicting targets for these 4 miRNAs has identified 48 
osteoporosis associated genes including sclerostin and low density lipoprotein 
receptor/related protein 6, TNF receptor-associated factor 6 and CD47, estrogen, 
androgen and follicle stimulating hormone -subunit, insulin-like growth factor and 
its receptor, bone morphogenetic protein and secreted protein acidic and cysteine 
rich, mitogen activated protein kinases 1 and 3 and the vitamin D receptor. These 
genes play critical roles in bone related signalling pathways.  Thus, miRNAs hsa-miR-
373-5p, hsa-miR-122-5p, hsa-miR-215-5p and hsa-4516 and the predicted target 
genes are potentially valuable biomarkers for the detection of osteoporosis.  
6.2 Future Work 
The present study has identified 4 miRNAs as potential markers of osteoporosis. The 
next step will be to replicate the present findings in a clinical trial with a larger 
number of samples from age matched control and study groups using interval 
samples for a set period of time. As well, correlates miRNA expression findings with 
current biomarkers in use, to put the preanalytical variations such as life style, diet, 
health condition and circadian rhythm as well as analytical variabilities into account 
(Hackl et al., 2016), to test the diagnostic value, which, if successful, could lead to a 
multi-centre National or international clinical trial. However, taking blood is an 
invasive technique and it would be advantageous to be able to detect the miRNAs in 
body fluids. Testing of circulating miRNAs in osteoporosis patients’ urine sample 
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could make sampling easier and is possible because of the stability of miRNAs in body 
fluids (Mall et al., 2013).   
In order to experimentally test the function of the miRNAs identified in this project, 
cultured cell systems could be established, in which the miRNAs are individually 
knocked out/knocked in, and the effect of the reduced miRNA level on the expression 
of the relevant osteoporosis-related genes identified on the present project will be 
directly tested. Particular attention will be paid to the relevant signalling pathways 
identified in the present project. 
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8.1 Honorary Contract Letter 
 
Figure 8-1: Honorary Contract Letter 
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8.2 NHS Trust Approval Letter for Non-clinical trial of an investigational 
medicinal product (Non-CTIMP) Studies 
 
Figure 8-2: NHS Trust Approval Letter for Non-clinical trial of an investigational 
medicinal product (Non-CTIMP) Studies. 
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8.3 Participant Information Sheet 
 
Figure 8-3: Participant Information Sheet (PIS) - Regulators in Osteoporosis 
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We would like to invite you to take part in a research study. Before you decide 
whether to take part, you need to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and 
discuss it with others if you wish.  
Our research team, based in the Institute of Ageing and Chronic Disease at the 
University of Liverpool, has a strong scientific research interest in metabolic bone 
diseases such as osteoporosis. We wish to analyse blood/urine samples to investigate 
the causes, development and biological regulators of these diseases. It is hoped that 
the resulting knowledge will help patients in the future.   
Why have you been invited?   
You have been invited to participate because you may be at risk of one of the 
metabolic bone disorders that we are researching.   
What will happen if I choose to take part?   
We would like your informed consent to take a small sample of blood and/or urine 
samples. Blood samples will be approximately 20-50 mL, approximately 2-4 
tablespoons. Urine samples will be approximately 100 mL, approximately 8 
tablespoons. This will extend your outpatient stay by 20-30 minutes.  
What are the advantages and disadvantages of taking part?   
The results of research carried out using your samples, and those of others, may help 
in the future discovery of new drugs and treatments for patients suffering from 
metabolic bone disorders.  
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There will be no direct benefit to yourself as you will not be identifiable to the 
research team.   
There will be no additional risks if you choose to participate.   
When the blood sample is taken, occasionally, this may require an additional entry 
site to the routine blood sample. On the small number of occasions that this may 
occur, there is the small chance you may experience some bruising at the site.   
In the event that something does go wrong and you are harmed during the research 
and this is due to someone’s negligence then you may have grounds for a legal action 
for compensation against the University of Liverpool, but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate).  
Do I have to take part?   
It is up to you to decide whether or not to allow us to collect a sample of your blood 
or urine. If you do decide to take part, then you can keep this information booklet 
and you will be asked to sign an informed consent form. If you decide not to take 
part, you do not need to give a reason.   
Whatever your decision, it will not affect the standard of care that you receive.   
What will happen to my blood/urine sample?  
All samples will be anonymised, catalogued and stored in the lockable ultra-low 
temperature -80⁰C freezer in the designated University laboratory which is locked 
when not in use. Our research team will be able to use your gift of samples to 
understand the causes of a bone disease and to improve treatment and care for 
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patients in the future. All research will be carried out in the lockable designated 
University clinical medicine research laboratory. Your blood will not be used for 
transplantation or reproductive cloning. Nor will the blood/urine samples be used for 
non-medical or non-scientific purposes.   
We will use some of blood/urine samples to obtain genetic related material (DNA, 
RNA and protein) and/or to isolate cells and culture them. [Note: Your genes are 
made up of DNA which contains information that determines in part the traits, such 
as eye colour, height or disease risk, which are passed on from parent to child. RNA 
is made from DNA. RNA has a major role in making proteins. Proteins are the building 
blocks of your body, cells and organs].  
Because we do not perform whole genome studies, there will be no risk of incidental 
findings. We will only analyse RNA samples to investigate differentially expressed 
RNA profiles. We will not use DNA, RNA or protein samples or cells for any purpose 
other than research and the research team will not be able to identify you in any way. 
You do not need to declare to your insurance company the fact that we have taken 
a sample of your genetic material. Any part of the sample you donate which has not 
been used for research will be stored in the licenced Liverpool Tissue Bank at the 
University of Liverpool and an application for ethical review for future bone related 
research will be obtained. If no further research ethics application is approved by the 
NRES, all samples will be disposed in accordance with the Human Tissue Authority’s 
Code of Practice.  
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What if researchers find new information about my condition?   
All blood/urine donations will be anonymous and the researchers will not be able to 
identify you from the sample.  
Will anybody make a profit from my blood/urine samples?   
You are asked to donate your blood/urine samples for research as a gift and will not 
receive a financial reward either now or in the future. The University will not sell your 
blood/urine samples for profit to any other researcher or organisation. However, 
your blood/urine samples may be used in a research project that may lead to the 
development of new drugs or treatments. It will not be possible for you to make a 
claim for money as you will be waiving all commercial rights relating to the samples 
you donate. Any drug, treatment or test developed may help all of us in the future.   
What will happen to the results of the research study?   
Research studies using blood/urine samples may take several years to complete. 
Results will be published when appropriate in scientific papers and magazines and 
presented at scientific meetings.   
You will not be able to be identified if research using your blood/urine samples is 
published in any scientific papers.   
Will my taking part in this study be kept confidential?   
All information that is collected related to your medical condition will be kept strictly 
confidential. No personal information will be stored with blood/urine samples and 
you will not be able to be identified.
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8.4 Osteoporosis Patients Medical Record 
Table 8-1: Osteoporosis Medical Record-without ID 2012-2013 
No. Date of 
Clinic 
Sample ID 
YYMMDDOP## 
DOB Age Sex  
F/M 
T Score 
Lumbar 
Spine 
(LS) 
T Score 
Femoral 
Neck 
(FN) 
T score 
Total  
IP (TH) 
Number 
of 
Fractures 
Position of 
Fracture 
Wrist [W] 
Vertebrae [V] 
Hip [H] 
Rib [R] 
Ankle [A 
Other [O] 
Date of last 
Fracture 
Medication 
History 
Calcium 
Vitamin D 
Bisphosphonates 
Prodelos 
Denosumab 
Others 
Risk Factors Type 
OP 
Notes 
1 6/2/12 120206OP01 30/7/75 37 F -4.0 -2.9  1 H   smoker C  
2 6/2/12 120206OP02 1/3/43 69 F -2.8 -2.3  2 R 2005/06 Prodelos VD C  
3 6/2/12 120206OP03 3/6/55 57 F -4.9 -3.5  0   Ca/Vd/Bis  B  
4 6/2/12 120206OP04 15/5/47 65 F -2.8 -2.8  0   Ca/Vd  B  
5 6/2/12 120206OP05 22/7/26 86 M -1.0 -1.5  multiple V  ca/Bis/Preotact  D  
6 27/2/12 120227OP01 15/7/56 56 F -2.2   2 A+foot  Vd Vd+smoking D  
7 27/2/12 120227OP02 13/6/38 74 F -2.8 -2.1  3 2W+V >3Y Ca+BP  C  
8 27/2/12 120227OP03 29/4/41 71 F -4.0 -2.5     Ca Coeliac B  
9 27/2/12 120227OP04 7/8/43 69 F     tib  Ca  A OPE 
10 27/2/12 120227OP05 9/8/29 83 F -2.8 -3.1     Ca+BP  C  
11 27/2/12 120227OP06 22/12/32 79 F -1.4 -2.5  1 V >5Y Ca+BP  C  
12 28/2/12 120228OP01 2/9/60 52 F -2.1 -1.2  2 O (shoulder+ 
elbow) 
2011/12 BP/Prodelos  D SIOP+hx of 
asthma 
13 28/2/12 120228OP02 20/3/50 62 F -2.5 -2  4 3R+O (pelvis) 2008/11 No pretreat  C OP spine, OPN 
hips 
14 28/2/12 120228OP03 12/1/45 67 F -3.0 -1.8  5 W+2V+R+O 
(foot) 
 Ca+BP  C Hx asthma, 
COPD 
15 28/2/12 120228OP04 28/3/51 61 F -1.5 -2.8  2 W+tib/fib  Ca+BP  C Previous 
Raloxifene 
16 28/2/12 120228OP05 3/9/32 80 F -2.2 -3.0  0   Ca/BP  B  
17 5/3/12 120305OP01 31/7/54 58 F -2.0 -2.0  2 Wx2 2009 No pretreat FH of OP D hysterectomy 
45yrs 
18 5/3/12 120305OP02 29/7/48 64 F -0.5 -0.5  0   VD VitD 
deficiency 
Norm NBD 
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No. Date of 
Clinic 
Sample ID 
YYMMDDOP## 
DOB Age Sex  
F/M 
T Score 
Lumbar 
Spine 
(LS) 
T Score 
Femoral 
Neck 
(FN) 
T score 
Total  
IP (TH) 
Number 
of 
Fractures 
Position of 
Fracture 
Wrist [W] 
Vertebrae [V] 
Hip [H] 
Rib [R] 
Ankle [A 
Other [O] 
Date of last 
Fracture 
Medication 
History 
Calcium 
Vitamin D 
Bisphosphonates 
Prodelos 
Denosumab 
Others 
Risk Factors Type 
OP 
Notes 
19 6/3/12 120306OP01 22/6/64 48 F    0   No pretreat   Due scan May 
2012 scan 
elsewhere no 
results 
20 8/3/12 120308OP01 17/3/40 72 M -3.2   1 W 2006 BP VitD 
deficiency 
C  
21 8/3/12 120308OP02 17/10/40 71 F    1 H 2005 BP Rh arthritis C  
22 8/3/12 120308OP03 4/7/24 88 F    5 V, 2H,2O 2011 Ca, VD, Deno 
sumab 
 C On BP, 
Prodelos in 
past, 
Denosumab 
starting today 
23 12/3/12 120312OP01 21/11/58 53 F -2.3 -1.8  1 Toe 1999 Ca, BP  A Oral BP3yrs 
about to start 
IV 
24 13/3/12 120313OP01 24/9/37 75 F    1 V  Ca  C Due to start IV 
Zol 
25 13/3/12 120313OP02 16/10/29 82 F -3.0 -2.1  6 3xW,2xR,1h 
umerus 
2001 Ca, BP  C Due to start 
Denosumab 
26 15/3/12 120315OP01 3/11/46 65 F -2.8 -2.7  0   BP  B Primary Hyper 
parathyroidism 
27 15/3/12 120315OP02 2/6/40 72 F -1.9 -2.4  2 W,R femur 2010 BP Smoking D  
28 15/3/12 120315OP03 25/5/62 50 F -1.1 -3.8  0   No pretreat Excess 
alcohol, 
VitD 
deficiency, 
family 
history of 
B  
29 15/3/12 120315OP04 28/5/32 80 F -1.1 -2.0  0   VitD,BP VitD 
deficiency 
A  
30 19/3/12 120319OP01 12/1/55 57 F -2.5 -1.1  0   Aledronate  B  
31 20/3/12 120320OP01 26/1/42 70 F -1.8 -1.6  1 femur 2011 Ca,BP  A nsedronate 
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No. Date of 
Clinic 
Sample ID 
YYMMDDOP## 
DOB Age Sex  
F/M 
T Score 
Lumbar 
Spine 
(LS) 
T Score 
Femoral 
Neck 
(FN) 
T score 
Total  
IP (TH) 
Number 
of 
Fractures 
Position of 
Fracture 
Wrist [W] 
Vertebrae [V] 
Hip [H] 
Rib [R] 
Ankle [A 
Other [O] 
Date of last 
Fracture 
Medication 
History 
Calcium 
Vitamin D 
Bisphosphonates 
Prodelos 
Denosumab 
Others 
Risk Factors Type 
OP 
Notes 
32 20/3/12 120320OP02 9/3/54 58 F -2.5 -0.6  0   VD,prodelos VitD 
deficiency 
B  
33 20/3/12 120320OP03 9/6/58 54 F -3.0   0   Ca,BP  B OP, Premature 
menopause 
34 22/3/12 120322OP01 20/8/25 87 F -2.5 -1.8  3 1W, 2x 
shoulder 
2006 BP Primary 
hyperpaxa 
C  
35 22/3/12 120322OP02 27/10/58 53 M -2.1 -2.5  0   No pretreat Excess 
alcohol, 
VitD 
deficiency, 
B  
36 22/3/12 120322OP03 29/5/42 70 F -0.2 -2.6  3 1W, 1V, 1H 2009 BP Excess 
alcohol, 
VitD 
deficiency, 
Severe 
C  
37 22/3/12 120322OP04 2/3/29 83 F -0.9 -1.7  3 1W,2xmete 
rtarsal 
2010 BP Polymyalgia 
rheumatica 
D  
38 22/3/12 120322OP05 18/9/32 80 F -2.4 -1.8  0   BP Breast 
cancer 
A  
39 22/3/12 120322OP06 14/4/27 85 M -3.9 -3.2  0   Prodelos VitD 
deficiency, 
CVA 
B  
40 10/4/12 120410OP01 9/4/64 48 F 0.9 -1.1  1 W  previous 
BP, Ca 
Excess 
Alcohol 
D  
41 13/4/12 120413OP01 27/6/41 71 F -2.1 -1.0  0   Ca, VitD Barrett's 
oesophagitis 
A Osteopenia, no 
fractures 
42 16/4/12 120416OP01 2/2/43 69 F -2.3 -1.5  0   Ca  A  
43 16/4/12 120416OP02 23/11/44 67 F -1.8 -1.1  0   Ca  A  
44 17/4/12 120417OP01 3/1/25 87 F -3.5 -3.0  0   Ca  B OP, no 
treatment 
45 17/4/12 120417OP02 14/6/38 74 F -2.1 -1.1  0   VitD, BP  A  
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No. Date of 
Clinic 
Sample ID 
YYMMDDOP## 
DOB Age Sex  
F/M 
T Score 
Lumbar 
Spine 
(LS) 
T Score 
Femoral 
Neck 
(FN) 
T score 
Total  
IP (TH) 
Number 
of 
Fractures 
Position of 
Fracture 
Wrist [W] 
Vertebrae [V] 
Hip [H] 
Rib [R] 
Ankle [A 
Other [O] 
Date of last 
Fracture 
Medication 
History 
Calcium 
Vitamin D 
Bisphosphonates 
Prodelos 
Denosumab 
Others 
Risk Factors Type 
OP 
Notes 
46 8/5/12 120508OP01 6/3/55 57 F -0.4 -1.8  2 Foot, Hand 2006 Ca, VitD VitD 
deficiency 
D CTx= 0.26 
47 8/5/12 120508OP02 12/2/44 68 F -0.9 -2.0  0   Ca  A  
48 10/5/12 120510OP01 14/1/54 58 F -2.1 -1.3  2 Rib, L 
shoulder 
Rib (06) 
Shoulder (08) 
Ca, VitD Ulcerative 
Colitis 
D  
49 15/10/12 121015OP01 5/12/68 44 M -3.5 -2.4  1 H 31/05/12 Ca, VitD, Excess 
alcohol, 
VitD 
deficiency, 
C  
50 16/10/12 121016OP01 10/11/45 67 F -3.2 -1.6  0   Ca  C Osteopenia 
history 
51 16/10/12 121016OP02 8/3/44 69 F -3.4 -2.1     Ca, VitD, BP, 
protelos 
 C  
52 22/10/12 121022OP01 26/10/30 82 F -5.2 -3.7  2 shoulder 2009 Ca, VitD, 
BP, 
VitD 
deficiency 
C  
53 30/10/12 121030OP01 30/4/35 78 F -1.8 -1.7  0   Ca, VitD, 
BP, 
VitD 
deficiency 
A  
54 5/11/12 121105OP1 5/4/39 74 F -3.5 -1.0     Ca, VitD, BP, 
protelos 
VitD 
deficiency 
C  
55 15/7/13 130715OP01 28/9/49 64 F -2.9 -2.5  0   VitD, BP, 
Ibandronate 
VitD 
deficiency 
C  
56 15/7/13 130715OP02 18/12/38 75 M    3 V 2011 Ca, VitD, BP   No report for 
BMD T Score 
57 15/7/13 130715OP03 7/5/34 79 F -2.7  -2.1 multiple V 2009 Ca, VitD, BP  C BP was taken 
>7 years 
58 15/7/13 130715OP04 31/7/42 71 F -3.3 -2.0  0   Ca, VitD, BP  C  
59 15/7/13 130715OP05 17/3/40 73 M -2.3   1 W 2010 Ca, VitD, BP VitD 
deficiency 
 S. No. 20 for 
same Patient 
BP (2002-
2012) 
60 16/7/13 130716OP01 28/4/50 63 F -3.0 -1.0     BP VitD 
deficiency 
C S. No. 2 for 
same Patient 
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No. Date of 
Clinic 
Sample ID 
YYMMDDOP## 
DOB Age Sex  
F/M 
T Score 
Lumbar 
Spine 
(LS) 
T Score 
Femoral 
Neck 
(FN) 
T score 
Total  
IP (TH) 
Number 
of 
Fractures 
Position of 
Fracture 
Wrist [W] 
Vertebrae [V] 
Hip [H] 
Rib [R] 
Ankle [A 
Other [O] 
Date of last 
Fracture 
Medication 
History 
Calcium 
Vitamin D 
Bisphosphonates 
Prodelos 
Denosumab 
Others 
Risk Factors Type 
OP 
Notes 
Excess 
Alcohol 
BP (2007-
2010) 
61 17/9/13 130917OP01 12/10/49 64 F -2.4   1 O    B Left Foot 
62 23/9/13 130923OP01 19/2/40 74 F -2.1   multiple V 2006 Ca, BP  B  
63 21/10/13 131021OP01 6/1/50 64 M    1 V 2012  Excess 
alcohol 
A  
 
Table 8-2: Osteoporosis Medical Record-without ID 2015-2016 
# Date of 
Clinic 
Sample 
ID 
DOB 
A
ge
 
Se
x 
F/
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p
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(L
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T 
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 F
em
o
ra
l N
ec
k 
T 
sc
o
re
 T
o
ta
l H
IP
 (
TH
) 
B
M
D
 [
g/
cm
2
] 
Medical 
Diagnosis 
Clinical History 
1 03/09/2
015 
150903
HC01 
 
30 M No No Yes No No 
   
No Arab 
     
Healthy 
 
2 03/09/2
015 
150903
HC02 
 
30-
40 
M No No Yes No No 
   
No Arab 
     
Healthy 
 
3 26/10/2
015 
151026
HC01 
09/11/1
957 
58 F No No Yes No No 
   
No Eu -0.5 -1.5 -1.7 
 
0.773 Osteopenia Family history of 
Osteoporosis 
4 26/10/2
015 
151026
OP01 
03/11/1
947 
68 F No No Yes No Yes 1 W 20
07 
Ca Eu -2 -0.9 -1.7 
 
0.771 Osteopenia
/Normal 
Osteopenia 
5 26/10/2
015 
151026
OP02 
27/02/1
948 
67 F No No No Yes Yes 
   
Ca/VitD Asian
/In 
-2.2 -1.9 -1.6 
 
0.787 Osteopenia On regular steroids 
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# Date of 
Clinic 
Sample 
ID 
DOB 
A
ge
 
Se
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F/
M
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H
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 o
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b
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p
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T 
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o
re
 T
o
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l H
IP
 (
TH
) 
B
M
D
 [
g/
cm
2
] 
Medical 
Diagnosis 
Clinical History 
6 26/10/2
015 
151026
OP03 
23/03/1
950 
65 M 
 
No No No No 
   
Steriod Eu -1 0.3 -1.6 
 
0.857 Osteopenia
/Normal 
Osteopenia 
7 27/10/2
015 
151027
OP01 
07/01/1
949 
66 F No No Yes No Yes 
   
Yes Eu -1.6 -0.8 -1.9 
 
0.75 Osteopenia Fracture 
8 27/10/2
015 
151027
OP02 
07/05/1
948 
67 F Yes Yes Yes 
 
Yes 
   
Yes Eu -1.7 -2.3 -2 
 
0.74 Osteopenia 
 
9 27/10/2
015 
151027
OP03 
19/05/1
960 
55 F No No No No No 
   
No Eu -1.3 -1.4 -0.8 
 
0.886 Osteopenia
/Normal 
Coeliac disease 
10 27/10/2
015 
151027
OP04 
16/07/1
960 
55 F Yes Yes No No No 
   
Yes Eu -1.3 -1.3 -1.6 
 
0.784 Osteopenia 
 
11 27/10/2
015 
151027
OP05 
05/02/1
954 
61 F No No No No No 
   
Yes Eu -1.5 -0.5 -0.5 
 
0.923 Normal/Ost
eopenia 
Asthma 
12 28/10/2
015 
151028
OP01 
21/01/1
951 
64 F No No No No Yes 
   
Yes Eu -1.9 -1.3 -0.7 
 
0.896 Osteopenia
/Normal 
Fracture 
13 28/10/2
015 
151028
OP02 
22/02/1
947 
68 F No No Yes No No 
   
Yes Eu 0.8 3.2 1.3 
 
1.138 Normal  Falls 
14 28/10/2
015 
151028
HC01 
08/02/1
977 
38 F Yes No No No No 
   
No Eu -1.3 -0.8 -0.3 
 
0.944 Normal/ost
eopenia 
 Low Vitamin D 
15 29/10/2
015 
151029
OP01 
31/12/1
935 
80 F No No No No No 
   
Yes, 
Thymain,
HBP 
Eu -1.1 0 -1.6 
 
0.794 Osteopenia
/Normal 
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# Date of 
Clinic 
Sample 
ID 
DOB 
A
ge
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re
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u
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ar
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p
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e 
(L
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-
L4
) 
T 
Sc
o
re
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em
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ra
l N
ec
k 
T 
sc
o
re
 T
o
ta
l H
IP
 (
TH
) 
B
M
D
 [
g/
cm
2
] 
Medical 
Diagnosis 
Clinical History 
16 29/10/2
015 
151029
OP02 
09/01/1
931 
84 M No No No No No 
   
Aspirin,Vit
D 
Eu -0.9 1 -2.4 
 
0.752 Osteopenia Osteopenia 
17 29/10/2
015 
151029
OP03 
11/04/1
943 
72 M No No No No No 
   
Aspirin Eu -2.9 -2.3 -2.4 
 
0.754 Osteopenia Osteoporosis 
18 29/10/2
015 
151029
OP04 
25/03/1
931 
84 F No No No No No 
   
No Eu -3.2 -3.2 -2.5 
 
0.68 Osteoporosi
s 
Falls. 
19 29/10/2
015 
151029
OP05 
21/08/1
977 
38 M No No No No No 
   
Ca+VitD Asian -0.1 -0.1 -1.9 
 
0.819 Osteopenia Prolonged steroid 
use 
20 02/11/2
015 
151102
OP01 
02/04/1
952 
63 F No No Yes No No 
   
YES,multi-
Vit for 3-
4Y 
Eu -0.8 -0.8 -0.1 
 
0.972 Normal Osteopenia 
21 02/11/2
015 
151102
OP02 
29/12/1
959 
56 F No No Yes No Yes 
 
W 
 
Yes,VitD Eu -0.2 -1.4 0.5 
 
1.043 Osteopenia Vitamin D deficiency 
22 02/11/2
015 
151102
OP03 
06/08/1
953 
62 F No No No No No 
   
Yes, 
Alendrona
te 
Eu -2.5 -2.9 -2.4 
 
0.693 Osteoporosi
s 
 
23 03/11/2
015 
151103
OP01 
19/12/1
951 
64 F No Yes Yes No No 
   
BP+VitD Eu -2.8 -3.3 -1.7 
 
0.776 Osteoporosi
s 
Osteoporosis 
24 03/11/2
015 
151103
OP02 
28/05/1
942 
73 F No No Yes No Yes 
   
Yes, 
allopurino
l for gout 
 
-0.4 -0.4 -0.5 
 
0.925 Normal/ost
eopenia 
 
25 03/11/2
015 
151103
OP03 
27/05/1
930 
85 F No No No Yes No 
   
Yes, Eu -2.5 -3 -1.9 
 
0.749 Osteoporosi
s 
Taking 
bisphosphonate 
26 03/11/2
015 
151103
OP04 
18/08/1
973 
42 F No Yes Yes No Yes 
   
No Eu -1.6 -1.2 0.7 
 
1.061 Osteopenia several fractures 
27 03/11/2
015 
151103
OP05 
04/01/1
946 
69 F No No Yes No No 
   
Yes 
 
-2.6 -1.7 -2.4 
 
0.698 Osteopenia Early menopause 
28 04/11/2
015 
151104
OP01 
30/04/1
944 
71 F No No No No No 
   
No Eu -2.1 -1.1 -1.3 
 
0.821 Osteopenia Family history of 
osteoporosis 
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# Date of 
Clinic 
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Sc
o
re
 L
u
m
b
ar
 S
p
in
e 
L1
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u
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p
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-
L4
) 
T 
Sc
o
re
 F
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o
ra
l N
ec
k 
T 
sc
o
re
 T
o
ta
l H
IP
 (
TH
) 
B
M
D
 [
g/
cm
2
] 
Medical 
Diagnosis 
Clinical History 
29 05/11/2
015 
151105
OP01 
30/06/1
945 
70 M No No Yes No No 
   
drug for 
high 
cholester
ol 
 
-1.7 -1 -1.6 
 
0.861 Osteopenia. Taking alendronic 
acid 
30 05/11/2
015 
151105
OP02 
26/12/1
940 
75 M No Yes Yes No Yes 
   
Aspirin, 
BP 
Eu -0.1 1 -0.4 
 
1.014 Normal Stress fracture 
31 05/11/2
015 
151105
OP03 
14/08/1
963 
52 F Yes Yes Yes No Yes 
   
alendroni
c acid 
Eu -0.2 0 -1.4 
 
0.816 Osteopenia Osteopenia 
32 05/11/2
015 
151105
OP04 
08/02/1
952 
63 F No No No No No 
   
No Eu -1.7 -1.4 -2.1 
 
0.723 Osteopenia Osteopenia 
33 05/11/2
015 
151105
OP05 
01/12/1
941 
74 M No No Yes No No 
   
No Eu -1.5 -1.1 -1.3 
 
0.819 Osteopenia Osteopenia 
34 16/11/2
015 
151116
OP01 
24/03/1
994 
21 F No No No No No 
   
No Eu -3.4 -3.6 -1.8 
 
0.76 Osteoporosi
s 
Osteoporosis 
35 16/11/2
015 
151116
OP2 
10/06/1
950 
65 F No No Yes No No 
   
alendroni
c acid 
Eu -0.9 -1.3 -2.4 
 
0.686 Osteopenia Osteoporosis  
36 17/11/2
015 
151117
OP01 
26/07/1
950 
65 F No No No No Yes 
   
Calcium Eu -2.1 -1.8 -2.5 
 
0.677 Osteoporosi
s 
Osteopenia 
37 17/11/2
015 
151117
OP02 
14/10/1
955 
60 M No No No No Yes 
   
No Eu -1.1 -1.6 -0.7 
 
0.983 Osteopenia Osteopenia 
38 17/11/2
015 
151117
OP03 
03/11/1
947 
68 F No No No No No 
   
VitD Eu -0.8 -0.8 0 
 
0.98 Normal Osteoporosis 
39 17/11/2
015 
151117
OP04 
06/03/1
941 
74 F No No No No Yes 
   
No Eu 1.1 1.7 -0.8 
 
0.886 Normal Falls 
40 17/11/2
015 
151117
OP05 
21/10/1
949 
66 M Yes No No No Yes 
   
No Eu -0.7 0 -1.7 
 
0.855 Osteopenia 
 
41 18/11/2
015 
151118
OP01 
19/05/1
934 
81 F No No No No Yes 
   
Cal+Alend
ronic 
Eu -3.9 -3.5 -2.3 
 
0.701 Osteoporosi
s 
Fragility fracture 
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# Date of 
Clinic 
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o
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) 
B
M
D
 [
g/
cm
2
] 
Medical 
Diagnosis 
Clinical History 
42 19/11/2
015 
151119
OP01 
03/01/1
974 
41 F No No Yes No No 
   
No Eu 0.2 0 -1.2 
 
0.834 Normal/Ost
eopenia 
Osteopenia 
43 19/11/2
015 
151119
OP02 
20/04/1
947 
68 F No No Yes No No 
   
Yes Eu -2.6 -2.6 -1.6 
 
0.791 Osteoporosi
s 
Fracture 
44 19/11/2
015 
151119
OP03 
17/03/1
970 
45 F No No Yes No No 
   
Yes Eu -0.2 0.5 -1.3 
 
0.824 Osteopenia
/Normal 
Crohns 
45 23/11/2
015 
151123
OP01 
30/05/1
980 
35 F No No Yes Yes Yes 
   
Yes, 
Ca+VitD 
Eu -0.5 -0.9 -1.1 
 
0.849 Normal/Ost
eopenia 
Osteoporosis 
46 23/11/2
015 
151123
OP02 
29/09/1
957 
58 F No No Yes No No 
   
Yes, 
Ca+VitD 
Eu -1.8 -2.1 -1.5 
 
0.796 Osteopenia 
 
47 23/11/2
015 
151123
OP03 
28/03/1
954 
61 F No No Yes No No 
   
Yes, BP Eu -0.7 -1.1 -1 
 
0.855 Osteopenia Vit D deficiency 
48 23/11/2
015 
151123
OP04 
01/06/1
944 
71 F No No Yes No Yes 
   
Yes, 
Ca+pain 
killer 
Eu -2.6 -0.3 -2.5 
 
0.682 Osteoporosi
s. 
Fragility fracture 
49 24/11/2
015 
151124
OP01 
21/04/1
949 
66 F Yes No No No Yes 
   
No Eu -1.9 -1.7 -1.5 
 
0.8 Osteopenia Fracture 
50 24/11/2
015 
151124
OP02 
08/09/1
948 
67 F Yes No Yes No Yes 
   
Ca+ Eu -1.2 -0.1 -1.3 
 
0.826 Osteopenia Rheumatoid arthritis 
51 24/11/2
015 
151124
OP03 
29/04/1
940 
75 F No No Yes No No 
   
BP+VitD Eu -2.1 -1.9 -2.2 
 
0.719 Osteopenia 
 
52 25/11/2
015 
151125
OP01 
23/02/1
967 
48 M No No Yes No No 
   
No Eu -1.8 -2.4 -1.5 
 
0.88 Osteopenia Osteopenia 
53 26/11/2
015 
151126
OP01 
31/12/1
956 
59 M No No Yes No No 
   
Ca Eu -0.8 -1.6 -3.2 
 
0.66 Osteoporosi
s 
Osteoporosis 
54 26/11/2
015 
151126
OP02 
20/01/1
949 
66 F No No Yes No Yes 
   
YES Eu -0.8 -2.3 -0.6 
 
0.905 Osteopenia Fractures 
55 26/11/2
015 
151126
OP03 
03/01/1
947 
68 F No No No No Yes 
   
Ca Eu -3 -2.7 -2.8 
 
0.643 Osteoporosi
s 
Osteopenia 
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B
M
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 [
g/
cm
2
] 
Medical 
Diagnosis 
Clinical History 
56 30/11/2
015 
151130
OP01 
01/01/1
934 
81 M No No Yes No No 
   
No Eu 0.5 -2.1 -3.1 
 
0.667 Osteoporosi
s. 
Fracture 
57 30/11/2
015 
151130
OP02 
06/03/1
938 
77 F No No No No Yes 
   
Yes Eu -0.1 0 -1.8 
 
0.763 Osteopenia Fragility fracture 
58 30/11/2
015 
151130
OP03 
06/07/1
947 
68 F No No Yes No Yes 
   
No Eu 0.2 0.2 -1.6 
 
0.794 Osteopenia Fragility fracture 
59 01/12/2
015 
151201
OP01 
31/03/1
954 
61 F No No Yes No No 
   
VitD+B12 Eu -0.9 -0.8 -1.5 
 
0.801 Osteopenia 
 
60 01/12/2
015 
151201
OP02 
03/01/1
939 
76 F No No No No No 
   
No Eu -0.3 -0.4 -0.5 
 
0.914 Normal Regular steroids 
61 01/12/2
015 
151201
OP03 
20/09/1
934 
81 F No No No No No 
   
BP+choles
terol 
Eu -2.4 -1.2 -3.6 
 
0.547 Osteoporosi
s 
Insufficiency fracture 
62 01/12/2
015 
151201
OP04 
07/06/1
954 
61 F No No Yes No No 
   
Ca+VitD Eu -0.3 0.1 -1.1 
 
0.852 Osteopenia
/Normal 
Family history of 
osteoporosis 
63 03/12/2
015 
151203
OP01 
20/08/1
959 
56 F No No No No No 
   
No Eu -1.5 -2.3 -2.1 
 
0.726 Osteopenia
/Osteoporo
sis 
Family history of 
osteoporosis 
64 03/12/2
015 
151203
OP02 
21/11/1
944 
71 F No No Yes No Yes 
   
ALendroni
c 
acid+VitD 
Eu -1.3 -0.1 -1.3 
 
0.819 Osteopenia Osteopenia 
65 03/12/2
015 
151203
OP03 
12/06/1
951 
64 F Yes No Yes No Yes 
   
Yes Eu 0.9 2.4 -0.1 
 
0.964 Normal Fragility fracture 
66 14/12/2
015 
151214
OP01 
09/09/1
957 
58 F No No No No No 
   
Yes Eu -3.6 -2.9 -2.2 
 
0.721 Osteoporosi
s 
Osteoporosis 
67 14/12/2
015 
151214
OP02 
22/01/1
958 
57 F No No Yes No No 
   
Yes,+VitD-
Ca 
Afr -1 -1.5 0.8 
 
1.081 Osteopenia Family history of 
osteoporosis 
68 15/12/2
015 
151215
OP01 
20/09/1
949 
66 M Yes No No No Yes 
   
No Eu -0.7 -3.1 -1.3 
 
0.905 Osteoporosi
s 
 
Appendix 
241 | P a g e  
 
# Date of 
Clinic 
Sample 
ID 
DOB 
A
ge
 
Se
x 
F/
M
 
Sm
o
ki
n
g 
Ye
s/
N
o
 
Ex
ce
ss
 a
lc
o
h
o
l Y
es
/N
o
 
R
eg
u
la
r 
Ex
er
ci
se
 Y
es
/N
o
 
V
eg
et
ar
ia
n
 Y
es
/N
o
 
Fr
ac
tu
re
s 
H
is
to
ry
 Y
es
/N
o
 
N
u
m
b
er
 o
f 
Fr
ac
tu
re
s 
P
o
si
ti
o
n
 o
f 
Fr
ac
tu
re
 
D
at
e 
o
f 
la
st
 F
ra
ct
u
re
 
M
ed
ic
at
io
n
 H
is
to
ry
 
Et
h
n
ic
 o
ri
gi
n
 
T-
Sc
o
re
 L
u
m
b
ar
 S
p
in
e 
L1
 
T 
Sc
o
re
 L
u
m
b
ar
 S
p
in
e 
(L
2
-
L4
) 
T 
Sc
o
re
 F
em
o
ra
l N
ec
k 
T 
sc
o
re
 T
o
ta
l H
IP
 (
TH
) 
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 [
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Medical 
Diagnosis 
Clinical History 
69 15/12/2
015 
151215
OP02 
15/02/1
956 
59 F No No No No Yes 
   
BP Eu -1.6 -1.7 0.1 
 
0.997 Osteopenia Fragility fracture 
70 15/12/2
015 
151215
OP03 
09/11/1
948 
67 F No No No No No 
   
No Eu -1.6 -0.8 -1.1 
 
0.851 Osteopenia 
 
71 16/12/2
015 
151216
OP01 
19/02/1
940 
75 F No No Yes No Yes 
   
Ca Eu -4.3 -3.7 -3 
 
0.617 Osteoporosi
s 
op post Zoledronate 
72 16/12/2
015 
151216
OP02 
06/12/1
941 
74 F Yes No No No No 
   
Yes Eu -2.5 -1.5 -1.5 
 
0.803 Osteopenia Rheumatoid arthritis 
73 16/12/2
015 
151216
OP03 
02/01/1
951 
64 F Yes No No No No 
   
Ca Eu -0.5 1.5 -1.4 
 
0.811 Osteopenia coelaic disease 
74 16/12/2
015 
151216
OP04 
22/04/1
951 
64 F No No No No No 
   
Ca+VitD Eu -0.9 -0.6 -1.4 
 
0.816 Osteopenia Osteopenia 
75 21/01/2
016 
160121
OP01 
02/05/1
961 
55 F No No Yes Yes No 
    
Eu -2.8 -2.3 -1.6 
 
0.789 Osteopenia Family history of 
Osteoporosis 
76 27/01/2
016 
160127
OP01 
21/05/1
994 
22 F No No Yes No No 
   
VitD Eu 1 1.6 2.1 
 
1.231 Normal Oestoporosis/Crohn'
s disease 
77 27/01/2
016 
160127
OP02 
09/04/1
955 
61 F No No No No No 
   
YES EU 0.6 0 -1.9 
 
0.751 Osteopenia
/Normal 
Coelaic disease 
78 27/01/2
016 
160127
OP03 
01/10/1
944 
72 F No No Yes No No 
   
YES EU -1 -1.7 -0.3 
 
0.942 Osteopenia
/Normal 
Rheumatoid arthritis 
79 28/01/2
016 
160128
OP01 
24/05/1
935 
81 F No No No No Yes 
   
VitD EU -1.8 -0.1 -1.1 
 
0.846 Osteopenia
/Normal 
 
80 28/01/2
016 
160128
OP02 
03/05/1
971 
45 F No No No No No 
   
Ca Eu 1.8 1.5 0.4 
 
1.028 Normal Early menopause 
81 28/01/2
016 
160128
OP03 
29/12/1
943 
73 F No No No No Yes 
   
YES EU -2.6 -1.9 -1.2 
 
0.842 Osteopenia Osteoporosis 
82 29/01/2
016 
160129
OP01 
30/12/1
936 
80 M No No No No Yes 
   
No EU 1.5 1.8 -2.4 
  
Osteopenia
/with 
Fractures 
Osteoporosis 
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 [
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2
] 
Medical 
Diagnosis 
Clinical History 
83 29/01/2
016 
160129
OP02 
28/06/1
952 
64 F No No No No No 
   
VitD+Ca EU -4.4 -3.7 -2.6 
 
0.665 Osteoporosi
s 
OP 
84 29/01/2
016 
160129
OP03 
07/02/1
946 
70 F No No Yes No No 
   
VitD Eu -1.5 -1.4 -2.5 
 
0.684 Osteoporosis/Osteopenia 
85 29/01/2
016 
160129
OP04 
09/07/1
945 
71 F No No Yes Yes No 
   
YES EU -1.1 -1.6 -1.9 
 
0.752 Osteopenia Osteopenia 
86 02/02/2
016 
160202
OP01 
24/08/1
946 
70 F No No Yes No Yes 
   
YES EU -3.8 -2.9 -1 
  
Osteoporosi
s 
OP 
87 02/02/2
016 
160202
OP02 
04/04/1
954 
62 F No No Yes No Yes 
   
No EU -1.7 -1.6 -0.2 
 
0.957 Osteopenia
/Normal 
Osteopenia 
88 02/02/2
016 
160202
OP03 
17/09/1
960 
56 F No No Yes No Yes 
   
No EU -1.3 -1 -1.4 
 
0.817 Osteopenia
/Normal 
Early Menopause 
89 02/02/2
016 
160202
OP04 
06/11/1
930 
86 F No No Yes No Yes 
   
VITD EU -2.2 -1.3 -2 
 
0.738 Osteopenia Osteoporosis 
90 03/02/2
016 
160203
OP01 
10/06/1
944 
72 F No No Yes No No 
   
VITD EU -1.1 -2 0 
 
0.978 Osteopenia Osteoporosis 
91 03/02/2
016 
160203
OP02 
26/04/1
950 
66 F Yes No Yes No Yes 
   
VITD EU -1.8 -2.3 -1.6 
 
0.79 Osteopenia Osteopenia 
92 03/02/2
016 
160203
OP03 
08/06/1
941 
75 F Yes No No No Yes 
   
CA EU -2.3 -2.3 -2.1 
 
0.728 Osteopenia Osteopenia 
93 03/02/2
016 
160203
OP04 
30/06/1
945 
71 F No No No No Yes 
   
YES EU -2.4 -1.9 -1.3 
 
0.82 Osteopenia taking alendronate 
94 03/02/2
016 
160203
OP05 
05/11/1
942 
74 F Yes No No No No 
   
YES EU -3.4 -3.7 -1.8 
 
0.769 Osteoporosi
s 
Osteopenia 
95 08/02/2
016 
160208
OP01 
02/02/1
956 
60 M Yes No Yes No No 
   
No EU -3.2 -2.1 -1.6 
 
0.864 Osteopenia
/osteoporos
is 
Vertebral wedging 
96 08/02/2
016 
160208
OP02 
11/05/1
959 
57 F Yes No Yes No Yes 
   
Y EU -2.5 -1.1 1.1 
 
1.112 Osteopenia Fragility fracture 
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Medical 
Diagnosis 
Clinical History 
97 08/02/2
016 
160208
OP03 
05/11/1
939 
77 F No Yes Yes No No 
   
Y EU -1 -0.4 -1 
 
0.856 Normal Osteopenia 
98 09/02/2
016 
160209
OP01 
15/05/1
954 
62 M No No Yes No No 
   
Y EU -1.6 -2.5 -2.6 
 
0.726 Osteoporosi
s 
long term steroids 
99 09/02/2
016 
160209
OP02 
18/08/1
943 
73 F No No No No Yes 
   
Y EU -3 -2.7 -2.4 
 
0.695 Osteoporosi
s 
 
10
0 
09/02/2
016 
160209
OP03 
14/03/1
959 
57 F No No Yes No No 
   
Y EU -1.3 -1.3 0.8 
 
1.081 Osteopenia osteopenia 
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8.5 General Equipment 
No. Item Cat# Source 
1.  ESCO Class II BS Cabinet AC2-
4G1SP Biological safety cabinet 
class II. 
CAB7019 ESCO 
2.  Thermo Heraeus Megafuge 16R 
Centrifuge (Refrigerated) 
75004270 Thermo Fisher, UK 
3.  Thermo TX-400 Swinging Bucket 
Rotor, Capacity (4 x 400mL)  
75003181 Thermo Fisher, UK 
4.  Thermo Round Buckets for TX-
400 Rotor (4) 
75003655 Thermo Fisher, UK 
5.  Thermo Scientific Heraeus Fresco 
Centrifuge 17R (Refrigerated) 
75002420 Thermo Fisher Ltd, UK 
6.  Microcentrifuge SCF2 CFH-500-020B Fisher Scientific UK 
7.  Genies2 Vortex mixer  MIX5000 Scientific Laboratory 
Supplies Ltd 
8.  BIO-RAD T100 Thermocycler. 186-1096 Bio-Rad Laboratories 
Ltd., UK 
9.  Roche Lightcycler® 96 Real-Time 
PCR System. 
05815 916 001 Roche Diagnostics Ltd, 
UK 
10.  Roche LightCycler®480 Multi-well 
Plate 96, white 5 x 10 plates 
(with sealing foils). 
04729692001 Roche Diagnostics Ltd, 
UK 
11.  Thermo Scientific NanoDrop™ 
2000 spectrophotometer 
ND-2000C Thermo Fisher Ltd, UK 
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8.6 Circulating serum and plasma miRNA qPCR 2^-Ct data Summary Table 
Table 8-3: Circulating serum and plasma miRNA qPCR 2^-Ct data Summary Table 
Average 2- Ct (Log10) of 6 circulating serum/plasma miRNAs: hsa-miR-100-5p, hsa-miR-
122-5p, hsa-miR-215-5p, hsa-miR-373-5p, hsa-miR-4516 and hsa-miR-99a-5p in Non-
Osteoporosis, Osteopenia (with/without fracture) and Osteoporosis (with/without 
fracture) 
Circulating 
miRNA 
N
o
n
-O
st
eo
p
o
ro
ti
c 
 
2
-
C
t  M
ea
n
 ±
 S
D
 
(N
) 
O
st
eo
p
en
ia
 
2
-
C
t  M
ea
n
 ±
 S
D
 
(N
) 
O
st
eo
p
en
ia
 w
it
h
 
Fr
ac
tu
re
 
2
-
C
t  M
ea
n
 ±
 S
D
 
(N
) 
O
st
eo
p
o
ro
si
s 
2
-
C
t  M
ea
n
 ±
 S
D
 
(N
) 
O
st
eo
p
o
ro
si
s 
w
it
h
 
Fr
ac
tu
re
 
2
-
C
t  M
ea
n
 ±
 S
D
 
(N
) 
hsa-miR-100-5p 
Serum 
3 ± 3.1 
(30) 
2.2 ± 2.8 
(63) 
1.5 ± 1 
(15) 
1.7 ± 1.8 
(34) 
2.5 ± 3 
(19) 
hsa-miR-100-5p 
Plasma 
2.7 ± 1.5 
(15) 
4.9 ± 7.3 
(63) 
2.2 ± 1.3 
(15) 
4.5 ± 6.2 
(34) 
3.2 ± 2.2 
(15) 
hsa-miR-122-5p 
Serum 
111.7 ± 
122.7 
(30) 
101.5 ± 
198 
(63) 
97.4 ± 
96.3 
(15) 
52.8 ± 
52.3 
(34) 
67.4 ± 
146.1 
(19) 
hsa-miR-122-5p 
Plasma 
128.5 ± 
85.6 
(15) 
131.4 ± 
175.7 
(63) 
101.5 ± 
100.6 
(15) 
130.5 ± 
259.1 
(34) 
57.2 ± 
60.6 
(15) 
hsa-miR-215-5p 
Serum 
0.9 ± 0.8 
(29) 
0.6 ± 0.5 
(61) 
0.4 ± 0.3 
(13) 
0.5 ± 0.5 
(30) 
0.6 ± 1 
(12) 
hsa-miR-215-5p 
Plasma 
0.5 ± 0.3 
(15) 
0.7 ± 0.9 
(61) 
0.6 ± 0.5 
(13) 
0.8 ± 0.9 
(30) 
0.8 ± 0.4 
(9) 
hsa-miR-373-5p 
Serum 
2.3 ± 2.5 
(29) 
2.7 ± 2.6 
(61) 
2 ± 1.7 
(15) 
2.4 ± 2.7 
(33) 
1.8 ± 4.6 
(19) 
hsa-miR-373-5p 
Plasma 
0.1 ± 0.1 
(12) 
0.1 ± 0.1 
(61) 
0.1 ± 0 
(15) 
0.1 ± 0.1 
(33) 
0 ± 0 
(15) 
hsa-miR-4516 
Serum 
101 ± 
131.3 
(30) 
108.1 ± 
122.1 
(63) 
70.4 ± 
59.1 
(15) 
104.7 ± 
89.4 
(34) 
84.8 ± 
89.8 
(19) 
hsa-miR-4516 
Plasma 
57.6 ± 
93.3 
(15) 
38.4 ± 
43.3 
(63) 
15.6 ± 
12.1 
(15) 
31.2 ± 
43.7 
(34) 
14 ± 19.4 
(15) 
hsa-miR-99a-5p 
Serum 
9.1 ± 8.5 
(29) 
4 ± 6.3 
(61) 
3.8 ± 2.4 
(13) 
3.4 ± 3.4 
(30) 
16.8 ± 
22.1 
(12) 
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(N
) 
hsa-miR-99a-5p 
Plasma 
3.4 ± 4.4 
(15) 
6 ± 7.6 
(61) 
7.4 ± 6.4 
(13) 
8.9 ± 10.2 
(30) 
8.6 ± 9.2 
(15) 
Total number of tested samples for: hsa-miR-100-5p (serum n= 161, plasma n= 142), hsa-
miR-122-5p (Serum n= 161, plasma n=142), hsa-miR-215-5p (serum n= 145, plasma n= 
128), hsa-miR-373-5p (serum n= 157, plasma n= 136), hsa-miR-4516 (serum n= 161, 
plasma n= 142) and hsa-miR-99a-5p (serum n= 145, plasma n= 134). 
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8.7 Geneontology 
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Table 8-4: Geneontology 
Geneontology (GO) Evidence Codes; a) Experimental Evidence codes; IDA: Inferred from Direct Assay, IMP: Inferred from Mutant Phenotype, 
IGI: Inferred from Genetic Interaction, IEP: Inferred from Expression Pattern. b) Computational Analysis evidence codes; ISS: Inferred from 
Sequence or structural Similarity, IBA: Inferred from Biological aspect of Ancestor. c) Author Statement evidence codes; TAS: Traceable Author 
Statement, NAS: Non-traceable Author Statement. d) Curatorial Statement codes; IC: Inferred by Curator, Automatically-Assigned evidence 
code; IEA: Inferred from Electronic Annotation. e) Automatically-assigned Evidence Codes; IEA: Inferred from Electronic Annotation. 
Reactome:R-HAS-   is open-source, curated and peer reviewed pathway database (Fabregat et al., 2016). GO_REF:0000002= Gene Ontology 
annotation through association of InterPro records with GO terms. GO_REF:0000107= Automatic transfer of experimentally verified manual GO 
annotation data to orthologs using Ensembl., GO_REF:0000024= Manual transfer of experimentally-verified manual GO annotation data to 
orthologs by curator judgment of sequence similarity. GO_REF:0000033= Annotation inferences using phylogenetic trees. GO_REF:0000037= 
Gene Ontology annotation based on manual assignment of UniProtKB keywords in UniProtKB/Swiss-Prot entries. 
Gene UniProtKB 
ID 
Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
ABCB1 P08183 Multidrug resistance 
protein 1 
ceramide translocation 
(GO:0099040) 
PTHR24221 [IDA; (van Helvoort et al., 
1996)] 
ceramide-translocating ATPase 
activity (GO:0099038) 
[IDA; (van Helvoort et al., 
1996)] 
G2/M transition of mitotic cell cycle 
(GO:0000086) 
[IDA; (Yamamoto et al., 
2009)] 
phosphatidylcholine-translocating 
ATPase activity (GO:0090554) 
[IDA; (van Helvoort et al., 
1996)] 
phosphatidylethanolamine-
translocating ATPase activity 
(GO:0090555) 
[IDA; (van Helvoort et al., 
1996)] 
phospholipid translocation 
(GO:0045332) 
[IDA; (van Helvoort et al., 
1996)] 
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Gene UniProtKB 
ID 
Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
ALPL P05186 Alkaline 
phosphatase, tissue-
nonspecific isozyme 
cementum mineralization 
(GO:0071529) 
PTHR11596 [IEA; GO REF:0000107] 
endochondral ossification 
(GO:0001958) 
[IEA; GO REF:0000107] 
osteoblast differentiation 
(GO:0001649) 
[IDA; (Foster et al., 2005)] 
response to glucocorticoid 
(GO:0051384) 
[IEA; GO REF:0000107] 
response to vitamin D (GO:0033280) [IEP; (van Driel et al., 
2006)] 
skeletal system development 
(GO:0001501) 
[TAS; (Mornet et al., 
1998)] 
ANKH Q9HCJ1 Progressive 
ankylosis protein 
homolog 
regulation of bone mineralization 
(GO:0030500) 
PTHR28384:SF
2 
[ISS; GO REF:0000024], 
[TAS; (Nurnberg et al., 
2001)] 
skeletal system development 
(GO:0001501) 
[NAS; (Ho et al., 2000)] 
AR P10275 Androgen receptor activation of prostate induction by 
androgen receptor signalling 
pathway (GO:0060520) 
PTHR24084 [IEA; GO REF:0000107] 
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Gene UniProtKB 
ID 
Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
androgen receptor activity 
(GO:0004882) 
[IDA; (Amir et al., 2003, 
Thomas et al., 2010, Son 
et al., 2010, Hsu et al., 
2014)], [IMP; (Xu et al., 
2009)], [NAS; (Fujimoto 
et al., 1999), [TAS; (Lin et 
al., 2004)] 
androgen receptor signalling 
pathway (GO:0030521) 
[IDA; (Thomas et al., 
2010, Son et al., 2010)] 
cellular response to steroid hormone 
stimulus (GO:0071383) 
[IMP; (Li et al., 2003)] 
epithelial cell differentiation 
involved in prostate gland 
development (GO:0060742) 
[IEA; GO REF:0000107] 
epithelial cell morphogenesis 
(GO:0003382) 
[IEA; GO REF:0000107] 
lateral sprouting involved in 
mammary gland duct 
morphogenesis (GO:0060599) 
[IEA; GO REF:0000107] 
morphogenesis of an epithelial fold 
(GO:0060571) 
[IEA; GO REF:0000107] 
positive regulation of cell 
differentiation (GO:0045597) 
[IMP; (Chauhan et al., 
2003)] 
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Gene UniProtKB 
ID 
Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
positive regulation of insulin-like 
growth factor receptor signalling 
pathway (GO:0043568) 
[IEA; GO REF:0000107] 
positive regulation of intracellular 
estrogen receptor signalling 
pathway (GO:0033148) 
[IEA; GO REF:0000107] 
positive regulation of MAPK cascade 
(GO:0043410) 
[IEA; GO REF:0000107] 
positive regulation of NF-kappaB 
transcription factor activity 
(GO:0051092) 
[IMP; (Lamb et al., 2011)] 
prostate gland epithelium 
morphogenesis (GO:0060740) 
[IEA; GO REF:0000107] 
tertiary branching involved in 
mammary gland duct 
morphogenesis (GO:0060748) 
[IEA; GO REF:0000107] 
CD44 P16070 CD44 antigen cartilage development 
(GO:0051216) 
PTHR10225 [IEP; (Nicoll et al., 2002)] 
positive regulation of ERK1 and ERK2 
cascade (GO:0070374) 
[IDA; (Shi et al., 2006)] 
CD47 Q08722 Leukocyte surface 
antigen CD47 
positive regulation of cell 
proliferation (GO:0008284), positive 
regulation of cell-cell adhesion 
(GO:0022409), positive regulation of 
T cell activation (GO:0050870) 
PTHR10613 [IDA; (Piccio et al., 2005)] 
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Gene UniProtKB 
ID 
Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
CNR1 P21554 Cannabinoid 
receptor 1 
positive regulation of neuron 
projection development 
(GO:0010976) 
PTHR22750 [IEA; GO REF:0000107] 
regulation of insulin secretion 
(GO:0050796) 
[IEA; GO REF:0000107] 
CNR2 P34972 Cannabinoid 
receptor 2 
negative regulation of nitric-oxide 
synthase activity (GO:0051001) 
PTHR22750 [IEA; GO REF:0000107] 
COL1A1 P02452 Collagen alpha-1(I) 
chain 
bone trabecula formation 
(GO:0060346) 
PTHR24023 [IEA; GO REF:0000107] 
cartilage development involved in 
endochondral bone morphogenesis 
(GO:0060351) 
[IEA; GO REF:0000107] 
cellular response to tumour necrosis 
factor (GO:0071356) 
[IEA; GO REF:0000107] 
cellular response to vitamin E 
(GO:0071306) 
[IEA; GO REF:0000107] 
embryonic skeletal system 
development (GO:0048706) 
[IMP; (Kamoun-Goldrat et 
al., 2008)] 
endochondral ossification 
(GO:0001958) 
[IEA; GO REF:0000107] 
intramembranous ossification 
(GO:0001957) 
[IEA; GO REF:0000107] 
osteoblast differentiation 
(GO:0001649) 
[IEA; GO REF:0000107] 
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Gene UniProtKB 
ID 
Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
positive regulation of canonical Wnt 
signalling pathway (GO:0090263) 
[IDA; (Medici and 
Nawshad, 2010)] 
positive regulation of epithelial to 
mesenchymal transition 
(GO:0010718) 
[IDA; (Medici and 
Nawshad, 2010)] 
protein transport (GO:0015031) [IEA; GO REF:0000107] 
response to corticosteroid 
(GO:0031960) 
[IEA; GO REF:0000107] 
skeletal system development 
(GO:0001501) 
[IMP; (Chamberlain et al., 
2004, Tsuneyoshi et al., 
1991, Cohn et al., 1993)] 
tooth mineralization (GO:0034505) [IMP; (De Coster et al., 
2007)] 
CYP17A1 P05093 Steroid 17-alpha-
hydroxylase/17,20 
lyase 
androgen biosynthetic process 
(GO:0006702) 
PTHR24289:SF
5 
[TAS; Reactome: R-HSA-
193048] 
progesterone metabolic process 
(GO:0042448) 
[IDA; (DeVore and Scott, 
2012)] 
CYP19A1 P11511 Aromatase androgen catabolic process 
(GO:0006710) 
PTHR24294 [IDA; (Leitner et al., 
2015)] 
estrogen biosynthetic process 
(GO:0006703) 
[TAS; Reactome: R-HSA-
193144] 
CYP1B1 Q16678 Cytochrome P450 
1B1 
estrogen metabolic process 
(GO:0008210) 
PTHR24299:SF
16 
[IDA; (Nishida et al., 
2013)] 
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Protein name Biological Process (GO) PANTHER 
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Evidence with Reference 
negative regulation of NF-kappaB 
transcription factor activity 
(GO:0032088) 
[ISS; GO REF:0000024] 
retinol metabolic process 
(GO:0042572) 
[IDA; (Choudhary et al., 
2004)] 
trabecular meshwork development 
(GO:0002930) 
[ISS; GO REF:0000024] 
CYP3A4 P08684 Cytochrome P450 
3A4 
androgen metabolic process 
(GO:0008209) 
PTHR24292:SF
73 
[TAS; (Fisher et al., 2009)] 
ESR1 P03372 Estrogen receptor androgen metabolic process 
(GO:0008209) 
PTHR24084 [IEA; GO REF:0000107] 
cellular response to estrogen 
stimulus (GO:0071391) 
[IEA; GO REF:0000107] 
epithelial cell development 
(GO:0002064) 
[IEA; GO REF:0000107] 
epithelial cell proliferation involved 
in mammary gland duct elongation 
(GO:0060750) 
[IEA; GO REF:0000107] 
estrogen receptor activity 
(GO:0030284) 
[IDA; (Sabbah et al., 
1998), [NAS; (Greene et 
al., 1986), [TAS; 
(Anandappa et al., 2000)] 
intracellular estrogen receptor 
signalling pathway (GO:0030520) 
[IDA; (Sabbah et al., 
1998), [NAS; (Greene et 
al., 1986)] 
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family 
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intracellular steroid hormone 
receptor signalling pathway 
(GO:0030518) 
[ISS; GO REF:0000024] 
mammary gland branching involved 
in pregnancy (GO:0060745) 
[IEA; GO REF:0000107] 
negative regulation of I-kappaB 
kinase/NF-kappaB signalling 
(GO:0043124) 
[IDA; (Liu et al., 2005, 
Stein and Yang, 1995)] 
prostate epithelial cord arborization 
involved in prostate glandular acinus 
morphogenesis (GO:0060527) 
[IEA; GO REF:0000107] 
prostate epithelial cord elongation 
(GO:0060523) 
[IEA; GO REF:0000107] 
regulation of branching involved in 
prostate gland morphogenesis 
(GO:0060687) 
[IEA; GO REF:0000107] 
response to estrogen (GO:0043627) [IDA; (Yahata et al., 
2001)] 
RNA polymerase II transcription 
factor activity, estrogen-activated 
sequence-specific DNA binding 
(GO:0038052) 
[IDA; (Laganiere et al., 
2005), [IGI; (Kim et al., 
2008)] 
steroid hormone receptor activity 
(GO:0003707) 
[TAS; (Kahlert et al., 
2000)] 
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ID 
Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
FSHB P01225 Follitropin subunit 
beta 
positive regulation of bone 
resorption (GO:0045780) 
PTHR11515 [IEA; GO REF:0000107] 
progesterone biosynthetic process 
(GO:0006701) 
[TAS; (Liu et al., 2003)] 
regulation of osteoclast 
differentiation (GO:0045670) 
[IEA; GO REF:0000107] 
GH1 P01241 Somatotropin bone maturation (GO:0070977) PTHR11417 [IDA; (van Gool et al., 
2010)] 
positive regulation of insulin-like 
growth factor receptor signalling 
pathway (GO:0043568) 
[IDA; (Goddard et al., 
1995)] 
positive regulation of MAP kinase 
activity (GO:0043406) 
[TAS; (VanderKuur et al., 
1994)] 
IGF1 P05019 Insulin-like growth 
factor I 
activation of MAPK activity 
(GO:0000187) 
PTHR11454 [IMP; (Fujita et al., 2012)] 
bone mineralization involved in 
bone maturation (GO:0035630) 
[IDA; (Koch et al., 2005)] 
ERK1 and ERK2 cascade 
(GO:0070371) 
[IMP; (Jeong et al., 2014)] 
negative regulation of oocyte 
development (GO:0060283) 
[IMP; (Velazquez et al., 
2011)] 
positive regulation of cell growth 
involved in cardiac muscle cell 
development (GO:0061051) 
[IDA; (Song et al., 2014)] 
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Gene UniProtKB 
ID 
Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
positive regulation of insulin-like 
growth factor receptor signalling 
pathway (GO:0043568) 
[IDA; (Imai et al., 2000, 
Freund et al., 1993)] 
positive regulation of MAPK cascade 
(GO:0043410) 
[IDA; (Munoz et al., 
2009)] 
positive regulation of osteoblast 
differentiation (GO:0045669) 
[IDA; (Koch et al., 2005)] 
positive regulation of protein import 
into nucleus, translocation 
(GO:0033160) 
[IDA; (Munoz et al., 
2009)] 
positive regulation of protein 
secretion (GO:0050714) 
[IMP; (Sunic et al., 1998)] 
positive regulation of smooth 
muscle cell proliferation 
(GO:0048661) 
[IDA; (Imai et al., 2000, 
Jia et al., 2006)] 
skeletal muscle satellite cell 
maintenance involved in skeletal 
muscle regeneration (GO:0014834) 
[IDA; (Ates et al., 2007)] 
skeletal system development 
(GO:0001501) 
[TAS; (Semsarian et al., 
1999)] 
IGF1R P08069 Insulin-like growth 
factor 1 receptor 
inactivation of MAPKK activity 
(GO:0051389) 
PTHR24416 [IDA; (Galvan et al., 
2003)] 
regulation of JNK cascade 
(GO:0046328) 
[IDA; (Galvan et al., 
2003)] 
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Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
IL1B P01584 Interleukin-1 beta activation of MAPK activity 
(GO:0000187) 
PTHR10078 [IDA; (Madge and Pober, 
2000)] 
MAPK cascade (GO:0000165) [IMP; (Wu et al., 2011)] 
negative regulation of adiponectin 
secretion (GO:0070164) 
[ISS; (Lagathu et al., 
2006)] 
negative regulation of MAP kinase 
activity (GO:0043407) 
[ISS; (Lagathu et al., 
2006)] 
positive regulation of interleukin-6 
secretion (GO:2000778) 
[IEA; GO REF:0000107] 
positive regulation of JNK cascade 
(GO:0046330) 
[IBA; GO REF:0000033] 
positive regulation of NF-kappaB 
import into nucleus (GO:0042346) 
[IDA; (Al-Sadi et al., 
2008)] 
positive regulation of NF-kappaB 
transcription factor activity 
(GO:0051092) 
[IDA; (Wesche et al., 
1999, Jung et al., 2003)] 
positive regulation of protein export 
from nucleus (GO:0046827) 
[NAS; (Luo et al., 2009)] 
regulation of establishment of 
endothelial barrier (GO:1903140) 
[IDA; (Clark et al., 2015)] 
regulation of I-kappaB kinase/NF-
kappaB signalling (GO:0043122) 
[IDA; (Madge and Pober, 
2000)] 
regulation of insulin secretion 
(GO:0050796) 
[IDA; (Corbett et al., 
1993)] 
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family 
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INSL3 P51460 Insulin-like 3 positive regulation of epithelial cell 
migration (GO:0010634) 
PTHR10423 [IDA; (Hampel et al., 
2013)] 
positive regulation of wound healing 
(GO:0090303) 
[IDA; (Hampel et al., 
2013)] 
IRS2 Q9Y4H2 Insulin receptor 
substrate 2 
MAPK cascade (GO:0000165) PTHR10614 [TAS; Reactome: R-HSA-
5673001] 
positive regulation of insulin 
secretion (GO:0032024) 
[ISS; GO REF:0000024] 
KIT P10721 Mast/stem cell 
growth factor 
receptor Kit 
actin cytoskeleton reorganization 
(GO:0031532) 
PTHR24416 [IDA; (Blume-Jensen et 
al., 1991)] 
activation of MAPK activity 
(GO:0000187) 
[IDA; (Kim et al., 2011)] 
MAPK cascade (GO:0000165) [TAS; Reactome: R-HSA-
5673001] 
megakaryocyte development 
(GO:0035855) 
[ISS; GO REF:0000024] 
positive regulation of long-term 
neuronal synaptic plasticity 
(GO:0048170) 
[IEA; GO REF:0000107] 
positive regulation of MAPK cascade 
(GO:0043410) 
[IMP; (Kim et al., 2011)] 
positive regulation of vascular 
smooth muscle cell differentiation 
(GO:1905065) 
[IDA; (Davis et al., 2009)] 
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Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
LRP6 O75581 Low-density 
lipoprotein receptor-
related protein 6 
axis elongation involved in 
somitogenesis (GO:0090245) 
PTHR10529 [IBA; GO REF:0000033] 
beta-catenin destruction complex 
disassembly (GO:1904886) 
[TAS; Reactome: R-HSA-
4641262] 
canonical Wnt signalling pathway 
(GO:0060070) 
[IDA; (Holmen et al., 
2002, Zilberberg et al., 
2004, Nam et al., 2006, 
George et al., 2007, 
Davidson et al., 2009, 
Gnad et al., 2010)], [IMP; 
(Li et al., 2008)], [TAS; 
(Berwick and Harvey, 
2012)] 
canonical Wnt signalling pathway 
involved in neural crest cell 
differentiation (GO:0044335) 
[IC; (Tamai et al., 2000)] 
canonical Wnt signalling pathway 
involved in regulation of cell 
proliferation (GO:0044340) 
[IC; (Wang et al., 2004)] 
convergent extension (GO:0060026) [IBA; GO REF:0000033] 
coreceptor activity involved in 
canonical Wnt signalling pathway 
(GO:1904928) 
[NAS; (Arenas, 2014)] 
coreceptor activity involved in Wnt 
signalling pathway (GO:0071936) 
[IDA; (Tamai et al., 2000)] 
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family 
Evidence with Reference 
midbrain-hindbrain boundary 
development (GO:0030917) 
[IBA; GO REF:0000033] 
negative regulation of canonical Wnt 
signalling pathway (GO:0090090) 
[TAS; Reactome: R-HSA-
3772470] 
neural crest cell differentiation 
(GO:0014033), neural crest 
formation (GO:0014029) 
[IDA; (Tamai et al., 2000)] 
neural tube closure (GO:0001843) [IBA; GO REF:0000033] 
pericardium morphogenesis 
(GO:0003344) 
[IBA; GO REF:0000033] 
positive regulation of canonical Wnt 
signalling pathway (GO:0090263) 
[IDA; (Semenov et al., 
2001, Li et al., 2002, 
Wang et al., 2004, Piao et 
al., 2008, Jeong et al., 
2010)] 
positive regulation of Wnt signalling 
pathway involved in dorsal/ventral 
axis specification (GO:2000055) 
[IDA; (Semenov et al., 
2005)] 
regulation of canonical Wnt 
signalling pathway (GO:0060828) 
[IGI; (Caruso et al., 2006)] 
trachea cartilage morphogenesis 
(GO:0060535) 
[IBA; GO REF:0000033] 
Appendix 
262 | P a g e  
 
Gene UniProtKB 
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Protein name Biological Process (GO) PANTHER 
family 
Evidence with Reference 
Wnt signalling pathway 
(GO:0016055) 
[IDA; (Mao et al., 2001, Li 
et al., 2005), [IMP; (Tamai 
et al., 2000, Cruciat et al., 
2010)] 
Wnt signalling pathway involved in 
dorsal/ventral axis specification 
(GO:0044332) 
[IDA; (Tamai et al., 2000)] 
Wnt signalling pathway involved in 
midbrain dopaminergic neuron 
differentiation (GO:1904953) 
[TAS; (Arenas, 2014)] 
Wnt signalling pathway involved in 
somitogenesis (GO:0090244) 
[IBA; GO REF:0000033] 
Wnt-activated receptor activity 
(GO:0042813) 
[IBA; GO REF:0000033] 
MAPK1 P28482 Mitogen-activated 
protein kinase 1 
activation of MAPK activity 
(GO:0000187) 
PTHR24055 [TAS; Reactome: R-HSA-
112409] 
cardiac neural crest cell 
development involved in heart 
development (GO:0061308) 
[IEA; GO REF:0000107] 
ERK1 and ERK2 cascade 
(GO:0070371) 
[IDA; (Pandey et al., 
2005)] 
mammary gland epithelial cell 
proliferation (GO:0033598) 
[IEA; GO REF:0000107] 
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Evidence with Reference 
MAP kinase activity (GO:0004707) [IBA; GO REF:0000033], 
[TAS; Reactome: R-HSA-
5654560, -5654562, -
5654565, -5654566], 
[TAS; Reactome: R-HSA-
5654560, -5654562, -
5654565, -5654566] 
MAPK cascade (GO:0000165) [TAS; Reactome: R-HSA-
5673001] 
MAPK import into nucleus 
(GO:0000189) 
[IEA; GO REF:0000107] 
negative regulation of cell 
differentiation (GO:0045596) 
[IEA; GO REF:0000107] 
regulation of cytoskeleton 
organization (GO:0051493) 
[TAS; (Yao and Seger, 
2009)] 
regulation of ossification 
(GO:0030278) 
[IEA; GO REF:0000107] 
regulation of stress-activated MAPK 
cascade (GO:0032872) 
[TAS; (Yao and Seger, 
2009)] 
response to estrogen (GO:0043627) [IEA; GO REF:0000107] 
stress-activated MAPK cascade 
(GO:0051403) 
[IDA; (Ko et al., 2001)] 
MAPK3 P27361 Mitogen-activated 
protein kinase 3 
activation of MAPK activity 
(GO:0000187) 
PTHR24055 [TAS; Reactome: R-HSA-
112409] 
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cardiac neural crest cell 
development involved in heart 
development (GO:0061308) 
[IEA; GO REF:0000107] 
cartilage development 
(GO:0051216) 
[IEA; GO REF:0000107] 
ERK1 and ERK2 cascade 
(GO:0070371) 
[IEA; GO REF:0000107] 
MAP kinase activity (GO:0004707) [IDA; (Zheng and Guan, 
1993)], [NAS; (Charest et 
al., 1993)], [TAS; 
Reactome: R-HSA-
5654560, -5654562, -
5654565, -5654566, -
73722] 
MAPK cascade (GO:0000165) [NAS; (Wang et al., 
2010)], [TAS; Reactome: 
R-HSA-5673001] 
MAPK import into nucleus 
(GO:0000189) 
[IEA; GO REF:0000107] 
positive regulation of cytokine 
secretion involved in immune 
response (GO:0002741) 
[IEA; GO REF:0000107] 
positive regulation of ERK1 and ERK2 
cascade (GO:0070374) 
[IMP; (Yang et al., 2009)] 
Appendix 
265 | P a g e  
 
Gene UniProtKB 
ID 
Protein name Biological Process (GO) PANTHER 
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regulation of cytoskeleton 
organization (GO:0051493) 
[TAS; (Yao and Seger, 
2009)] 
regulation of ossification 
(GO:0030278) 
[IEA; GO REF:0000107] 
regulation of stress-activated MAPK 
cascade (GO:0032872) 
[TAS; (Yao and Seger, 
2009)] 
stress-activated MAPK cascade 
(GO:0051403) 
[IDA; (Ko et al., 2001)] 
MTHFR P42898 Methylenetetrahydr
ofolate reductase 
response to folic acid (GO:0051593) PTHR21091:SF
136 
[IEA; GO REF:0000107] 
response to vitamin B2 
(GO:0033274) 
[IEA; GO REF:0000107] 
PON1 P27169 Serum 
paraoxonase/arylest
erase 1 
aromatic compound catabolic 
process (GO:0019439) 
PTHR11799 [IDA; (Draganov et al., 
2005)] 
aryldialkylphosphatase activity 
(GO:0004063) 
[IDA; (Harel et al., 2004), 
7638166] 
carboxylic acid catabolic process 
(GO:0046395) 
[IDA; (Sorenson et al., 
1995)] 
not negative regulation of plasma 
lipoprotein particle oxidation 
(GO:0034445) 
[IDA; (Teiber et al., 2004)] 
organophosphate catabolic process 
(GO:0046434) 
[IDA; (Sorenson et al., 
1995)] 
phosphatidylcholine metabolic 
process (GO:0046470) 
[IDA; (Rosenblat et al., 
2005)] 
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positive regulation of binding 
(GO:0051099) 
[IDA; (Rosenblat et al., 
2005)] 
positive regulation of cholesterol 
efflux (GO:0010875) 
[IDA; (Rosenblat et al., 
2005)] 
positive regulation of transporter 
activity (GO:0032411) 
[IDA; (Rosenblat et al., 
2005)] 
PTHLH P12272 Parathyroid 
hormone-related 
protein 
adenylate cyclase-activating G-
protein coupled receptor signalling 
pathway (GO:0007189) 
PTHR17223 [IDA; (Lanske et al., 
1998)] 
negative regulation of chondrocyte 
differentiation (GO:0032331) 
[IDA;(Amling et al., 1997)] 
osteoblast development 
(GO:0002076) 
[IBA; GO REF:0000033] 
positive regulation of cAMP 
biosynthetic process (GO:0030819), 
regulation of gene expression 
(GO:0010468) 
[IDA; (Amling et al., 
1997)] 
skeletal system development 
(GO:0001501) 
[IDA; (Amling et al., 
1997)] 
RUNX2 Q13950 Runt-related 
transcription factor 
2 
chondrocyte development 
(GO:0002063) 
PTHR11950 [IEA; GO REF:0000107] 
chondrocyte differentiation 
(GO:0002062) 
[IBA; GO REF:0000033] 
embryonic cranial skeleton 
morphogenesis (GO:0048701) 
[IEA; GO REF:0000107] 
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endochondral ossification 
(GO:0001958) 
[IEA; GO REF:0000107] 
ossification (GO:0001503) [TAS; (Backstrom et al., 
2002)] 
osteoblast development 
(GO:0002076) 
[IEA; GO REF:0000107] 
osteoblast differentiation 
(GO:0001649) 
[IEP; (Lambertini et al., 
2010)], [TAS; (Backstrom 
et al., 2002)] 
osteoblast fate commitment 
(GO:0002051) 
[IEA; GO REF:0000107] 
positive regulation of chondrocyte 
differentiation (GO:0032332) 
[IEA; GO REF:0000107] 
positive regulation of osteoblast 
differentiation (GO:0045669) 
[IEA; GO REF:0000107] 
regulation of cell differentiation 
(GO:0045595) 
[IBA; GO REF:0000033] 
SOST Q9BQB4 Sclerostin negative regulation of canonical Wnt 
signalling pathway (GO:0090090) 
PTHR14903 [IDA; (Semenov et al., 
2005)], [TAS; Reactome: 
R-HSA-3772470] 
negative regulation of ossification 
(GO:0030279) 
[NAS; (Balemans et al., 
2001, Leupin et al., 
2007)] 
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negative regulation of Wnt signalling 
pathway involved in dorsal/ventral 
axis specification (GO:2000054) 
[IDA; (Semenov et al., 
2005)] 
ossification (GO:0001503) [IEA; GO REF:0000107] 
Wnt signalling pathway 
(GO:0016055) 
[IEA; GO REF:0000037] 
SPARC P09486 SPARC bone development (GO:0060348) PTHR13866 [IEA; GO REF:0000107] 
ossification (GO:0001503) [IEA; GO REF:0000107] 
response to glucocorticoid 
(GO:0051384) 
[IEA; GO REF:0000107] 
response to L-ascorbic acid 
(GO:0033591) 
[IEA; GO REF:0000107] 
STAT1 P42224 Signal transducer 
and activator of 
transcription 1-
alpha/beta 
metanephric mesenchymal cell 
differentiation (GO:0072162) 
PTHR11801 [ISS; GO REF:0000024] 
metanephric mesenchymal cell 
proliferation involved in 
metanephros development 
(GO:0072136) 
[ISS; GO REF:0000024] 
negative regulation of I-kappaB 
kinase/NF-kappaB signalling 
(GO:0043124) 
[IMP; (Wang et al., 2000)] 
negative regulation of mesenchymal 
to epithelial transition involved in 
metanephros morphogenesis 
(GO:0003340) 
[ISS; GO REF:0000024] 
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negative regulation of metanephric 
nephron tubule epithelial cell 
differentiation (GO:0072308) 
[ISS; GO REF:0000024] 
positive regulation of smooth 
muscle cell proliferation 
(GO:0048661) 
[ISS; GO REF:0000024] 
renal tubule development 
(GO:0061326) 
[IMP; (Kim et al., 2010)] 
tumour necrosis factor-mediated 
signalling pathway (GO:0033209) 
[IDA; (Wang et al., 2000)] 
THBS1 P07996 Thrombospondin-1 activation of MAPK activity 
(GO:0000187) 
PTHR10199 [IMP; (Staniszewska et 
al., 2007)] 
cellular response to tumour necrosis 
factor (GO:0071356) 
[IEA; GO REF:0000107] 
positive regulation of smooth 
muscle cell proliferation 
(GO:0048661) 
[IDA; (Hamakawa et al., 
2014)] 
response to progesterone 
(GO:0032570) 
[TAS; (Adams, 1997)] 
TNFRSF1
B 
P20333 Tumour necrosis 
factor receptor 
superfamily member 
1B 
tumour necrosis factor-activated 
receptor activity (GO:0005031) 
PTHR23097:SF
161 
[IBA; GO REF:0000033] 
tumour necrosis factor-mediated 
signalling pathway (GO:0033209) 
[TAS; Reactome: R-HSA-
5668541] 
TRAF6 Q9Y4K3 TNF receptor-
associated factor 6 
activation of MAPK activity 
(GO:0000187) 
PTHR10131 [TAS; Reactome: R-HSA-
450302] 
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activation of NF-kappaB-inducing 
kinase activity (GO:0007250) 
[IMP; (Sun et al., 2004)] 
bone resorption (GO:0045453) [IEA; GO REF:0000107] 
JNK cascade (GO:0007254) [TAS; Reactome: R-HSA-
450321] 
neural tube closure (GO:0001843) [IEA; GO REF:0000107] 
ossification (GO:0001503) [IEA; GO REF:0000107] 
osteoclast differentiation 
(GO:0030316) 
[IEA; GO REF:0000107] 
positive regulation of I-kappaB 
kinase/NF-kappaB signalling 
(GO:0043123) 
[IDA; (Lamothe et al., 
2007)], [TAS; Reactome: 
R-HSA-937039] 
positive regulation of JUN kinase 
activity (GO:0043507) 
[IDA; (Shin et al., 2002)], 
[NAS; (Lamothe et al., 
2007)] 
positive regulation of NF-kappaB 
transcription factor activity 
(GO:0051092) 
[IDA; (Zapata et al., 2001) 
(Shin et al., 2002, Wang 
et al., 2006)], [IMP; (Lee 
et al., 2002)], [TAS; 
Reactome: R-HSA-
445989] 
positive regulation of osteoclast 
differentiation (GO:0045672) 
[IDA; (Lamothe et al., 
2007)] 
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positive regulation of smooth 
muscle cell proliferation 
(GO:0048661) 
[IEA; GO REF:0000107] 
regulation of immunoglobulin 
secretion (GO:0051023) 
[IEA; GO REF:0000107] 
VDR P11473 Vitamin D3 receptor calcitriol receptor activity 
(GO:0008434) 
PTHR24082 [IDA; (Makishima et al., 
2002, Kemmis et al., 
2006, Hawker et al., 
2007)] 
decidualization (GO:0046697) [IEP; (Vigano et al., 2006)] 
mammary gland branching involved 
in pregnancy (GO:0060745) 
[IEA; GO REF:0000107] 
positive regulation of keratinocyte 
differentiation (GO:0045618) 
[IMP; (Hawker et al., 
2007)] 
skeletal system development 
(GO:0001501) 
[IEA; GO REF:0000107] 
steroid hormone mediated signalling 
pathway (GO:0043401) 
[IEA; GO REF:0000002] 
steroid hormone receptor activity 
(GO:0003707) 
[IEA; GO REF:0000002] 
vitamin D receptor signalling 
pathway (GO:0070561) 
[IDA; (Kemmis et al., 
2006)] 
VPS13B Q7Z7G8 Vacuolar protein 
sorting-associated 
protein 13B 
protein transport (GO:0015031) PTHR12517 [IEA; GO REF:0000037] 
 
